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Diabetes	   mellitus	   is	   a	   multifactorial	   metabolic	   disease	   characterized	   by	   elevated	   blood	  
glucose	  due	  to	  pancreatic	  β-­‐cell	  dysfunction	  and	  insulin	  resistance.	  The	  mechanisms	  of	  the	  
initiation	   and	   progression	   of	   the	   disease	   are	   not	   fully	   understood	   but	   there	   is	   increasing	  
evidence	  that	   inflammation	  plays	  a	  crucial	  effector	  role	   in	  the	  development	  of	  both	  type	  1	  
and	  type	  2	  diabetes	  (T1D	  and	  T2D),	  leading	  to	  β-­‐cell	  damage	  and	  β-­‐cell	  death.	  Remaining	  β-­‐
cells	   compensate	   for	   the	   higher	   insulin	   demand	   until	   they	   fail.	   In	   T1D,	   additionally	  
dysregulated	   immune	  tolerance	  along	  with	  autoantibodies	  against	  self-­‐antigens	   leads	  to	  β-­‐
cell	  destruction.	  In	  this	  work,	  we	  are	  focusing	  on	  the	  role	  of	  two	  inflammatory	  modulators	  in	  
the	  development	  of	  diabetes,	  angiotensin	  II	  (Ang	  II)	  and	  sirtuin	  1	  (SIRT1).	  	  
Ang	   II	   as	   central	   player	   of	   the	   renin-­‐angiotensin-­‐system	   (RAS)	   is	   classically	   known	   as	  
regulator	  for	  local	  and	  systemic	  blood	  flow,	  body	  fluid	  homeostasis	  and	  electrolyte	  balance.	  
However,	   after	   the	   discovery	   of	   a	   pancreatic	   local	   RAS,	   the	   connection	   between	   RAS	  
blockage	  and	   the	   reduction	  of	  new	  onset	  diabetes	  has	  been	   found.	   In	   this	  work,	  we	  show	  
that	   Ang	   II	   induces	   islet	   inflammation,	   β-­‐cell	   dysfunction	   and	   β-­‐cell	   death	   in	   rodent	   and	  
human	  islets	  and	  in	  a	  mouse	  model	  of	  T2D,	  independently	  of	  vasoconstriction.	  Blockage	  of	  
the	  master	  regulating	  pro-­‐inflammatory	  cytokine	  interleukin-­‐1β	  (IL-­‐1β)	  by	  specific	  antibodies	  
improved	  glucose	  tolerance	  and	  islet	   inflammation	   in	  Ang	  II-­‐treated	  mice.	  This	  provides	  an	  
additional	  rationale	  for	  the	  treatment	  of	  type	  2	  diabetes	  with	  anti-­‐IL-­‐1β	  antibodies.	  	  
The	  NAD+	  dependent	  histone	  and	  protein	  deacetylase	  SIRT1,	  the	  closest	  homolog	  to	  Sir2	  in	  
yeast,	  has	  attracted	  interest	  as	  a	  regulator	  of	  stress	  responses	  and	  longevity.	  The	  enzyme	  is	  
implicated	   in	  various	  age-­‐dependent	  diseases	  because	  of	   its	  potential	   to	  modulate	  cellular	  
processes	  of	  metabolism	  and	  immune	  responses.	  In	  this	  work,	  we	  demonstrate	  an	  enhanced	  
metabolic	  and	  islet	  activity	  along	  with	  reduced	  regulatory	  T-­‐cells	  in	  a	  knock-­‐in	  mouse	  model	  
carrying	  a	  SIRT1	  mutation,	  which	  is	  associated	  with	  familial	  autoimmune	  diabetes	  and	  colitis.	  
Further,	  we	  show	  the	  beneficial	  influence	  of	  β-­‐cell	  specific	  SIRT1	  knock-­‐out	  in	  the	  induction	  
of	  T1D	  in	  mice.	  We	  hypothesize	  that	  context	  dependent	  overactivation	  by	  the	  mutated	  SIRT1	  
leads	  to	  enhanced	  insulin	  secretion,	   islet	   inflammation	  and	  an	  autoimmune-­‐like	  phenotype	  
along	  with	  reduced	  regulatory	  T-­‐cells	  in	  our	  SIRT1	  knock-­‐in	  mice.	  	  
6	  	  
In	  turn,	  β-­‐cell	  specific	  deletion	  of	  SIRT1	  protects	  from	  the	  development	  of	  T1D,	  possibly	  by	  
the	  induction	  of	  a	  “β-­‐cell	  rest”	  and	  therefore	  islet	  recovery.	  Accordingly,	  SIRT1	  inhibition	  and	  
not	  activation	  in	  the	  context	  of	  T1D	  may	  have	  beneficial	  effects.	  	  
Altogether,	  immunomodulatory	  treatments	  by	  targeting	  inflammatory	  players	  such	  as	  Ang	  II	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  activated	  receptor	  γ	  coactivator-­‐1α	  
PPARα	  	   Peroxisome	  proliferator	  activated	  receptor	  α	  
PPARγ	   	   Peroxisome	  proliferator	  activated	  receptor	  γ	  
RORγt	   	   RAR-­‐related	  orphan	  receptor	  gamma	  t	  
ROS	   	   Reactive	  oxygen	  species	  
SEM	   	   Standard	  error	  of	  mean	  
Sir2	   	   Silent	  information	  regulator	  2	  
SIRT1	   	   Sirtuin	  1	  
STZ	   	   Streptozotocin	  
T1D	   	   Type	  1	  diabetes	  
T2D	   	   Type	  2	  diabetes	  
TGFβ	   	   Transforming	  growth	  factor	  β	  
TLR	   	   Toll-­‐like	  receptor	  
TNF	   	   Tumor	  necrosis	  factor	  
Ucp2	   	   Uncoupling	  protein	  2	  




1	  Overview	  	  
	  
1.1 The	  endocrine	  pancreas	  	  	  
The	  body	  needs	   a	   system	   to	   rapidly	   and	   reliably	   react	   to	   changes	   in	   blood	   glucose	   levels.	  
Specialized	   cells	   in	   the	   endocrine	   pancreas	   are	   responsible	   for	   the	   secretion	   of	   regulating	  
hormones	   to	  ensure	   glycemic	  homeostasis.	   These	   cells	   are	  organized	   in	   clusters,	   so	   called	  
islets	  of	  Langerhans.	  As	  shown	  in	  Figure	  1,	  these	  islets	  of	  Langerhans	  are	  composed	  of	  three	  
main	  cell	   types:	  glucagon	  secreting	  α-­‐cells	   (in	  green),	   insulin	  producing	  β-­‐cells	   (in	   red)	  and	  
somatostatin	  containing	  δ-­‐cells	  (in	  blue).	  This	  system	  is	  highly	  conserved	  in	  animals,	  even	  if	  
there	   is	  wide	   species	   variability	   in	   islet	   structure	  and	   cell	   composition	  which	  might	   reflect	  
evolutionary	  adaptations.	  In	  mouse	  islets,	  α-­‐	  and	  δ-­‐cells	  are	  organized	  in	  the	  periphery	  and	  
insulin	  producing	  β-­‐cells	  are	  found	  in	  the	  center	  of	  the	   islets	  (Fig.	  1B).	   In	  humans,	  the	   islet	  
architecture	  is	  generally	   less	  organized	  (Fig.	  1A).	  Pancreatic	   islets	  are	  highly	  vascularized	  to	  
enable	   a	   rapid	   distribution	   of	   the	   secreted	   hormones	   to	   the	   circulation.	   Additionally,	  
immune	   cells,	   mainly	   macrophages,	   are	   found	   in	   the	   islets.	   After	   a	   glucose	   challenge,	  
synthesis	  and	  secretion	  of	  the	  hormone	  insulin	  leads	  to	  a	  lowering	  of	  blood	  glucose	  levels	  by	  
facilitating	  uptake	  and	  storage	  of	  glucose	  in	  peripheral	  tissues	  including	  fat,	  muscle	  and	  liver.	  
Glucagon	   has	   antagonistic	   effects;	   it	   provides	   glucose	   to	   the	   circulation	   by	   inducing	  
glycogenolysis	  and	  gluconeogenesis	   in	  the	   liver	  under	   low	  glucose	  conditions.	   In	  this	  work,	  
we	  are	   focusing	  on	   the	  effects	   of	   insulin	   secreting	  β-­‐cells,	  which	   act	   as	   important	   glucose	  








Figure	  1.	  Fluorescent	  stainings	  of	  pancreatic	  islets	  in	  humans	  (A)	  and	  mice	  (B).	  Green	  =	  glucagon,	  red	  =	  insulin,	  
blue	  =	  somatostatin.	  Adapted	  from	  [1].	  	  	  
B	  
10	  	  
1.1.1	  Insulin	  secretion	  
	  
	  
In	  response	  to	  nutrient	  load,	  insulin	  is	  secreted	  by	  pancreatic	  β-­‐cells	  in	  a	  glucose	  dependent	  
mechanism	   (Fig.	   2).	   Glucose	   enters	   the	   β-­‐cell	   via	   facilitated	   diffusion	   through	   type	   2	   and	  
type	  1	   (in	  human)	  glucose	  transporters	   (GLUT2/GLUT1)	  and	  glucose	  processing	   initiated	  by	  
the	   enzyme	   glucokinase	   and	   via	   oxidative	   glycolysis	   leads	   to	   an	   elevation	   of	   the	   ratio	   of	  
ATP/ADP.	  Thus,	  physiologically	  opened	  ATP-­‐sensitive	  potassium	  channels	   close	  and	   induce	  
the	  depolarization	  of	  the	  plasma	  membrane.	  Voltage	  dependent	  Ca2+	  channels	  open	  and	  the	  
increasing	  cytosolic	  concentration	  of	  free	  Ca2+	  triggers	  exocytosis	  of	  insulin	  vesicles	  (Fig.	  2).	  	  
	  
	  
Figure	  2.	  Glucose-­‐stimulated	  insulin	  secretion	  in	  rodent	  pancreatic	  β-­‐cells.	  Glucose	  enters	  the	  cell	  via	  type	  2	  
glucose	  transporters	  (GLUT2)	  and	  is	  metabolized	  in	  different	  steps	  including	  glycolysis,	  initiated	  by	  the	  enzyme	  
glucokinase,	   citric	   acid	   cycle	   and	   oxidative	   phosphorylation	   in	   the	   mitochondria.	   Thereby,	   ATP/ADP	   ratio	  
increases,	   followed	   by	   closure	   of	   ATP-­‐dependent	   K+	   channels.	   The	   cell	   membrane	   depolarizes	   and	   voltage-­‐
gated	   Ca2+	   channels	   open	   causing	   Ca2+	   influx	   and	   exocytosis	   of	   insulin	   vesicles.	   cAMP:	   cyclic	   adenosine	  




The	  secretion	  of	  insulin	  is	  regulated	  by	  nutrients,	  glucose	  levels,	  hormonal	  and	  neural	  factors	  
[3].	  Gene	  expression	   levels	  of	   insulin	   are	   glucose	  dependently	   regulated	  via	   acetylation	  of	  
histone	  H4	  in	  the	  insulin	  promoter	  [4].	  The	  glucagon-­‐like	  peptide	  1	  (GLP-­‐1)	  is	  one	  of	  the	  most	  
important	   modulating	   hormones	   [5].	   This	   incretin,	   which	   is	   mainly	   released	   by	   intestinal	  
cells,	   is	   enhancing	   intracellular	   cyclic	   adenosine	  monophosphate	   and	   Ca2+	   concentrations.	  
Thereby	   insulin	   secretion	   and	  β-­‐cell	   proliferation	   are	   stimulated	   and	   glucagon	   secretion	   is	  
inhibited	   [6].	   Additionally,	   modulators	   of	   the	   mitochondrial	   respiratory	   chain,	   such	   as	  
uncoupling	   protein	   2	   (Ucp2),	   influence	   insulin	   secretion	   by	   uncoupling	   mitochondrial	  
substrate	  oxidation	   from	  ADP	  phosphorylation	   [7].	   Since	   the	  main	   function	  of	  β-­‐cells	   is	   to	  
sense	   glucose	   and	   directly	   translate	   into	   insulin	   secretion,	   they	   have	   low	   lactate-­‐
dehydrogenase	   levels	   leading	   to	   the	  production	  of	  mainly	   pyruvate	   and	  not	   lactate	   in	   the	  
glycolytic	  cycle	  [8].	  
	  
The	   glycolytic	   and	   respiratory	   metabolism	   is	   also	   coupled	   to	   the	   production	   of	   reactive	  
oxygen	  species	  (ROS)	  in	  β-­‐cells	  [9].	  Oxidative	  stress	  is	  known	  to	  be	  an	  essential	  risk	  factor	  for	  
β-­‐cell	   dysfunction.	   It	   is	  defined	  as	   imbalance	  of	  ROS	  and	  antioxidative	  enzymes	   leading	   to	  
the	   induction	   of	   genes	   involved	   in	   pro-­‐inflammatory	   cytokine	   and	   chemokine	   production	  
such	  as	  NF-­‐kB.	  Oxidative	  stress	  disturbs	  the	  physiological	  function	  of	  DNA,	  proteins	  or	  lipids	  
and	  impairs	  metabolism-­‐secretion	  coupling	  [10].	  Suppression	  of	  elevated	  ROS	  in	  a	  non-­‐obese	  
model	   of	   diabetes	   was	   shown	   to	   improve	   glucose-­‐stimulated	   insulin	   secretion	   and	   ATP	  
production	   by	   inhibiting	   lactate	   overproduction	   [11].	   Since	   β-­‐cells	   have	   low	   antioxidative	  
capacities	  they	  are	  more	  susceptible	  to	  oxidative	  stress	  damage	  than	  other	  cell	  types	  [12].	  	  
However,	  growing	  evidence	  indicates	  also	  messenger	  function	  of	  ROS,	  especially	  H2O2,	  in	  the	  









1.2 Principles	  of	  inflammation	  and	  immunity	  	  	  	  
The	  principles	  of	  immunity	  are	  based	  on	  two	  major	  subsystems,	  the	  innate	  and	  the	  adaptive	  
immune	  system.	  Acute	   inflammation	   is	   classically	   known	  as	   the	   initial	  defense	  mechanism	  
orchestrated	  by	   the	   innate	   immune	   system	  against	  bacterial	   infections	  and	   tissue	  damage	  
[16].	  It	  evolved	  as	  a	  physiological	  adaptive	  response	  to	  restore	  homeostasis	  but	  it	  may	  lead	  
to	  chronic	  inflammation	  if	  unresolved.	  	  
	  
The	  recruitment	  of	  leukocytes,	  specifically	  macrophages	  and	  neutrophils,	  leads	  to	  a	  classical	  
non-­‐specific	   inflammatory	   reaction	   including	   engulfment	   of	   pathogens,	   cytokine	   and	  
chemokine	  release	  and	  transport	  of	  plasma	  proteins	  to	  the	  affected	  tissue.	  This	  response	  is	  
triggered	  by	  receptors	  of	  the	  innate	  immune	  system,	  including	  toll-­‐like	  receptors	  (TLRs)	  and	  
cytokine	  release	  upon	  activation,	  such	  as	  IL-­‐1,	  IL-­‐6,	  IL-­‐10	  and	  TNFα.	  Several	  chemokines	  are	  
involved	   in	   the	   recruitment	   and	   activation	   of	   innate	   immune	   cells	   at	   the	   site	   of	  
inflammation,	  such	  as	  monocyte	  chemoattractant	  protein-­‐1	   (MCP-­‐1)	  and	  chemokine	   (C-­‐x-­‐c	  
motif)	  ligand	  1	  (Cxcl1).	  
	  
Interestingly,	   inflammation	   can	   also	   be	   induced	   in	   the	   absence	   of	   any	   exogenous	  
microorganism	  but	   in	   response	   to	   tissue	  malfunction	  or	  stress.	  This	   sterile	   inflammation	   is	  
suggested	  to	  contribute	  to	  chronic	  inflammatory	  diseases	  [17]	  and	  it	  is	  likely	  to	  happen	  also	  
in	  obesity,	  induced	  by	  metabolic	  stress.	  	  
	  
T-­‐lymphocytes,	  special	  cells	  of	  the	  adaptive	  immune	  system	  characterized	  by	  the	  expression	  
of	   CD3,	   are	   able	   to	   react	   specifically	   to	   pathogens	   in	   an	   antigen-­‐dependent	   manner	   and	  
provide	  long-­‐time	  immunity.	  Antigen-­‐presenting	  cells	  (APCs)	  including	  monocytes,	  dendritic	  
cells	   and	   B-­‐cells	   induce	   the	   activation	   and	   clonal	   expansion	   of	   naïve	   lymphocytes	   in	  














Figure	   3.	   T-­‐cell	   antigen	   recognition	   in	   the	   immunological	   synapse.	   T-­‐cell	   activation	   and	   differentiation	   is	  
induced	   via	   antigen	  presentation	  by	   antigen-­‐presenting	   cells	   (APCs)	   and	   costimulation	   via	   receptors	   and	   the	  
cytokine	  environment.	  TCR:	  T-­‐cell	  receptor.	  CTLA-­‐4:	  cytotoxic	  T-­‐lymphocyte	  associated	  protein-­‐4.	  MHC:	  major	  
histocompatibility	  complex.	  Adapted	  from	  [18].	  
	  
	  
Mainly	  two	  types	  of	  effector	  T-­‐cells	  are	  discriminated:	  CD8+	  cytotoxic	  T-­‐cells	  and	  CD4+	  helper	  
T-­‐cells.	  Cytotoxic	  T-­‐cells	   recognize	  antigens	  presented	  by	  major	  histocompatibility	  complex	  
class	  I	  (MHC	  I)	  molecules	  leading	  to	  direct	  killing	  of	  infected	  cells	  via	  production	  of	  cytokines	  
and	   perforins.	   Naïve	   CD4	   T-­‐lymphocytes	   can	   differentiate	   in	   distinct	   subpopulations	   of	   T-­‐
cells	  after	  recognition	  of	  antigens	  presented	  via	  MHC	  II	  molecules.	  Each	  lymphocyte	  carries	  a	  
distinct	   antigen	   receptor	   and	   the	   ones	   binding	   ubiquitous	   self-­‐antigens	   have	   to	   be	  
eliminated	   during	   development	   to	   ensure	   self-­‐tolerance.	   If	   costimulation	   via	   CD28	   as	   the	  
second	   signal	   for	   activation	   is	   missing	   during	   the	   first	   antigen	   exposure	   (Fig.	   3),	   T-­‐cells	  
become	   anergic	   and	   do	   not	   respond	   to	   subsequent	   stimulation,	   ensuring	   self-­‐tolerance.	  
Depending	  on	  costimulatory	  signals,	  CD4+	  helper	  T-­‐cells	  can	  differentiate	  into	  four	  different	  
subsets	  with	  distinct	  immune	  properties:	  Th1,	  Th2,	  Tregs	  and	  Th17	  cells.	  
	  
Each	  T	  helper	  subset	  is	  defined	  by	  specific	  cytokines	  required	  for	  polarization,	  transcription	  





























Figure	  4.	  Model	  of	  naïve	  CD4	  T-­‐cell	  differentiation	  into	  major	  T-­‐cell	  subsets	  with	  characteristic	  transcriptions	  
factors	   (black),	   cytokines	   for	   their	   fate	   determination	   (colored)	   and	   unique	   products	   (colored,	   alongside).	  	  






Activated	  Th1	  and	  Th17	  cells	  are	  mainly	   involved	  in	  bacterial	   infections	  and	  autoimmunity,	  
whereas	  Th2	  cells	  are	  responsible	  for	  allergic	  inflammatory	  diseases	  and	  protection	  against	  
parasitism.	  The	  differentiation	  into	  Th1	  cells	  activates	  macrophages	  and	  cytotoxic	  T-­‐cells	  and	  
promotes	   CD4	   T-­‐cell	  memory.	   The	   production	   of	   cytokines	   by	   Th2	   cells	   stimulates	   B-­‐cells,	  
eosinophils	  and	  mast	  cells	  and	  can	  also	  suppress	  Th1	  immune	  responses.	  
	  
Of	  particular	  interest,	  regulatory	  T-­‐cells	  (Tregs)	  are	  specialized	  cells,	  which	  exert	  cell	  extrinsic	  
immunosuppression	  [20].	  The	  transcription	  factor	  Foxp3	  is	  required	  for	  the	  development	  of	  
Tregs	  [21]	  and	  its	  continuous	  expression	  is	  crucial	  for	  the	  maintenance	  of	  self-­‐tolerance	  and	  
tissue	   homeostasis	   [22],	   [23],	   as	   Scurfy	  mice	  with	   loss-­‐of-­‐function	  mutations	   in	   the	  Foxp3	  





There	   are	   mainly	   four	   mechanisms	   used	   by	   Tregs	   to	   suppress	   immune	   responses:	   direct	  
modulation	  of	  APC	  function	  by	  suppressing	  the	  costimulatory	  receptors	  CD80/CD86	  through	  
molecules	   such	   as	   cytotoxic	   T-­‐lymphocyte	   associated	   protein-­‐4	   (CTLA-­‐4),	   killing	   of	   target	  
cells	  via	  granzymes	  and	  perforins,	  disruption	  of	  metabolic	  pathways	  through	  degradation	  of	  
ATP	  and	  the	  production	  of	  anti-­‐inflammatory	  cytokines,	  such	  as	  TGFβ,	  IL-­‐10	  and	  IL-­‐35.	  Tregs	  
express	   the	   highest	   levels	   of	   CD25	   (IL-­‐2	   receptor	   α),	   which	   suggests	   the	   importance	   of	  
interleukin	   2	   for	   their	   suppressive	   function,	   although	   all	   activated	   T-­‐cells	   express	   CD25.	  
Defective	   numbers	   or	   functions	   of	   Tregs	   were	   linked	   to	   several	   autoimmune	   diseases	  
including	  T1D	  [25],	  [26],	  [27],	  although	  there	  are	  discrepancies	  in	  the	  literature.	  	  
	  
Interestingly,	   IL-­‐22,	   which	   is	   classically	   involved	   in	   Th17	   cell-­‐induced	   inflammation,	   was	  
shown	   to	   reverse	   obesity-­‐induced	   metabolic	   disturbances	   and	   pancreatitis	   [28],	   [29].	   Of	  
note,	  the	  highest	   levels	  of	   IL-­‐22	  receptor	  1	  expression	  are	  found	  in	  the	  pancreas,	   including	  
islet	  cells	  [30].	  	  
	  
Beside	  the	  distinct	  differentiation	  factors	  for	  each	  T-­‐cell	  subset,	  T-­‐cell	  activation	  requires	  the	  
involvement	   of	   other	   transcription	   factors,	   including	   AP-­‐1,	   NF-­‐κB,	   and	   nuclear	   factor	   of	  
activated	  T-­‐cells	  (NFAT).	  	  
Antigens	  presented	  in	  the	  periphery	  can	  also	  bind	  directly	  to	  B-­‐cells,	  which	  are	  characterized	  
by	   the	   expression	  of	   CD19	   and	  B220,	   and	   a	   second	   signal	   for	   differentiation	   into	   antigen-­‐
producing	  plasma	  cells	  is	  delivered	  by	  activated	  T-­‐cells.	  After	  infection	  defense,	  memory	  B-­‐	  
and	   T-­‐cells	   are	   generated	   to	   ensure	   immunological	   memory	   in	   response	   to	   a	   second	  










1.3 Diabetes	  and	  Inflammation	  
	  
	  
Diabetes	  mellitus	   is	   a	   chronic	  metabolic	   disease	   characterized	   by	   elevated	   levels	   of	   blood	  
glucose.	  It	   is	  a	  major	  cause	  of	  morbidity	  and	  mortality	  worldwide.	  90%	  of	  diabetic	  patients	  
have	   type	   2	   diabetes	   (T2D).	   The	   development	   of	   the	   metabolic	   disorder	   has	   underlying	  
genetic	  factors	  and	  environmental	  causes,	  including	  overnutrition	  and	  a	  sedentary	  lifestyle.	  
Typically,	  the	  development	  of	  T2D	  is	  associated	  with	   insulin	  resistance	   in	  the	   insulin	  target	  
tissues	  while	  β-­‐cells	  compensate	  for	  the	  higher	  insulin	  demand.	  Failure	  of	  β-­‐cell	  adaptation	  
results	   in	   hyperglycemia	   and	  β-­‐cell	   destruction	   [31],	   [32].	  However,	  many	   insulin-­‐resistant	  
subjects	  never	  become	  diabetic	  because	  their	  β-­‐cells	  can	  adjust	  their	  insulin	  production	  [33].	  
In	   the	   last	   years	   it	   became	   increasingly	   evident	   that	   a	   pathological	   involvement	   of	   the	  
immune	  system	  plays	  a	  major	  role	  in	  the	  development	  of	  T2D	  (Fig.	  5).	  Overnutrition	  causes	  a	  
chronic	  pro-­‐inflammatory	  state	  in	  many	  organs	  including	  the	  pancreatic	  islets	  [34],	  [35],	  [36],	  
[37].	  Inflammatory	  cytokines,	  immune	  cell	  infiltrations,	  apoptosis	  and	  fibrosis	  are	  elevated	  in	  
islets	  of	  T2D	  animal	  models	  and	  in	  T2D	  patients	  [38],	  [39],	  [40],	  [41],	  [42].	  
	  
	  
Figure	  5.	  Model	  of	  inflammation	  in	  response	  to	  metabolic	  stress	  in	  pancreatic	  islets.	  Increased	  circulating	  free	  
fatty	   acids	   (FFA),	   modified	   LDL	   (mLDL)	   particles	   and	   advanced	   glycation	   end	   products	   (AGE)	   bind	   to	   their	  
cognate	  receptors	  leading	  to	  NF-­‐κB	  activation	  and	  the	  production	  of	  various	  proinflammatory	  chemokines	  and	  
cytokines,	  including	  the	  proform	  of	  IL-­‐1β.	  Glucose-­‐activated	  caspase-­‐1	  inflammasome	  causes	  overproduction	  of	  
IL-­‐1β	   in	   both	   β-­‐cells	   and	  macrophages,	   which	   in	   turn	   triggers	   an	   autoinflammatory	   chronic	   response	   in	   the	  
islets.	  Adapted	  from	  [34].	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Persistently	  elevated	  levels	  of	  glucose	  and	  free	  fatty	  acid	  (FFA)	  lead	  to	  chronically	  increased	  
concentrations	   of	   Interleukin-­‐1β	   (IL-­‐1β),	   which	   is	   one	   of	   the	   master	   regulating	   pro-­‐
inflammatory	   cytokines	   [35],	   [43].	   Glucose-­‐activated	   caspase-­‐1	   inflammasome	   causes	  
overproduction	  of	  IL-­‐1β,	  which	  in	  turn	  triggers	  an	  autoinflammatory	  process	  [43],	  [44].	  The	  
emerging	   imbalance	   of	   IL-­‐1β	   and	   its	   naturally	   occurring	   antagonist	   interleukin-­‐1	   receptor	  
antagonist	   (IL-­‐1Ra)	   was	   shown	   to	   be	   involved	   in	   islet	   inflammation	   [39].	   IL-­‐1β	   producing	  
macrophages	   are	   activated	   and	   contribute	   to	   the	   development	   of	   insulitis	   [41],	   [38].	  
Inhibitors	  of	   IL-­‐1β	  such	  as	  anakinra,	   the	   recombinant	   form	  of	   IL1-­‐Ra,	  or	  antibodies	  against	  	  	  
IL-­‐1β	  were	   shown	   to	   improve	  hyperglycemia,	  β-­‐cell	   function	  and	  systemic	   inflammation	   in	  
T2D	  and	  obese	  patients	   [45],	   [46],	   [47],	   [48],	   [49],	   [50],	   [51].	  Hence,	   these	  blockers	   are	   in	  
clinical	  development	  for	  the	  treatment	  of	  diabetes.	  	  
	  
Type	  1	  diabetes	  (T1D)	   is	  a	  heterogeneous	  chronic	  disease	  characterized	  by	  T-­‐cell-­‐mediated	  
autoimmune	  reactions	  to	  pancreas-­‐specific	  antigens	  leading	  to	  destruction	  of	  pancreatic	  β-­‐
cells	   and	   insulin	   deficiency.	   Autoantibodies	   are	   present	   in	   85-­‐90%	   of	   T1D	   patients,	   who	  
mostly	  become	  dependent	  on	  insulin	  treatment.	  The	  multifactorial	  disease	  is	  influenced	  by	  
genetic	   and	  environmental	   factors	   such	  as	   viruses	   and	   toxins.	   It	   is	   thought	   to	  begin	  when	  
unexplainable	   β-­‐cell	   death	   leads	   to	   the	   exposure	   of	   β-­‐cell	   antigens	   followed	   by	   T-­‐cell	  
activation	   through	   antigen-­‐presenting	   cells.	   Further,	   there	   is	   emerging	   evidence	   that	  
regulatory	  T-­‐cells	  (Tregs)	  are	  less	  functional	  in	  suppressing	  effector	  T-­‐cells	  leading	  to	  failure	  
of	   maintaining	   self-­‐tolerance	   in	   T1D	   [52].	   However,	   the	   mechanisms	   involved	   in	   the	  
destruction	   of	   β-­‐cells	   and	   how	   they	   can	   be	   targeted	   is	   not	   fully	   understood.	   The	  
development	  of	  combination	  immunotherapies	  with	  drugs	  that	  stimulate	  β-­‐cell	  regeneration	  
are	  promising	  and	  raise	  hope	  for	  finding	  a	  cure	  for	  T1D	  [53].	  Besides	  the	  non-­‐obese	  diabetic	  
(NOD)	   mouse,	   a	   commonly	   used	   model	   for	   T1D	   in	   animals	   is	   the	   multiple	   low	   dose	  
streptozotocin	  (mldSTZ)	  model	  leading	  to	  pancreatic	  insulitis	  and	  β-­‐cell	  destruction	  [54].	  STZ	  
has	   structural	   similarity	   to	   glucose	   and	   enters	   the	   β-­‐cell	   via	   GLUT2.	   It	   activates	   the	   DNA	  
repair	   enzyme	   poly	   (ADP-­‐ribose)	   polymerase	   (PARP),	   which	   consumes	   the	   coenzyme	  




1.4 The	  renin-­‐angiotensin	  system	  (RAS)	  	  
	  
The	  renin-­‐angiotensin	  system	  (RAS)	  is	  originally	  known	  to	  play	  a	  crucial	  role	  in	  the	  regulation	  
of	  local	  and	  systemic	  blood	  flow,	  body	  fluid	  homeostasis	  and	  electrolyte	  balance.	  The	  system	  
consists	  of	  several	  components	  in	  various	  tissues,	  which	  act	  together	  in	  a	  complex	  enzymatic	  
setup	  [55].	  Renin,	  a	  kidney-­‐derived	  protease,	  is	  released	  by	  the	  juxtaglomerular	  apparatus	  to	  
cleave	   the	   hepatic	   precursor	   angiotensinogen.	   Subsequently,	   the	   inactive	   product	  
angiotensin	  I	  (Ang	  I)	   is	  hydrolyzed	  by	  the	  angiotensin-­‐converting-­‐enzyme	  (ACE)	  to	  form	  the	  
octapeptide	  angiotensin	  II	  (Ang	  II)	  that	  is	  highly	  active	  and	  the	  major	  effector	  of	  the	  RAS.	  Ang	  
II	   has	   several	   receptors	   but	  most	   of	   the	   known	   effects	   are	  mediated	   by	   two	   opposing	   G	  
protein-­‐coupled	  receptors:	  Ang	  II	  type	  1	  receptor	  (AT1R)	  and	  Ang	  II	  type	  2	  receptor	  (AT2R)	  
[56],	   [57].	   Binding	   of	   Ang	   II	   to	   the	   AT1R	   triggers	   vasoconstriction	   and	   the	   release	   of	  
aldosterone.	  The	  steroid	  hormone	  aldosterone	  is	  increasing	  sodium	  and	  water	  retention	  by	  
binding	   to	   the	  mineralocorticoid	   receptor	   and	   thereby	   increasing	   also	   blood	   pressure	   and	  
blood	  volume.	  However,	   there	  are	  many	  more	  known	  biological	  actions	  of	  Ang	   II	   including	  
the	   induction	   of	   ROS,	   fibrosis	   and	   proliferation.	   Additionally,	   there	   are	   other	   angiotensin	  
peptides	   including	  Ang	   III,	   Ang	   IV	   and	   the	   vasodilative	   angiotensin	   1-­‐7	   (Ang	   1-­‐7),	  which	   is	  
formed	  by	  the	  angiotensin-­‐converting	  enzyme	  2	  (ACE	  2)	  opposing	  the	  signal	  of	  Ang	   II	   [58],	  
[59].	  There	  are	  clinically	  used	  blockers	  of	  the	  RAS,	  which	  are	  either	  inhibiting	  AT1R	  (names	  
are	  ending	  on	  “-­‐sartan”)	  or	  inhibiting	  ACE	  (names	  are	  ending	  on	  “-­‐pril”).	  
	  
1.4.1	  Local	  tissue	  RAS	  	  	  
In	   the	  past	   few	  years,	   the	  existence	  of	   functional	   local	  RAS	   in	  various	  tissues	   including	  the	  
brain,	  kidney,	  heart,	   liver,	  skin,	  vasculature,	   immune	  cells,	  adipose	  tissue	  and	  the	  pancreas	  
[60],	   [61],	   [62],	   [63],	   [64],	   [65]	   has	   become	   increasingly	   clear.	   All	   of	   the	   local	   RAS	  
components	  are	  regulated	  within	  local	  tissues	  [66].	  Abadir	  et	  al.	  even	  identified	  a	  functional	  
mitochondrial	  angiotensin	  system	  [67].	  These	  discoveries	  have	  expanded	  the	  understanding	  




1.4.2	  Local	  pancreatic	  RAS	  	  	  
In	   1991,	   Chappell	   et	   al.	   discovered	   an	   intrinsic	   angiotensin	   system	   in	   the	   canine	   pancreas	  
[68].	  Further	  components	  of	  the	  RAS	  were	  also	  found	  in	  the	  pancreatic	  islets	  of	  rodents	  and	  
humans.	  Ang	  II	  was	  immunohistochemically	  localized	  in	  the	  mouse	  pancreas	  by	  Leung	  et	  al.	  
in	  1998	  [69]	  and	  a	  tissue	  RAS	  was	  discovered	  also	  in	  human	  islets	  by	  Tahmasebi	  et	  al.	  [70].	  
Furthermore,	  the	  expression	  of	  ACE	  and	  AT1R	  was	  shown	  in	  islets	  by	  immunohistochemistry	  
and	  quantitative	  PCR	   [71].	  AT1R	  have	  been	   reported	   to	   co-­‐localize	  with	  β-­‐cells	   in	   the	   islet	  
core,	  whereas	  AT2R	  mostly	  are	  found	  in	  the	  outer	  islet	  areas	  co-­‐localizing	  with	  δ-­‐cells.	  It	  was	  
proposed	   that	   this	   local	   pancreatic	   RAS	   system	   contributes	   to	   the	   regulation	   of	   islet	  


















Figure	  6.	  Local	  renin-­‐angiotensin	  system	  (RAS)	  in	  pancreatic	  islets.	  	  Angiotensinogen	  is	  produced	  mainly	  in	  the	  
areas	  of	  α-­‐cells,	  it	  is	  cleaved	  by	  renin	  to	  yield	  angiotensin	  I	  which	  is	  processed	  by	  ACE	  to	  obtain	  angiotensin	  II.	  
Acting	  via	   two	  receptors,	  angiotensin	  1	   receptors	   (co-­‐localizing	  with	  β-­‐cells)	  and	  angiotensin	  2	   receptors	   (co-­‐
localizing	  with	  δ-­‐cells),	  angiotensin	  II	  is	  influencing	  metabolic	  homeostasis	  by	  modulating	  insulin	  secretion	  and	  
inflammation.	   The	   enzyme	   ACE	   2	   is	   transforming	   angiotensin	   II	   to	   angiotensin	   (1-­‐7),	   which	   is	   opposing	   the	  
effects	  of	  angiotensin	  II	  via	  the	  Mas	  receptor.	  Inhibitors	  of	  the	  RAS,	  including	  angiotensin	  1	  receptor	  blockers	  
(“-­‐sartane”)	  and	  angiotensin	  converting	  enzyme	  blockers	  (“-­‐prile”),	  are	  clinically	  used.	  Adapted	  from	  [72].	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Several	   major	   islet	   RAS	   components	   are	   elevated	   under	   hyperglycemic	   conditions,	   even	  
independently	  of	  the	  presence	  of	  hypertension	  [73],	  [74],	  [75].	  
	  
	  
1.4.3	  RAS	  and	  the	  metabolic	  syndrome	  	  	  
In	  addition	  to	  the	  discovery	  of	  a	   local	  pancreatic	  RAS,	  a	  connection	  between	  RAS	  blockage	  
and	  improvement	  of	  metabolic	  diseases	  has	  been	  found.	  Hypertensive	  patients	  have	  a	  3.3-­‐
fold	  higher	  risk	  to	  develop	  diabetes	   [76].	  Vice	  versa,	   the	  metabolic	  syndrome	   is	  associated	  
with	   hypertension	   and	   activation	   of	   the	   RAS	   [77].	   Blocking	   of	   this	   RAS	   activation	   for	   anti-­‐
hypertensive	   treatment	  also	   reduced	   the	   incidence	  of	  metabolic	  disorders.	  Therefore,	  RAS	  
inhibition	  has	  been	  shown	  in	  a	  variety	  of	  clinical	  trials	  to	  delay	  new-­‐onset	  of	  T2D	  [78],	  [79],	  
[80],	   [81],	   [82].	   Searching	   for	   explanations,	   Ang	   II	  was	   found	   to	   inhibit	   glucose-­‐stimulated	  
insulin	   secretion	   [83],	   [84],	   to	   decrease	   islet	   blood	   flow	   [85],	   [86],	   [87]	   and	   to	   drive	   islet	  
fibrosis.	   Furthermore,	   Ang	   II	   can	   induce	   insulin	   resistance	   [88],	   [89]	   by	   decreasing	   blood	  
perfusion	   in	   insulin	   target	   tissues	   [90]	   and	   affecting	   skeletal	  muscle	   insulin	   signaling	   [91].	  
Several	  groups	  demonstrated	  the	  improvement	  of	  islet	  function,	  glucose	  tolerance	  and	  other	  
diet-­‐induced	  damages	  in	  animal	  models	  of	  T2D	  after	  RAS	  blockage	  [74],	  [92],	  [93],	  [94],	  [95],	  
[71],	   [96].	   Inhibition	  of	  the	  RAS	   in	   isolated	   islets	  of	  diabetic	  mice	  revealed	  direct	  effects	  of	  
Ang	  II	  on	  islets.	  This	  includes	  improvements	  of	  insulin	  secretion	  and	  a	  lowering	  of	  elevated	  
glucagon	  release	  [97],	  [84],	  [73].	  	  
However,	  the	  exact	  mechanisms	  of	  RAS	  blockage	  in	  vivo	  are	  only	  partly	  understood	  and	  it	  is	  
not	  clear	  whether	  normalization	  of	  the	  blood	  pressure	  or	  direct	  inhibition	  of	  local	  RAS	  leads	  
to	  the	  observed	  improvements	  of	  metabolic	  parameters.	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1.4.4	  Angiotensin	  II	  and	  inflammation	  	  	  
Although	  Ang	  II	  was	  classically	  known	  to	  regulate	  circulatory	  homeostasis,	  focus	  has	  recently	  
turned	   to	  Ang	   II	   as	   a	  powerful	   pro-­‐inflammatory	  mediator	   [98],	   [99],	   [100].	  Activated	  RAS	  
induces	  oxidative	  stress	  by	  stimulation	  of	  the	  NADPH	  oxidase	  [101]	  and	  may	  thereby	  trigger	  
inflammation.	  Ang	  II	  plays	  a	  role	  in	  inflammatory	  processes	  in	  the	  kidney	  [102]	  and	  induces	  
MCP-­‐1	  in	  pancreatic	  cancer	  cells	  [103]	  and	  the	  β-­‐cell	  line	  RIN	  [104].	  Ang	  II	  is	  involved	  in	  the	  
recruitment	   of	   macrophages	   in	   atherogenesis	   [105]	   and	   in	   the	   arterial	   expression	   of	   the	  
chemokines	   IL-­‐8	   and	  MCP-­‐1	   [106].	   In	   blood	  mononuclear	   cells,	   AT1R	   antagonists	   and	  ACE	  
inhibitors	  decrease	  the	  production	  of	  tumor	  necrosis	  factor	  (TNF),	  IL-­‐6	  and	  IL-­‐1,	  independent	  
of	  antihypertensive	  effects	  [107],	  whereas	  the	  anti-­‐inflammatory	  cytokine	  IL-­‐1Ra	  is	  increased	  
[108].	   In	   RAW	   264.7	   cells	   and	   various	   other	   cell	   types,	   Ang	   II	   induces	   the	   production	   of	  
cytokines	   and	   the	   transcription	   factors	   NF-­‐kB	   and	   AP-­‐1	   [109],	   [110],	   [111],	   [112].	  
Additionally,	  clinical	   trials	  revealed	  anti-­‐inflammatory	  effects	  of	  RAS	  blockage,	   indicated	  by	  
reduced	   levels	   of	   the	   proinflammatory	   markers	   TNFα,	   IL-­‐6	   and	   C-­‐reactive	   protein	   [113],	  
[114],	   as	   well	   as	   MCP-­‐1	   in	   the	   circulation	   of	   patients	   with	   cardiovascular	   diseases	   [115].	  
Similarly,	   blockage	   of	   the	   RAS	   in	   high-­‐fat	   diet	   or	   streptozotocin	   (STZ)-­‐induced	   diabetic	  
rodents	   lowers	  MCP-­‐1	   and	   interferon	   y	   (IFNy)	   levels	   in	   the	   circulation	   and	  MCP-­‐1	  mRNA	  
expression	  in	  the	  kidney	  [116],	  [94].	  In	  pancreatic	  islets	  of	  high-­‐fat	  diet	  fed	  mice	  treated	  with	  
















1.5 Sirtuins	  	  	  
The	   silent	   information	   regulator	   2	   (Sir2)	   gene	   was	   originally	   discovered	   in	   1979	   as	   an	  
enzymatic	   chromatin	   regulator	   in	   the	   yeast	   strain	   Saccharomyces	   cerevisiae	   [117].	   It	   was	  
found	   to	   increase	   yeast	   replicative	   lifespan	   and	   to	   slow	   down	   aging	   by	   supporting	   caloric	  
restriction-­‐induced	  processes	  [118],	  [119].	  Since	  principles	  of	  energy	  metabolism	  are	  similar	  
between	  species,	  structural	  and	  functional	  Sir2	  homologs	  were	  also	  found	  in	  bacteria,	  plants	  
and	   mammals,	   the	   so-­‐called	   sirtuins	   [120].	   Sirtuins	   are	   a	   conserved	   family	   of	   NAD+	  
dependent	  cellular	  stress	  sensors,	  which	  affect	  a	  wide	  range	  of	  biological	  pathways	  related	  
to	   aging,	   glucose	   and	   lipid	   metabolism,	   circadian	   rhythm	   and	   inflammation	   [121].	   They	  
couple	   metabolism	   with	   longevity	   since	   they	   induce	   the	   adaptation	   of	   numerous	   cellular	  
activities	   during	   stress	   and	   aging	   such	   as	   cell	   cycle	   control,	   differentiation,	   microtubule	  
organization	  and	  repair	  of	  DNA	  breaks	  [122].	  
The	  molecules	   are	   class	   III	   histone	   deacetylases	   (HDACs)	   that	   remove	   acetyl	   groups	   from	  
histones	   to	   facilitate	   compact	   chromatin	   structures	   and	   gene	   silencing,	   thereby	  
counteracting	  the	  effects	  of	  histone	  acetyltransferases.	  Despite	  their	  name,	  HDACs	  can	  also	  
deacetylate	   non-­‐histone	   proteins.	   There	   are	   other	   classes	   of	   HDACs,	   class	   I	   and	   class	   II,	  
which	  regulate	  transcriptional	  activity	  but	  have	  no	  sequence	  similarity	  to	  sirtuins	  [123].	  	  
Seven	  different	  mammalian	  sirtuins	   (SIRT1-­‐7)	  with	  different	   localizations	  and	   functions	  are	  
known.	   They	   are	   activated	   tissue	   dependently	   to	   mainly	   regulate	   metabolic	   homeostasis	  
during	   low	   energy	   availability,	   when	   the	   NAD+/NADH	   ratio	   rises,	   or	   through	   cellular	  
stressors.	  A	  conserved	  catalytic	  core	  that	  is	  able	  to	  bind	  NAD+	  and	  acetyl-­‐lysine	  substrate	  is	  
shared	   by	   all	   sirtuins.	   They	   act	   as	   deacetylases,	   ADP-­‐ribosyltransferases	   and	   have	   other	  
deacylase	   activites	   to	   modify	   the	   expression	   of	   target	   genes	   or	   directly	   interact	   with	  
proteins.	  In	  their	  function	  as	  protein	  deacetylases,	  sirtuins	  transfer	  acetyl	  groups	  from	  lysine	  
residues	   of	   target	   proteins	   to	   ADP-­‐ribose	   (Fig.	   7),	   leading	   to	   the	   generation	   of	   the	  
deacetylated	  end	  product,	  nicotinamide	  (Nam)	  and	  O-­‐acetyl-­‐ADP-­‐ribose.	  
	  
SIRT1	  and	  6	  are	  mainly	  nuclear	  sirtuins,	  whereas	  SIRT2	   is	   found	   in	   the	  cytoplasm,	  SIRT3,	  4	  
and	  5	  in	  the	  mitochondria	  and	  SIRT7	  in	  the	  nucleolus	  [124].	  SIRT2	  was	  shown	  to	  regulate	  cell	  
cycle	  control	  and	  microtubule	  organization	  [125],	  [126]	  and	  SIRT6	  has	  been	  implicated	  with	  
caloric	   restriction	  and	  genome	  protection	   [127].	   SIRT3	   is	   the	  most	   studied	  member	  of	   the	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mitochondrial	   sirtuins,	   which	   are	   suggested	   to	   regulate	  mitochondrial	   physiology,	   glucose	  
and	   lipid	   metabolism.	   SIRT3	   supports	   mitochondrial	   oxidation	   by	   suppressing	   glycolysis	  
[128],	  [129],	  [130],	  induces	  insulin	  sensitivity	  and	  is	  involved	  in	  the	  regulation	  and	  protection	  
of	  pancreatic	  β-­‐cells	  in	  mice	  and	  T2D	  patients	  [131].	  Contrary,	  SIRT4	  blunts	  insulin	  secretion	  
by	   inhibition	  of	  glutamate	  dehydrogenase	  and	  suppresses	   fatty	  acid	  oxidation	   [132].	  SIRT5	  
was	  reported	  to	  detoxify	  excess	  ammonia	  by	  controlling	  the	  urea	  cycle.	  SIRT6	  and	  SIRT7	  are	  
suggested	  to	  be	   involved	   in	  aging	  and	  tumorigenesis	   [133].	  However,	   little	   is	  known	  about	  
























Figure	  7.	  The	  enzymatic	  deacetylation	  activity	  of	  sirtuins.	  (a)	  Nicotinamide	  dinucleotide	  (NAD)	  acts	  as	  cofactor	  
in	  deacetylation	  processes	  of	  sirtuins.	   (b)	  An	   intermediate	  enzyme-­‐NAD-­‐acetylated	  substrate	  complex	   is	  built	  




1.5.1	  NAD+	  	  	  
In	   mitochondria,	   energy	   is	   stored	   in	   carrier	   molecules	   such	   as	   reduced	   nicotinamide	  
dinucleotide	  (NADH)	  and	  reduced	  flavin	  adenine	  dinucleotide	  (FADH2),	  which	  can	  be	  oxidized	  
to	  nicotinamide	  dinucleotide	  (NAD+)	  and	  flavin	  adenine	  dinucleotide	  (FAD+)	  to	  generate	  ATP	  
in	   the	  mitochondrial	  electron	   transport	   chain.	  The	  carrier	  molecules	  act	  as	  electron	  donor	  
and	  the	  generated	  energy	  is	  used	  to	  create	  a	  proton	  gradient	  that	  drives	  ATP	  synthesis.	  
	  
When	  carbohydrates	  or	   fatty	  acids	  are	  metabolized	   in	  catabolic	  cellular	  processes,	  NAD+	   is	  
reduced	   to	   NADH.	   By	   contrast,	   when	   energy	   levels	   in	   the	   cell	   are	   low,	   NAD+	   levels	   rise.	  
Furthermore,	  NAD+	   acts	   as	   cofactor	   for	  many	  dehydrogenases	   and	  deacetylases,	   including	  
sirtuins,	   in	   various	  metabolic	   processes.	  When	  NAD+	   levels	   increase,	   indicating	   starving	   or	  
stress	  conditions	   like	  exercise,	   sirtuins	  are	  activated	  tissue	  dependently	   to	   regulate	  energy	  
supply	  [135],	  [136],	  [137].	  Thus,	  NAD+	  is	  an	  important	  sensor	  and	  modulator	  of	  bioenergetic	  
states.	   In	   its	   function	   as	   cofactor	   for	   SIRT1	   and	   because	   rising	  NAD+	   levels	   activate	   SIRT1,	  
precursors	  of	  NAD+	  are	  used	  as	  SIRT1	  activators.	  	  
	  
NAD+	   can	   be	   synthesized	   de	   novo	   or	   by	   recycling	   from	   nicotinamide	   (Nam),	   which	   is	  
generated	  in	  NAD+	  dependent	  reactions	  (Fig.	  8)	  and	  may	  act	  as	  feedback	   inhibitor	  of	  NAD+	  
and	   SIRT1	   [138].	   The	   rate-­‐limiting	   enzyme	   in	   the	   NAD+	   biosynthesis	   is	   nicotinamide	  
phosphoribosyltransferase	   (NAMPT)	   that	   induces	   the	   conversion	   of	   Nam	   to	   nicotinamide	  
mononucleotide	  (NMN),	  which	  in	  turn	  is	  converted	  to	  NAD+	  by	  the	  NMN	  adenylyltransferase	  
(NMNAT)	  [139].	  The	  vitamin	  nicotinamide	  ribose	  (NR)	  is	  a	  natural	  precursor	  of	  NAD+,	  which	  
can	  be	  converted	  to	  NMN	  by	  the	  nicotinamide	  riboside	  kinase	  (NRK).	  NAD+	  biosynthesis	  was	  
impaired	   in	   obese,	   diabetic	   and	   aged	   animal	  models	   and	   diet-­‐	   and	   inflammation-­‐induced	  

























Figure	   8.	   Recycling	   route	   of	   NAD	   biosynthesis	   in	   mammals.	  NAD	   is	   used	   as	   cofactor	   by	   sirtuins	   and	   other	  
enzymes	  leading	  to	  the	  release	  of	  Nam.	  In	  recycling	  steps,	  Nam	  is	  converted	  to	  NMN	  by	  NAMPT	  and	  NMN	  is	  
converted	  back	   to	  NAD	  by	  NMNAT.	  The	  NMN	  pool	   can	   further	  be	   filled	  by	  NR	   that	   is	   converted	   to	  NMN	  via	  
NRK.	   NAD:	   nicotinamide	   dinucleotide,	   NMN:	   nicotinamide	   mononucleotide,	   Nam:	   nicotinamide,	   NR:	  
nicotinamide	   riboside,	   NAMPT:	   nicotinamide	   phosphoribosyltransferase.	   NMNAT:	   NMN	   adenylyltransferase,	  





1.5.2	  Sirtuin	  1	  	  	  
Sirtuin	   1	   (SIRT1)	   is	   an	   NAD+	   dependent	   class	   III	   histone	   and	   protein	   deacetylase,	   which	  
belongs	  to	  the	  highly	  conserved	  sirtuin	  family	  and	  has	  tissue	  specifically	  various	  functions.	  It	  
is	   the	   most	   studied	   sirtuin	   since	   it	   has	   attracted	   a	   lot	   of	   interest	   as	   the	   first	   identified	  
mammalian	  homolog	  of	  Sir2,	  which	  was	  shown	  to	  influence	  longevity	  in	  yeast	  [144].	  In	  adult	  
tissues,	  SIRT1	  is	  expressed	  ubiquitously;	  several	  studies	  showed	  its	  expression	  in	  liver,	  brain,	  
adipose	  tissue,	  lung,	  spleen,	  muscle,	  thymus,	  pancreas	  and	  less	  in	  heart	  and	  the	  kidney.	  The	  
highest	  expression	  levels	  were	  found	  in	  immune	  cells,	  especially	  B-­‐cells,	  and	  the	  uterus	  (Fig.	  
9).	  	  
The	  human	  SIRT1	  protein	   consists	  of	  747	  amino	  acids	  and	  has	  a	  molecular	  weight	  of	  81.7	  
kDa.	  It	  is	  mainly	  located	  in	  the	  nucleus	  where	  it	  acts	  as	  transcriptional	  repressor	  via	  histone	  
deacetylation	   [145]	   but	   also	   many	   cytosolic	   functions	   are	   known	   [124].	   The	   subcellular	  























Figure	  9.	  Relative	  mRNA	  expression	  levels	  of	  Sirt1	  
in	   humans.	   Sirt1	   is	   expressed	   ubiquitously	   in	  
humans	   but	   highest	   mRNA	   expression	   levels	   are	  
found	   in	   the	   uterus	   and	   in	   blood	   cells	   such	   as	   B-­‐









The	  functions	  of	  SIRT1	  are	  manifold;	  it	  mainly	  plays	  a	  role	  in	  adaptation	  to	  stress	  responses	  
by	   modulating	   metabolic	   homeostasis,	   circadian	   clock,	   immunity	   and	   more	   general	  
epigenetics.	   SIRT1	   has	   been	   linked	   to	   several	   age-­‐related	   diseases	   including	   cancer	   [146],	  
Alzheimer’s	  disease	  and	  atherosclerosis.	  	  
There	  are	  more	   than	  80	  known	  protein	  substrates	   (Fig.	  10)	   including	   forkhead	  box	  class	  O	  
(Foxo),	   peroxisome	   proliferator	   activated	   receptor	   γ	   (PPARγ),	   liver	   X	   receptor	   (LXR),	  
peroxisome	  proliferator	  activated	  receptor	  γ	  coactivator	  1α	  (PGC-­‐1α),	  uncoupling	  protein	  2	  
27	  	  
(Ucp2),	  forkhead	  box	  P3	  (Foxp3),	  nuclear	  factor-­‐kappa	  B	  (NF-­‐κB),	  hypoxia-­‐induced	  factor	  1α	  
(HIF-­‐1α),	  c-­‐Jun	  and	  c-­‐Myc	  that	  are	  components	  of	  the	  transcription	  factor	  complex	  activator	  









































During	   energy	   limitations,	   SIRT1	   levels	   are	   modulated	   tissue	   dependently.	   In	   mouse	  
pancreatic	  islets,	  SIRT1	  is	  suggested	  to	  exhibit	  decreased	  activity	  along	  with	  upregulation	  of	  
Ucp2	   leading	   to	   reduced	   ATP	   production	   and	   insulin	   secretion	   upon	   starvation	   [150].	   In	  
other	   tissues	   including	  brain,	  heart,	  muscle,	  white	  adipose	   tissue	   (WAT)	  and	  kidney,	   SIRT1	  
expression	  and	  promotor	  activity	  is	  upregulated	  during	  starving	  conditions	  in	  a	  Foxo3a	  and	  
p53	  dependent	  way	  [151],	  [152].	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In	  the	  liver,	  data	  about	  SIRT1	  expression	  and	  activity	  are	  somehow	  unclear	  [136].	  During	  late	  
stage	   of	   fasting,	   SIRT1-­‐mediated	   activation	   of	   the	   transcription	   factor	   Foxo1,	   inhibition	   of	  
STAT3	  and	  deacetylation	  of	  the	  transcriptional	  coactivator	  PGC-­‐1α	  induces	  gluconeogenesis	  
and	  lowers	  glycolytic	  gene	  levels	  [153],	  [154],	  [155],	  [156].	  
	  
Many	   endogenous	   activators	   and	   inhibitors	   of	   SIRT1	   are	   known	   (Fig.	   10)	   such	   as	   active	  
regulator	  of	  SIRT1	  (AROS),	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  or	  deleted	  in	  breast	  cancer	  
1	   (DBC1).	   The	   most	   investigated	   naturally	   occurring	   activator	   is	   the	   polyphenol	   and	  
antioxidant	  resveratrol	  (RSV)	  whose	  SIRT1	  specificity	  is	  still	  matter	  of	  debate.	  RSV	  has	  been	  
linked	   to	   improvements	  of	  mitochondrial	   function	  by	  activation	  of	  AMPK	  and	  PGC-­‐1α	   in	  a	  
SIRT1	   dependent	   manner	   in	   vitro	   and	   in	   vivo	   [157],	   [158]	   and	   to	   the	   prevention	   and	  
improvement	  of	  T1D	  or	  T2D	  in	  mice	  [159],	  [160],	  [161].	  However,	  oral	  RSV	  administration	  in	  
a	  recent	  clinical	  study	  did	  not	  affect	  metabolic	  conditions	  in	  obese	  patients	  [162].	  	  
	  
Small	   molecule	   activators	   of	   SIRT1	   were	   developed	   several	   years	   ago	   and	   were	   used	   in	  
numerous	  studies	  showing	  specific	  activation	  of	  SIRT1	  and	   improvements	   in	  mitochondrial	  
and	  metabolic	  functions	  in	  animal	  models	  of	  T2D	  and	  in	  in	  vitro	  settings	  [163],	  [164],	  [160],	  
[165].	   However,	   safety,	   specificity	   and	   function	   of	   those	   chemical	   activators	   have	   been	  
widely	   debated	   since	   the	   activator	   SRT1720	   caused	   unexpected	   death	   cases	   and	   failed	   to	  













1.5.3	  Role	  of	  Sirtuin	  1	  in	  diabetes	  	  	  
Various	   studies	   using	   cell	   and	   transgenic	   mouse	   models	   have	   described	   SIRT1	   as	   an	  
important	   beneficial	  metabolic	   regulator	   and	   key	   player	   in	   glucose	   sensing	   but	   the	   SIRT1	  
literature	  is	  full	  of	  contradictory	  findings.	  	  
	  
Via	  inhibition	  of	  the	  uncoupler	  Ucp2,	  which	  is	  suppressing	  ATP	  generation	  in	  β-­‐cells,	  insulin	  
secretion	   is	   enhanced	   in	   mice	   overexpressing	   SIRT1	   exclusively	   in	   β-­‐cells,	   or	   in	   adipose	  
tissue,	   brain	   and	  mouse	   embryonic	   fibroblasts	   [167],	   [168].	   Glucose	   tolerance	   and	   overall	  
metabolic	   conditions	   are	   improved	   in	   those	   mice.	   SIRT1	   overexpression	   was	   reported	   to	  
enhance	   energy	   efficiency	   and	   to	   prevent	   diabetes	   in	   mice	   [169].	   Furthermore,	   specific	  
deletion	   of	   SIRT1	   in	   β-­‐cells	   of	   mice	   leads	   to	   impaired	   insulin	   secretion	   and	   defects	   in	  
mitochondrial	  function	  [170].	  However,	  the	  SIRT1	  target	  protein	  PGC-­‐1α,	  which	  is	  suggested	  
to	   increase	   mitochondrial	   biogenesis,	   is	   elevated	   in	   islets	   of	   diabetic	   animal	   models	   and	  
overexpression	  of	  PGC-­‐1α	  in	  islets	  can	  lead	  to	  β-­‐cell	  dysfunction	  [171].	  	  
	  
SIRT1	   was	   shown	   to	   be	   a	   central	   regulator	   in	   adaptation	   to	   diet-­‐induced	   metabolic	  
dysfunctions	  [172],	  [173].	  Transgenic	  mice	  lacking	  SIRT1	  deacetylase	  activity	  are	  not	  able	  to	  
cope	  with	  high-­‐fat	  diet,	  accumulate	  hepatic	  lipids	  and	  are	  insulin	  resistant	  [174].	  It	  has	  been	  
shown	   that	   activation	   of	   SIRT1	   by	   NR,	   a	   precursor	   of	   NAD+,	   can	   protect	   HFD-­‐induced	  
metabolic	   damages	   through	   increased	   oxidative	   metabolism	   and	   mitochondrial	   function	  
[175].	  Interestingly,	  SIRT1	  null	  mice,	  which	  exhibit	  developmental	  defects	  and	  sterility,	  have	  
lower	  glucose	  and	  insulin	  levels	  and	  improved	  glucose	  tolerance	  [176],	  [150],	  [177].	  
	  
Moreover,	   SIRT1	   activation	   was	   reported	   to	   modulate	   insulin	   sensitivity	   in	   multiple	   and	  
sometimes	   unclear	   ways.	   In	   the	   skeletal	   muscle,	   it	   has	   been	   suggested	   that	   SIRT1	  
deacetylates	   PGC-­‐1α	   leading	   to	   peroxisome	   proliferator	   activated	   receptor	   α	   (PPARα)	  
activation,	   increased	   fatty	   acid	   oxidation	   and	   improved	   insulin	   sensitization	   [178],	   [179].	  
However,	  overexpression	  of	  SIRT1	  in	  rodent	  muscle	  was	  reported	  to	  downregulate	  PGC-­‐1α	  
protein	   expression	   and	   thereby	   inhibits	   mitochondrial	   biogenesis	   [180],	   despite	   the	  
characterized	   beneficial	   role	   of	   SIRT1	   in	   mitochondrial	   regulation	   [181],	   [154],	   [153].	  
Furthermore,	   HFD-­‐induced	   impairment	   of	   skeletal	   muscle	   insulin	   sensitivity	   could	   not	   be	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prevented	   by	   SIRT1	   overexpression	   [182].	   It	   was	   demonstrated	   in	   obese	   mice	   that	   the	  
positive	   effects	   of	   PGC-­‐1α	   overexpression	   on	   insulin	   sensitivity	   only	   occur	   in	   combination	  
with	  exercise	  [183].	  
In	  the	   liver,	  overexpression	  of	  SIRT1	  reduced	   insulin	  resistance	   in	  a	  study	  of	  Li	  et	  al.	   [184],	  
whereas	  knockdown	  of	  hepatic	  SIRT1	  in	  the	  context	  of	  T2D	  was	  reported	  to	  be	  beneficial	  as	  
indicated	   by	   decreased	   liver	   glucose	   production	   and	   increased	   whole	   body	   insulin	  
responsiveness	   in	  a	  rat	  model	  [185].	  Furthermore,	  hepatic	   insulin	  sensitivity	   is	   improved	  in	  
PGC1α	  deficient	  mice	  [186].	  	  
In	   WAT,	   SIRT1	   inhibits	   PPARγ	   and	   thereby	   suppresses	   adipogenesis	   and	   fat	   storage	   and	  
promotes	  lipolysis	  in	  response	  to	  nutrient	  restriction	  [187].	  Most	  recently,	  it	  was	  shown	  that	  
knock-­‐out	   of	   SIRT1	   in	   adipocytes	   promotes	   PPARγ	   activity	   and	   thereby	   increases	   glucose	  
tolerance	  and	  insulin	  sensitivity	  during	  chronic	  HFD	  [188].	  Brown	  adipocyte	  function	  can	  be	  
potentiated	  by	  SIRT1	  leading	  to	  improved	  glucose	  tolerance	  and	  insulin	  sensitivity	  [189].	  
	  
Oxidative	  stress	   is	  an	  essential	   factor	   in	   the	  pathogenesis	  of	  diabetes.	  Prolonged	  exposure	  
induces	   chronic	   inflammation	  by	  activation	  of	   transcription	   factors	   such	  as	  NF-­‐κB,	  AP-­‐1	  or	  
HIF-­‐1α	  leading	  to	  the	  expression	  of	  various	  pro-­‐inflammatory	  genes	  [190],	  [191].	  Pancreatic	  
β-­‐cells	  are	  protected	  from	  oxidative	  stress	  and	  the	  induction	  of	  pro-­‐inflammatory	  cytokines	  
via	  SIRT1-­‐mediated	  deacetylation	  of	  Foxo	  [192],	  [193]	  and	  NF-­‐κB	  as	  demonstrated	  in	  isolated	  
rat	  islets	  [194].	  SIRT1	  is	  able	  to	  induce	  the	  production	  of	  antioxidant	  enzymes	  leading	  to	  the	  
inhibition	  of	  HFD-­‐induced	  NF-­‐κB	  activation	  [172].	  Also	   in	  other	  tissues	  such	  as	  kidney	  cells,	  
adipocytes	   or	   macrophages,	   SIRT1	   protects	   from	   inflammatory	   processes	   and	   improves	  
insulin	   signaling	   [195],	   [196],	   [197].	   Nevertheless,	   overexpression	   of	   SIRT1	   was	   shown	   to	  
enhance	   TNFα-­‐induced	   apoptosis	   [198]	   and	   SIRT1	   inhibition	   improved	   hyperglycemia	   in	  
diabetic	  rats,	  despite	  elevation	  of	   inflammation	  [199].	  Altogether,	  apparently	  contradictory	  
effects	   reported	   in	   the	   literature	   point	   to	   tissue-­‐	   and	   context-­‐specific	   effects	   of	   SIRT1	  






Additional	   findings	   support	   the	   ambivalent	   role	   of	   SIRT1	   in	   the	   development	   of	   diabetes.	  
Histone	  deacetylase	  (HDAC)	  inhibitors	  are	  emerging	  as	  new	  modulators	  of	  glucose	  and	  fatty	  
acid	  metabolism	  in	  the	  treatment	  of	  diabetes.	  HDAC1	  and	  2	  inhibitors	  have	  beneficial	  effects	  
on	   insulin	   sensitivity	   and	   β-­‐cell	   function,	   partly	   via	   enhancement	   of	   AMPK	   activity	   [200].	  
HDAC3	   inhibitors	   were	   reported	   to	   increase	   PPARγ	   function	   with	   effects	   similar	   to	  
thiazolidinediones	   used	   in	   diabetes	   treatment,	   and	   to	   inhibit	   inflammation	   in	   obese	  mice	  
[201],	  [202];	  however,	  also	  negative	  metabolic	  effects	  were	  described	  [203].	  Thus,	  inhibiting	  
the	  function	  of	  SIRT1	  as	  a	  histone	  deacetylase	  may	  also	  be	  beneficial	  in	  metabolic	  diseases.	  
	  
A	  growing	  body	  of	  evidence	  points	  to	  a	  central	  role	  of	  SIRT1	  in	  the	  development	  of	  T1D.	  In	  
the	  mldSTZ	  model,	  a	  T1D	  model	  in	  animals,	  it	  is	  proposed	  that	  NAD+	  is	  depleted	  by	  activation	  
of	  PARP	  and	  DNA	  repair,	  leading	  to	  β-­‐cell	  death.	  In	  line	  with	  that,	  resistance	  to	  STZ-­‐induced	  
diabetes	  has	  been	  shown	  in	  PARP-­‐1	  knock-­‐out	  mice	  [204],	  [205].	  Several	  studies	  have	  proven	  
that	  nicotinamide,	  a	  precursor	  of	  NAD+	  and	  at	  the	  same	  time	  end-­‐product	  inhibitor	  of	  SIRT1,	  
protects	   against	   STZ-­‐induced	   β-­‐cell	   damage	   and	   diabetes	   in	   rodents,	   T1D	   patients	   and	   in	  
individuals	  with	   high	   risk	   [206],	   [207],	   [208],	   [209],	   [210]	   but	   it	   failed	   to	   prevent	   T1D	   in	   a	  
large	  clinical	  trial	  [211].	  It	  is	  still	  matter	  of	  debate	  if	  the	  inhibition	  of	  SIRT1	  or	  PARP	  inhibition	  
along	  with	   re-­‐filling	  of	   the	  NAD+	   stocks	   is	   predominant	   in	   causing	   the	  nicotinamide-­‐driven	  
effects	  [212],	  [213].	  However,	  a	  nicotinamide	  derivative,	  isonicotinamide,	  which	  antagonizes	  
nicotinamide-­‐induced	  SIRT1	  inhibition	  protects	  against	  STZ-­‐induced	  hyperglycemia	  and	  β-­‐cell	  
damage	   [214].	   Furthermore,	   SIRT1	   null	   mice	   are	   more	   prone	   to	   mldSTZ-­‐induced	  
autoimmune	   diabetes	   [215],	   whereas	   mice	   overexpressing	   SIRT1	   in	   the	   β-­‐cells	   have	  










1.5.4	  Sirtuin	  1	  and	  the	  immune	  system	  	  	  
SIRT1	  has	  mainly	  been	  linked	  to	  metabolism	  but	  it	  is	  increasingly	  recognized	  as	  regulator	  of	  
immune	  responses	  and	   inflammation.	  SIRT1	   is	  highly	  expressed	   in	  dendritic	  cells,	  activated	  
and	  anergic	  T-­‐cells	  and	  various	  other	  immune	  cells	  [217],	  [218].	  Several	  studies	  have	  focused	  
on	  the	  role	  of	  SIRT1	  in	  inflammation	  and	  the	  activation	  and	  differentiation	  of	  T-­‐cells	  but	  the	  
mechanisms	  are	  still	  poorly	  understood.	  
	  
Knock-­‐out	   animal	   models	   lacking	   SIRT1	   in	   myeloid	   cells,	   CD4+	   T-­‐cells	   or	   dendritic	   cells	  
revealed	   the	   central	   role	   of	   SIRT1	   in	   the	  modulation	   of	   both	   the	   innate	   and	   the	   adaptive	  
immune	   system.	  Myeloid-­‐specific	   knock-­‐out	   of	   SIRT1	   led	   to	   hyperacetylation	  of	   the	  NF-­‐kB	  
subunit	   p65	   and	   thereby	   caused	   the	   induction	   of	   proinflammatory	   genes	   and	   insulin	  
resistance	   in	  animals	   fed	  a	  HFD	   [219].	  Consistent	  with	   these	  data,	   activation	  of	   SIRT1	  was	  
shown	  to	  inhibit	  inflammation	  via	  deacetylation	  of	  the	  transcription	  factors	  AP-­‐1	  and	  NF-­‐kB	  
at	   lysine	   residues	   [220],	   [198].	   Further	   supporting,	   SIRT1	   knock-­‐out	   in	   peritoneal	  
macrophages	   in	  vitro	   increased	  LPS-­‐stimulated	  inflammation	  and	  SIRT1	  activation	  in	  Zucker	  
fatty	   rats	   improved	   glucose	   tolerance	   and	   insulin	   sensitivity	   by	   decreasing	   tissue	  
inflammation	  [196].	  Deletion	  of	  SIRT1	  in	  dendritic	  cells	  exhibited	  a	  regulatory	  role	  of	  SIRT1	  in	  
Th1	   and	   Treg	   differentiation	   through	   the	   modulation	   of	   IL-­‐12	   and	   TGF-­‐β	   expression,	  
respectively	  [217].	  However,	  Sirt1-­‐null	  dendritic	  cells	  have	  enhanced	  ability	  to	  produce	  IL-­‐27	  
and	   IFN-­‐β	   leading	   to	   the	   inhibition	   of	   Th17	   differentiation	   [221].	   Interestingly,	   SIRT1	  
contributes	   to	   immunometabolic	   reprogramming	   during	   acute	   inflammation	   by	   increasing	  
fatty	  acid	  oxidation	  and	  thereby	  supporting	  adaptation	  responses	  [222].	  
	  
SIRT1	   is	  able	   to	   inhibit	   transcription	  and	  production	  of	   IL-­‐2,	  which	   is	  a	  main	   factor	   for	   the	  
development	   of	   functional	   effector	   T-­‐cells	   and	  which	   is	   able	   to	   reverse	   T-­‐cell	   anergy	   and	  
tolerance	   [223],	   [218],	   [224].	   In	   parallel,	   IL-­‐2	   is	   a	   central	   regulator	   for	   the	   suppressive	  
function	   of	   Tregs	   and	   therefore	   immune	   tolerance	   [225],	   [21].	   In	   former	   studies,	  
cyclosporine	   was	   used	   as	   immunotherapeutical	   treatment	   against	   IL-­‐2-­‐mediated	  
autoreactive	  T-­‐cell	  activation	  in	  T1D	  patients	  but	  the	  beneficial	  effects	  were	  only	  temporary	  
[226].	  Interestingly,	  the	  lack	  of	  IL-­‐2	  has	  been	  shown	  to	  play	  a	  crucial	  role	  in	  the	  development	  
of	  T1D	  [227]	  and	  therapies	  with	  low-­‐dose	  IL-­‐2	  treatment	  to	  boost	  or	  restore	  Tregs	  protected	  
33	  	  
from	  the	  development	  of	  T1D	  in	  NOD	  mice	  and	  in	  clinical	  studies	  [228],	  [229].	  β-­‐cell	  specific	  
IL-­‐2	  therapy	  increased	  the	  islet	  Tregs	  pool	  and	  thereby	  prevented	  T1D	  in	  NOD	  mice	  [230].	  In	  
other	   autoimmune	   conditions,	   such	   as	   Hepatitis	   C	   virus-­‐induced	   vasculitis,	   low-­‐dose	   IL-­‐2	  
treatment	  in	  a	  clinical	  trial	  led	  to	  Treg	  recovery	  and	  clinical	  improvements	  [231].	  	  
	  
The	  transcription	  factor	  Foxp3,	  which	   is	  crucial	   for	  the	  development	  and	  function	  of	  Tregs,	  
was	   deacetylated	   by	   SIRT1	   leading	   to	   proteasomal	   degradation	   [23],	  whereas	   blockage	   of	  
SIRT1	  improved	  Treg	  suppressive	  function	  in	  vitro	  and	  in	  vivo	  [232].	  It	  has	  been	  convincingly	  
shown	   in	   a	   recent	   study	   that	   SIRT1	   deacetylates	   the	   transcription	   factor	   retinoic	   acid	  
receptor-­‐related	  orphan	  receptor-­‐γ	  t	  (RORγt),	  which	  is	  regulating	  the	  differentiation	  of	  Th17	  
effector	   cells,	   and	   thereby	   enhances	   the	   Th17/Treg	   ratio	   and	   the	   susceptibility	   to	  
autoimmune	  diseases	  [233].	  	  
	  
Additionally,	  inhibition	  of	  HDACs	  in	  autoimmune	  diseases	  including	  colitis	  was	  suggested	  to	  
improve	   Treg	   function	   [234],	   [235].	   There	   is	   evidence	   that	   also	   the	   deacetylase	   SIRT1	  
influences	  the	  development	  of	  colitis.	  Intestinal	  deletion	  of	  SIRT1	  protected	  from	  colitis	  and	  
colitis-­‐induced	   colorectal	   cancer	   by	   re-­‐arranging	   the	   gut	   microbiome	   [236]	   and	  
pharmacological	  inhibition	  of	  SIRT1	  increased	  Treg	  formation	  and	  attenuated	  colitis	  [237].	  	  
In	   contrast,	   whole	   body	   Sirt1	   -­‐/-­‐	   mice	   develop	   an	   autoimmune-­‐like	   phenotype	   with	  
increased	   anti-­‐nuclear	   antigen	   antibodies	   [238];	   however,	   they	   are	   developmentally	  
affected,	  infertile	  and	  have	  a	  small	  body	  size.	  Most	  recently,	  SIRT1	  was	  also	  associated	  with	  
the	   regulation	   of	   autoimmune	   regulator	   (AIRE)-­‐mediated	   immunological	   tolerance	   in	   the	  
thymus	  [239].	  
Despite	   the	   conflicting	   data,	   all	   of	   this	   is	   indicative	   for	   an	   essential	   role	   of	   SIRT1	   in	   T-­‐cell	  








1.5.5	  Sirtuin	  1	  mutation	  L107P	  in	  familial	  type	  1	  diabetes	  	  
	  
Recently,	  a	  SIRT1	  point	  mutation	  (L107P)	  was	  described	  in	  a	  family	  of	  Ashkenazy	  Jews	  as	  a	  
first	  monogenic	  form	  of	  diabetes	  by	  our	  group,	  among	  others	  [215].	  As	  shown	  in	  Figure	  11,	  
the	  thymidine	  to	  cytosine	  point	  mutation	  in	  exon	  1	  of	  the	  Sirt1	  gene	  leads	  to	  an	  exchange	  of	  
the	   amino	   acid	   leucine	   to	   proline	   at	   residue	   107	   (L107P).	   Five	   members	   of	   this	   family	  
carrying	  one	  mutated	  allele	  have	  autoimmune	  diseases;	  four	  have	  type	  1	  diabetes	  and	  one	  
has	  ulcerative	  colitis.	  The	  mutation	  is	  located	  outside	  of	  the	  catalytic	  core	  but	  in	  the	  amino	  
terminal	  region,	  which	   is	   involved	   in	  protein-­‐protein	   interactions.	  However,	  the	  top	  known	  
SIRT1	  substrates	  were	  not	  influenced	  in	  interaction	  assays.	  Cultured	  myotubes	  of	  the	  index	  
patient	   displayed	   reduced	   glucose	   uptake	   in	   response	   to	   insulin	   and	   the	   number	   of	  
regulatory	  T-­‐cells	  was	  decreased	  in	  the	  blood	  of	  the	  patient,	  compared	  to	  healthy	  controls	  
and	   other	   type	   1	   diabetes	   patients.	   Based	   on	   these	   findings,	   we	   generated	   INS-­‐1E	   cells	  
ectopically	   overexpressing	   the	   mutated	   human	   SIRT1	   and	   knock-­‐in	   mice	   carrying	   the	  
corresponding	  mouse	  mutation	  to	  further	  understand	  the	  role	  of	  SIRT1	  in	  the	  development	  
of	  autoimmune	  diseases	  including	  T1D	  and	  colitis.	  
	  
	  
Figure	   11.	   Characterization	   of	   the	   SIRT1	  mutation	   L107P	   associated	   with	   diabetes	   and	   colitis.	   Sirt1	   gene	  
structure	   with	   thymidine	   to	   cytosine	   point	   mutation	   (red	   arrow)	   and	   predicted	   protein	   structure	   with	   the	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2	  Aim	  of	  the	  study	  	  
	  
In	  this	  study,	  we	  investigated	  the	  modulatory	  effects	  of	  angiotensin	  II	  (Ang	  II)	  and	  sirtuin	  1	  
(SIRT1)	  on	  inflammation	  and	  the	  immune	  system	  in	  the	  development	  of	  diabetes.	  The	  thesis	  
is	  divided	  in	  three	  parts.	  
	  
The	   first	   published	   part	   focuses	   on	   the	   effects	   of	   Ang	   II	   on	   islet	   inflammation	   and	   β-­‐cell	  
dysfunction	   in	   the	   context	   of	   T2D.	   Much	   research	   was	   done	   on	   the	   role	   of	   the	   renin-­‐
angiotensin	   system	   (RAS)	   in	   the	   context	   of	   hypertension.	   Further,	   it	  was	   shown	   in	   clinical	  
studies	  and	  animal	  models	  that	  RAS	  inhibition	  has	  protective	  effects	   in	  the	  context	  of	  T2D.	  
However,	   little	   is	   known	   about	   the	   direct	   effects	   of	   Ang	   II	   on	   pancreatic	   islets	   and	   the	  
responsible	  mechanisms	  in	  the	  pathogenesis	  of	  diabetes.	  We	  specifically	  wanted	  to	  examine	  
inflammatory	   pathways	   underlying	   the	   effects	   of	   Ang	   II	   in	   the	   development	   of	   T2D,	  
independently	  of	  vasoconstriction.	  	  
	  
Second	  and	  third	  part	  of	  this	  work	  describe	  the	  immunomodulatory	  functions	  of	  SIRT1	  in	  the	  
context	   of	   diabetes,	   primarily	   autoimmune	   T1D.	   Commonly,	   SIRT1	   is	   implicated	   with	  
regulations	   of	   metabolism	   and	   longevity	   but	   the	   involvement	   in	   autoimmunity	   and	  
inflammation	  is	  less	  investigated.	  A	  family	  carrying	  a	  point	  mutation	  in	  the	  Sirt1	  gene	  (L107P)	  
was	  associated	  with	  autoimmune	  diseases,	  including	  T1D	  and	  ulcerative	  colitis.	  We	  wanted	  
to	   translate	   the	  phenotype	  of	   the	  patients	   to	   an	   INS-­‐1E	   cell	  model	   and	   a	   knock-­‐in	  mouse	  
model	  carrying	  the	  corresponding	  SIRT1	  mouse	  mutation	  (L102P)	  to	  further	  understand	  the	  
underlying	   mechanisms	   of	   this	   mutation	   and	   the	   general	   link	   between	   SIRT1,	   glucose	  
metabolism	  and	   immune	   responses.	   Finally,	  we	  used	   inducible	  β-­‐cell	   specific	   SIRT1	  knock-­‐
out	  mice	   to	   test	   the	   impact	  of	  SIRT1	  on	  β-­‐cell	  metabolism	  and	  diabetes,	  without	  affecting	  
the	  development	  of	  the	  mice.	  Based	  on	  the	  literature,	  little	  is	  known	  about	  the	  connection	  
of	  SIRT1	  modulation	  and	  the	  development	  of	  T1D.	  The	  aim	  of	  this	  part	  was	  to	  characterize	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3.2	  Unpublished	  data	  	  	  	  
3.2.1	  Angiotensin	  II-­‐induced	  glucose	  intolerance	  is	  independent	  of	  GLP-­‐1	  in	  vivo	  	  	  
Since	   the	   strong	   in	   vivo	   inhibitory	   effects	   of	   chronic	   Ang	   II	   treatment	   on	   insulin	   secretion	  
were	   lost	   ex	   vivo	   after	   islet	   isolation,	   we	   speculated	   that	   the	   inhibition	   of	   gut-­‐derived	  
incretins,	  which	  predominantly	  boost	   insulin	  secretion	  after	  food	  intake,	  might	  be	  involved	  
in	  the	  Ang	  II	  effects	  in	  vivo	  but	  not	  ex	  vivo.	  Therefore,	  we	  treated	  mice	  with	  hydralazine	  (250	  
mg/l)	   in	   the	   drinking	  water	   to	   avoid	   vasoconstriction	   and	  with	   100	  µg	  Ang	   II	   for	   4-­‐8	   days	  
intraperitoneally	  every	  day.	  At	  the	  last	  treatment	  day	  we	  performed	  oral	  glucose	  tolerance	  
tests	  to	  stimulate	  the	  GLP-­‐1	  secretion	  and	  to	  test	  the	  hypothesis	  of	  Ang	  II	  being	  an	  incretin	  
inhibitor.	  Glucose	  or	  saline	  were	  injected	  at	  time	  point	  0	  and	  blood	  glucose	  was	  measured	  at	  
time	  points	  0,	  10	  and	  30	  min.	  Blood	  for	  measuring	  active	  GLP-­‐1	  in	  the	  plasma	  was	  taken	  at	  
time	   point	   10	  min	   and	  was	   supplemented	  with	   EDTA	   and	   100	   μM	   dipeptidylpeptidase-­‐IV	  
inhibitor	  (Ile-­‐Pro-­‐Ile,	  Sigma,	  422	  Switzerland)	  to	  avoid	  rapid	  GLP-­‐1	  degradation.	  Chronic	  Ang	  
II	  treatment	  compared	  to	  the	  saline	  treated	  group	  impairs	  glucose	  tolerance	  when	  glucose	  is	  
given	  orally	   (Fig.	   12A	   solid	   lines);	   however,	   plasma	   insulin	   levels	   at	   time	  point	   10	  min	   are	  
unchanged	   (data	   not	   shown).	   Active	  GLP-­‐1	   levels	   are	   elevated	   at	   time	   point	   10	  min	   after	  
orally	  administered	  glucose	  but	  there	  are	  no	  significant	  differences	  between	  Ang	  II-­‐treated	  
and	  control	  mice	  (Fig.	  12B).	  If	  anything,	  GLP-­‐1	  levels	  tend	  to	  be	  higher	  in	  the	  Ang	  II-­‐treated	  





























Figure	  12.	  Angiotensin	  II-­‐induced	  glucose	  intolerance	  is	  independent	  of	  GLP-­‐1	  in	  vivo.	  C57Bl/6	  mice	  received	  
hydralazine	  (250	  mg/l)	  in	  the	  drinking	  water	  to	  avoid	  vasoconstriction	  and	  were	  treated	  intraperitoneally	  (i.p.)	  
with	  saline	  (black)	  or	  Ang	   II	   (red)	  every	  day	  for	  4-­‐8	  days.	   (A)	  Oral	  glucose	  tolerance	  tests	  with	  saline	  (dashed	  
lines)	  or	  glucose	  gavages	  (solid	  lines).	  Blood	  glucose	  was	  measured	  at	  time	  points	  0,	  10	  and	  30	  min.	  (B)	  Active	  
GLP-­‐1	   levels	   (Mesoscale	  Discovery)	  were	  measured	   in	   the	  plasma	  at	   time	  points	  10	  min	  after	  acute	  saline	  or	  
glucose	   gavages.	   Blood	  was	   directly	   supplemented	  with	   EDTA	   and	   a	   GLP-­‐1	   stabilizer	   (dipeptidylpeptidase-­‐IV	  
inhibitor).	  Statistics	  were	  performed	  using	  the	  Student	  t	  test.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Glucose	  
data	  are	  averages	  of	  3	  experiments	  with	  a	  total	  of	  19-­‐20	  mice	  per	  group.	  *p	  <	  0.05	  Ang	  II	  +	  glucose	  to	  saline	  +	  
glucose.	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4	  Role	  of	  Sirtuin	  1	  in	  the	  development	  of	  diabetes	  
	  
	  
4.1	  Manuscript	  No.	  1	  -­‐	  Sirtuin	  1	  mutation	  L107P	  and	  the	  development	  of	  type	  
1	  diabetes	  	  	  
4.1.1	  Abstract	  	  
Type	   1	   diabetes	   (T1D)	   is	   a	   multifactorial	   chronic	   disease	   characterized	   by	   autoimmune	  
reactions	   against	   pancreatic	   β-­‐cells	  with	  metabolic	   dysfunction	   involving	   destruction	   of	   β-­‐
cells	   and	   insulin	   deficiency.	   Sirtuin	   1	   (SIRT1)	   is	   an	   NAD+	   dependent	   class	   III	   histone	   and	  
protein	  deacetylase,	   implicated	  in	  various	  cellular	  processes	  ranging	  from	  the	  regulation	  of	  
metabolism,	  longevity	  and	  general	  stress	  resistance	  to	  inflammation	  and	  immune	  response.	  
However,	   the	   influence	   of	   SIRT1	   activation	   on	   metabolism	   and	   immunity	   is	   unclear.	  
Recently,	   a	   point	  mutation	   in	   the	   Sirt1	   gene,	  which	   causes	   an	   amino	   acid	   exchange	   from	  
leucine	  to	  proline	  (L107P),	  was	  characterized	   in	  several	  members	  of	  a	  family	  with	  T1D	  and	  
colitis.	   Based	   on	   the	   association	   of	   the	   familial	   SIRT1	   mutation	   L107P	   with	   autoimmune	  
diseases,	  we	   investigated	   the	   role	  of	  SIRT1	   in	   the	  development	  of	  autoimmunity	  and	  T1D.	  
Therefore,	   we	   generated	   rat	   INS-­‐1E	   cells	   ectopically	   overexpressing	   the	   human	   mutated	  
SIRT1	  and	  a	  knock-­‐in	  SIRT1	  mouse	  model	  carrying	  the	  corresponding	  mouse	  mutation	  L102P.	  
Besides	   elevated	   levels	   of	   reactive	   oxygen	   species,	   the	   modified	   INS-­‐1E	   β-­‐cells	   exhibited	  
glucose-­‐stimulated	  insulin	  secretion	  defects.	  However,	  our	  in	  vivo	  data	  with	  the	  SIRT1	  L102P	  
knock-­‐in	  mice	  revealed	  new	  perspectives	  to	  the	  SIRT1	  mutation	  and	   its	  effects	  on	   immune	  
responses	  and	  diabetes.	  The	  mutation	  of	  SIRT1	  enhanced	   insulin	  expression	  and	  secretion,	  
induced	   islet	   inflammation	   and	   an	   autoimmune-­‐like	   phenotype	   along	   with	   a	   reduced	  
number	   of	   regulatory	   T-­‐cells.	   We	   propose	   that	   these	   effects	   are	   due	   to	   a	   constitutive	  
overactivation	  of	   SIRT1,	  possibly	   leading	   to	  metabolic	  deterioration	  with	   increasing	  age	  or	  
additional	   triggers.	   Thus,	   SIRT1	   has	   complex	   functions	   in	   the	   regulation	   of	  metabolic	   and	  
immune	   reactions.	   Inhibition	   of	   SIRT1	  may	   have	   therapeutic	   value	   in	   the	   development	   of	  




4.1.2	  Introduction	  	  	  
Type	   1	   diabetes	   (T1D)	   is	   a	   multifactorial	   chronic	   disease	   with	   both	   genetic	   and	  
environmental	   causes	   but	   the	   exact	  mechanisms	  of	   the	   initiation	   and	  progression	   are	   not	  
fully	  understood.	  The	  disease	   is	  characterized	  by	  autoimmune	  reactions	  against	  pancreatic	  
β-­‐cells	   with	   metabolic	   dysfunction	   involving	   destruction	   of	   β-­‐cells	   and	   insulin	   deficiency.	  
There	   is	   increasing	   evidence	   that	   dysfunctional	   suppressive	   capacity	   of	   regulatory	   T-­‐cells	  
(Tregs)	   contributes	   to	   imbalanced	   autoreactive	   T-­‐cells	   and	   failure	   in	   maintaining	   self-­‐
tolerance	  [240],	  [228].	  In	  the	  last	  years,	  abundant	  research	  was	  done	  on	  sirtuins,	  a	  family	  of	  
proteins	   that	   are	   known	   to	   be	   involved	   in	   the	   regulation	   of	   numerous	   cellular	   processes	  
leading	   to	   metabolic	   and	   immunological	   homeostasis	   [121].	   Sirtuin	   1	   (SIRT1)	   is	   an	   NAD+	  
dependent	   class	   III	   histone	   and	   protein	   deacetylase,	   which	   has	   various	   functions	   ranging	  
from	  the	  regulation	  of	  metabolism,	  circadian	  rhythm,	  cell	  cycle,	  longevity	  and	  general	  stress	  
resistance	   to	   inflammation	   and	   immune	   response.	   SIRT1	   acts	   as	   energy	   sensor	   and	   its	  
overexpression	  enhances	  insulin	  secretion	  [167],	  [168].	  The	  lack	  of	  SIRT1	  has	  been	  linked	  to	  
the	  development	  of	  metabolic	  diseases,	  mainly	  type	  2	  diabetes	  (T2D),	  due	  to	  maladaptation	  
to	   metabolic	   stress	   [172],	   [173],	   [174].	   However,	   the	   influence	   of	   SIRT1	   activation	   on	  
metabolism	   and	   other	   physiological	   and	   pathophysiological	   processes	   is	   not	   fully	  
understood.	  	  
Recently,	  a	  point	  mutation	  in	  the	  sirtuin	  1	  gene,	  which	  causes	  an	  amino	  acid	  exchange	  from	  
leucine	   to	   proline	   (L107P),	   was	   characterized	   in	   several	   members	   of	   a	   family	   with	  
autoimmune	   diseases	   [215].	   The	   mutation	   lies	   outside	   of	   the	   catalytic	   core	   but	   may	  
influence	   protein-­‐protein	   interactions.	   Four	   patients	   displayed	   typical	   features	   of	   T1D	  
including	   autoantibodies	   against	   β-­‐cell	   antigens,	   hyperglycemia	   and	   rapid	   dependence	   on	  
insulin,	  whereas	  one	  family	  member	  developed	  ulcerative	  colitis.	  	  
SIRT1	   is	  highly	  expressed	   in	  dendritic	   cells,	   activated	  and	  anergic	  T-­‐cells	  and	  various	  other	  
immune	  cells	  [217],	  [218]	  but	  not	  much	  has	  been	  reported	  on	  SIRT1	  and	  its	  role	  in	  the	  innate	  
and	   adaptive	   immune	   response	   along	  with	   autoimmunity.	   There	   is	   evidence	   that	   SIRT1	   is	  
involved	   in	   T-­‐cell	   differentiation	   and	   tolerance	   by	   targeting	   transcription	   factors	   including	  
forkhead	   box	   p3	   (Foxp3),	   activator	   protein-­‐1	   (AP-­‐1),	   nuclear	   factor-­‐kappa	   B	   (NF-­‐κB)	   and	  
retinoic	  acid	  receptor-­‐related	  orphan	  receptor-­‐γt	  (RORγt).	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SIRT1	   inhibits	   transcription	   and	   production	   of	   IL-­‐2,	   which	   is	   a	   critical	   factor	   for	   the	  
development	   of	   functional	   effector	   T-­‐cells	   and	  which	   is	   able	   to	   reverse	   T-­‐cell	   anergy	   and	  
tolerance	  [218],	  [224].	   In	  parallel,	   IL-­‐2	   is	  a	  central	  regulator	  for	  the	  suppressive	  function	  of	  
regulatory	  T-­‐cells	  and	  therefore	  immune	  tolerance	  [225].	  In	  early	  studies,	  cyclosporine	  was	  
used	  as	   immunotherapeutical	   treatment	  against	   IL-­‐2-­‐induced	  autoreactive	  T-­‐cell	   activation	  
in	  T1D	  patients	  but	  the	  beneficial	  effects	  were	  only	  temporary	  [226].	  Interestingly,	  the	  lack	  
of	  IL-­‐2	  has	  been	  shown	  to	  play	  a	  crucial	  role	  in	  the	  development	  of	  T1D	  [227]	  and	  therapies	  
with	   low-­‐dose	   IL-­‐2	   treatment	   to	   boost	   or	   restore	   regulatory	   T-­‐cells	   protected	   from	   the	  
development	  of	  T1D	  in	  NOD	  mice	  and	  in	  clinical	  studies	  [228],	  [229].	  The	  transcription	  factor	  
Foxp3,	  which	   is	  a	  key	  factor	  for	  the	  development	  and	  function	  of	  Tregs,	   is	  deacetylated	  by	  
SIRT1	   leading	   to	   proteasomal	   degradation	   [23],	  whereas	   blockage	  of	   SIRT1	   improved	   Treg	  
suppressive	   function	   in	  vitro	  and	   in	  vivo	   [232].	   It	  has	  been	  convincingly	  demonstrated	   in	  a	  
recent	   study	   that	   SIRT1	   deacetylates	   the	   transcription	   factor	   RORγt,	   which	   regulates	   the	  
differentiation	   of	   Th17	   effector	   cells,	   and	   thereby	   enhances	   the	   Th17/Treg	   ratio	   and	   the	  
susceptibility	  to	  autoimmune	  diseases	  [233].	  Additionally,	  inhibition	  of	  histone	  deacetylases	  
(HDACs)	  was	   suggested	   to	   improve	  Treg	   function	   in	   autoimmune	  diseases	   including	   colitis	  
[234],	  [235].	  There	   is	  evidence	  that	  the	  deacetylase	  SIRT1	  also	   influences	  the	  development	  
of	   colitis	   since	   intestinal	   deletion	   of	   SIRT1	   protected	   from	   colitis	   and	   colitis-­‐induced	  
colorectal	   cancer	   by	   re-­‐arranging	   the	   gut	   microbiome	   [236].	   Contradictory	   observations	  
were	  made	  with	  whole	  body	  Sirt1	   -­‐/-­‐	  mice,	  which	  develop	  an	  autoimmune-­‐like	  phenotype	  
with	   increased	   anti-­‐nuclear	   antigen	   antibodies	   [238];	   however,	   they	   are	   developmentally	  
affected,	  infertile	  and	  have	  a	  small	  body	  size.	  
Based	  on	   the	  association	  of	   the	   familial	   SIRT1	  mutation	  L107P	  with	  autoimmune	  diseases,	  
we	   wanted	   to	   investigate	   the	   underlying	   mechanisms	   of	   SIRT1-­‐mediated	   effects	   in	   the	  
development	  of	  autoimmunity	  and	  T1D.	  Therefore,	  we	  generated	  rat	  INS-­‐1E	  cells	  ectopically	  
overexpressing	   the	  human	  mutated	  SIRT1	  and	  a	  knock-­‐in	  SIRT1	  mouse	  model	   carrying	   the	  
corresponding	   mouse	   mutation	   L102P.	   Our	   results	   support	   a	   new	   perspective	   for	  




4.1.3	  Methods	  	  
4.1.3.1	  INS-­‐1E	  cell	  lines	  	  
INS-­‐1E	   cells	   ([241],	   kindly	   provided	   by	   C.	  Wollheim)	  were	   stably	   transduced	  with	   pMSCV-­‐
SIRT1-­‐Flag	   plasmids	   containing	   human	   wildtype	   SIRT1	   (“WT”)	   or	   mutated	   SIRT1	   L107P	  
(“L107P”)	   or	   an	   empty	   plasmid	   (“empty”)	   as	   control	   using	   murine	   retroviruses	   (kindly	  
provided	  by	  Basil	  Hubbard,	  Harvard	  Medical	  School).	  Human	  SIRT1	  expression	  was	  analyzed	  
with	   TaqMan	   real-­‐time	   PCR	   assays	   and	   by	   Western	   blotting	   using	   anti-­‐human	   SIRT1	  
antibodies	  (H-­‐300,	  Santa	  Cruz	  Biotechnology)	  and	  anti-­‐FLAG	  antibodies	  (A9594,	  SIGMA).	  INS-­‐
1E	   cell	   lines	  were	   cultured	   in	   INS-­‐1E	  medium:	  RPMI	  medium	  containing	  11.1	  mM	  glucose,	  
100	  units/ml	  penicillin,	  100	  mg/ml	  streptomycin,	  2	  mM	  glutamax,	  10%	  FCS,	  10	  mM	  HEPES,	  
1	  mM	   sodium	   pyruvate,	   and	   50	   mM	   2-­‐mercaptoethanol	   and	   10	   µg/ml	   puromycin.	   For	  
glucose-­‐stimulated	   insulin	   secretion	   assays	   and	   RNA	   isolation,	   200’000	   cells/well	   were	  
seeded	  in	  24-­‐well	  plates	  in	  quadruplicates	  2	  days	  before	  the	  experiment.	  
	  
4.1.3.2	  Oxygen	  consumption	  assay	  	  
Seahorse	  Bioscience	  technology	  was	  used	  to	  test	  the	  mitochondrial	  function	  of	  INS-­‐1E	  cells.	  
250’000	   cells/well	   were	   plated	   on	   a	   poly-­‐D-­‐lysine	   pre-­‐coated	   XF24	   microplate	   (Seahorse	  
Bioscience)	   and	   incubated	   in	   normal	   INS-­‐1E	  medium	   for	   6	   h	   at	   37°C	   and	   5%	   CO2.	   In	   the	  
evening,	  the	  INS-­‐1E	  medium	  was	  discarded	  and	  changed	  to	  starvation	  medium	  (RPMI-­‐1640	  
medium	  supplemented	  with	  2.8	  mM	  glucose	  and	  without	  2-­‐mercaptoethanol)	  for	  18	  h.	  The	  
next	  day,	  the	  starvation	  medium	  was	  replaced	  by	  assay	  medium	  for	  2	  h	  at	  37°C	  in	  air:	  1:10	  
dilution	  of	  10	   times	  concentrated	  seahorse	  Krebs	  Ringer	  buffer	   (114	  mM	  sodium	  chloride,	  
4.7	  mM	  potassium	  chloride,	  2.5	  mM	  calcium	  chloride	  dihydrate,	  1.2	  mM	  mono	  potassium	  
sulfate,	   1.2	  mM	  magnesium	   sulfate	  heptahydrate),	   20	  mM	  HEPES	   and	  0.2%	  bovine	   serum	  
albumin	  (pH	  7.2)	  containing	  2.8	  mM	  glucose.	  To	  test	  the	  reaction	  to	  high	  glucose	  conditions,	  
ATP	  turnover,	  maximal	  respiratory	  capacity	  and	  non-­‐mitochondrial	  respiration	  of	  the	  islets,	  
16.7	   mM	   glucose,	   1	   µM	   oligomycin,	   7.7	   µM	   of	   the	   uncoupler	   carbonyl	   cyanide-­‐4-­‐
(trifluoromethoxy)phenylhydrazone	   (FCCP),	   1	   µM	   rotenone	   and	   1.7	   µM	  myxothiazol	   were	  
injected	  successively	  and	  oxygen	  consumption	  rates	  were	  determined.	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4.1.3.3	  Transmission	  electron	  microscopy	  	  
For	   transmission	   electron	   microscopy,	   5	   Mio	   INS-­‐1E	   cells	   of	   each	   group	   (empty,	  WT	   and	  
L107P)	  were	  seeded	  in	  75	  cm2	  flasks	  and	  incubated	  overnight	  at	  37°C	  and	  5%	  CO2.	  The	  next	  
day,	  cells	  were	  starved	  by	  changing	   the	  medium	  to	  PBS	  supplemented	  with	  1	  mM	  sodium	  
pyruvate	   for	   5	   h.	   Then,	   cells	   were	   harvested	   and	   processed	   for	   electron	   microscopy	   by	  
fixation	  with	   Karnovsky's	   paraformaldehyde-­‐glutaraldehyde	   [242]	   and	   1%	  osmiumtetroxid,	  
dehydratation	  with	  ethanol	  and	  embedding	  with	  Epon	  812	  (FLUKA,	  45345).	  60	  nm	  sections	  
were	  cut	  with	  a	  microtome	  (Ultracut	  E,	  Leica)	  and	  imaging	  was	  performed	  with	  a	  Morgagni	  
FEI	   microscope.	   Length	   and	   width	   at	   three	   different	   positions	   of	   the	   mitochondria	   was	  
measured	   and	   blinded	   analyzes	   were	   done	   evaluating	   nine	   pictures	   with	   several	  
mitochondria	  per	  condition.	  Aspect	  ratio	  of	  mitochondria	  was	  defined	  as	  length/average	  of	  
width.	  
	  
4.1.3.4	  MitoTracker	  staining	  for	  the	  determination	  of	  mitochondrial	  mass	  and	  
membrane	  potential	  	  
Mitchondrial	   mass	   and	   membrane	   potential	   of	   INS-­‐1E	   cells	   were	   measured	   using	  
MitoTracker	  Staining	  Green	  and	  Red,	  respectively	  (Life	  Technologies,	  M-­‐7514	  and	  M22425).	  
Green	   is	   a	   green-­‐fluorescent	   dye,	   which	   stains	   mitochondria	   in	   live	   cells	   and	   Red	   stains	  
mitochondrial	  membrane	   potential	   dependently.	   500’000	   cells/well	   were	   seeded	   in	   a	   24-­‐
well	   plate	   in	   INS-­‐1E	   medium	   the	   day	   prior	   to	   the	   experiment.	   The	   next	   day,	   cells	   were	  
stained	  either	  with	  100	  mM	  MitoTracker	  Green	  or	  250	  mM	  MitoTracker	  Red	  for	  30	  min	  at	  
37°C	  and	  5%	  CO2.	  After	  two	  washing	  steps	  with	  PBS,	  cells	  were	  resuspended	  in	  1	  ml	  PBS	  and	  
fluorescence	  levels	  were	  determined	  with	  a	  flow	  cytometer	  (FACS	  Calibur,	  BD	  Biosciences).	  
	  
4.1.3.5	  ATP	  measurements	  	  
ATP	   levels	  were	  measured	   using	   the	   bioluminescent	   ADP/ATP	   ratio	   assay	   kit	   from	   abcam	  
(ab65313).	   Luciferase	   catalyzes	   the	   conversion	   of	   ATP	   and	   luciferin	   to	   light	   that	   can	   be	  
measured	   in	   a	   luminometer.	   1000	   INS-­‐1E	   cells/well	  were	   seeded	   in	   a	   cell	   culture	   96-­‐well-­‐
plate	  and	   two	  days	   later	   supernatants	  were	   transferred	   into	  a	  white	  walled	  96-­‐well-­‐plate.	  
Experimental	  procedures	  were	  done	  following	  the	  manufacturer´s	  guidelines	  and	  ATP	  levels	  
were	  detected	  in	  a	  luminometer.	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4.1.3.6	  Protein	  determination	  by	  BCA	  assay	  	  
For	   the	  quantification	  of	   total	  protein	   in	   INS-­‐1E	  cells,	   the	  Pierce	  BCA	  protein	  assay	  kit	  was	  
used	  according	  to	  the	  manufacturer’s	  guidelines	  (Thermo	  Scientific,	  23225).	  
	  
4.1.3.7	  Detection	  of	  reactive	  oxygen	  species	  	  
The	   detection	   of	   reactive	   oxygen	   species	   (ROS)	   including	   hydrogen	   peroxide,	   hydroxyl	  
radicals	   and	   peroxynitrite	   was	   done	   by	   using	   5-­‐(and-­‐6)-­‐chloromethyl-­‐2,7-­‐
dichlorodihydrofluorescein	   diacetate	   (CM-­‐H2DCFDA;	   C6827,	   Invitrogen).	   This	   chloromethyl	  
derivative	   of	   dichlorofluorescein	   (DCF)	   diffuses	   passively	   into	   cells	   and	   is	   retained	   after	  
cleavage	  of	   its	  acetate	  groups	  by	   intracellular	  esterases.	  The	  non-­‐fluorescent	  CM-­‐H2DCFDA	  
turns	  into	  the	  highly	  fluorescent	  DCF	  upon	  oxidation	  by	  ROS	  and	  can	  be	  detected	  with	  a	  flow	  
cytometer.	  500’000	   INS-­‐1E	  cells/well	  of	  all	   three	   transfected	  cell	   lines	   (empty,	  WT,	   L107P)	  
were	  seeded	  in	  a	  24-­‐well	  plate.	  Two	  days	  later,	  the	  cells	  were	  trypsinized	  and	  resuspended	  
in	  DCF	  staining	  medium:	  Phenol	  red	  free	  DMEM	  (Gibco	  A14430-­‐01)	  with	  11.1	  mM	  glucose,	  
100	   units/ml	   penicillin,	   100	   mg/ml	   streptomycin,	   2	   mM	   glutamax,	   10	   mM	   HEPES,	   1	   mM	  
sodium	  pyruvate	  and	  10	  µg/ml	  puromycin.	  The	  cells	  were	  stained	  with	  10	  µM	  CM-­‐H2DCFDA	  
for	  20	  min	  at	  37°C	  in	  the	  dark.	  After	  washing	  twice	  with	  cold	  PBS,	  cells	  were	  resuspended	  in	  
1	  ml	  cold	  PBS	  and	  analyzed	  with	  a	  flow	  cytometer	  (FACS	  Calibur,	  BD	  Biosciences).	  	  	  
4.1.3.8	  Animals	  	  
Heterozygous	   knock-­‐in	   SIRT1	   L102P	   animals	  were	   generated	  by	  GenOway	   via	   homologues	  
recombination	   in	   embryonic	   stem	   cells.	   The	   point	   mutation	   (in	   mice	   called	   L102P)	   was	  
inserted	  into	  exon	  1a	  of	  the	  Sirt1	  gene,	  with	  a	  targeting	  vector	  containing	  regions	  homolog	  
to	   the	  genomic	  Sirt1	   sequences	  and	  a	  neomycin	   selection	  cassette,	   thereby	  disrupting	   the	  
murine	  Sirt1	  gene	  function	  (Fig.	  1).	  The	  mutated	  gene	  is	  expressed	  under	  the	  control	  of	  the	  



















Figure	  1.	  Targeting	  strategy	  of	  L102P	  SIRT1	  knock-­‐in	  mice.	  The	  point	  mutation	  L102P	  was	  inserted	  into	  exon	  1a	  
of	  the	  Sirt1	  gene	  via	  homologues	  recombination	  of	  embryonic	  stem	  cells	  and	  is	  expressed	  under	  the	  control	  of	  
the	  endogenous	  Sirt1	  promoter.	  A	  neomycin	  cassette	  flanked	  by	  loxP	  sites	  acted	  as	  positive	  selection	  marker.	  	  
	  
	  
The	  mice	  were	  backcrossed	  on	  a	  clean	  C57Bl/6	  J	  background.	  Heterozygous	  animal	  breeding	  
was	  performed	  to	  obtain	  wildtype	  (“WT”),	  heterozygous	  (“het”)	  and	  homozygous	  (“homo”)	  
littermates.	   Separate	   wildtype	   and	   homozygous	   breedings	   were	   started	   to	   obtain	   more	  
animals	  with	  the	  same	  age	  at	  the	  same	  week,	   leading	  to	  a	  mixture	  of	   littermates	  and	  non-­‐
littermates	   in	   single	   experiments.	   High-­‐fat	   diet	   feeding	   (D12331;	   Research	   Diets,	   New	  
Brunswick,	  NJ)	  was	  started	  at	  the	  age	  of	  5	  weeks	  and	  cages	  and	  food	  were	  changed	  once	  a	  
week.	  All	  animals	  were	  housed	  in	  a	  temperature-­‐controlled	  room	  with	  a	  12	  h	  light/12	  h	  dark	  
cycle	   and	   were	   allowed	   free	   access	   to	   food	   and	   water.	   Mice	   were	   sacrificed,	   blood	   was	  
obtained	  by	  heart	  puncture	  and	  plasma	  was	  collected	  for	  later	  measurements	  of	  IL-­‐2	  protein	  
(Mesoscale	  Discovery).	  All	  animals	  were	  conducted	  according	  to	  the	  swiss	  veterinary	  law	  and	  
to	  institutional	  guidelines.	  
	  
4.1.3.8	  Glucose	  and	  insulin	  tolerance	  tests	  	  
For	   intraperitoneal	   glucose	   tolerance	   tests,	  mice	   were	   fasted	   for	   6	   h	   in	   the	  morning	   and	  
injected	  intraperitoneally	  with	  2	  g	  glucose/kg	  body	  weight.	  Blood	  glucose	  was	  measured	  at	  
time	  points	  0,	  15,	  30,	  60,	  90,	  and	  120	  min	  using	  a	  glucometer	   (Freestyle;	  Abbott	  Diabetes	  
Care	   Inc.,	  Alameda,	  CA)	  and	  blood	  was	  collected	  at	  0,	  15	  and	  30	  min	   for	  measurement	  of	  
plasma	   insulin	   concentrations	   using	   mouse	   insulin	   assays	   (Mesoscale	   Discovery).	   For	  
intraperitoneal	   insulin	   tolerance	   tests,	   mice	   were	   fasted	   3	   h	   in	   the	   morning	   before	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administration	   of	   1	   or	   2	   units/kg	   insulin	   (Novo	   Nordisk,	   Bagsvaerd,	   Denmark),	   and	   blood	  
glucose	  was	  measured	  at	  time	  points	  0,	  15,	  30,	  60,	  and	  90	  min.	  	  
4.1.3.9	  Islet	  isolation	  	  
For	   mouse	   islet	   isolation,	   the	   pancreas	   was	   perfused	   with	   HBSS	   containing	   1.4	   mg/ml	  
collagenase	   (Worthington,	   Lakewood,	   NJ),	   10mg/ml	   DNase	   (1:3000,	   Roche,	   Cat.	   No.	  
11284932001)	  and	  0.5%	  w/v	  BSA	  (Merck,	  1120180100)	  and	  digested	  for	  30	  min	  at	  37°C	  and	  
5%	  CO2,	  followed	  by	  washing	  steps	  and	  filtration	  through	  70	  and	  500	  µm	  cell	  strainers.	  Islet	  
culture	  medium	  consisted	  of	  RPMI-­‐1640	  medium	  containing	  11.1	  mM	  glucose,	  100	  units/ml	  
penicillin,	   100	   mg/ml	   streptomycin,	   2	   mM	   glutamax,	   50	   mg/ml	   gentamicin,	   1:1000	  
Fungizone	  (Gibco),	  and	  10%	  FCS.	  Islets	  were	  cultured	  on	  extracellular-­‐matrix	  coated	  24-­‐well-­‐
plates	   (Novamed	   Ltd,	   Jerusalem,	   Israel)	   for	   36	   h	   prior	   to	   treatment	   with	   IL-­‐1β	   and	  
subsequent	  RNA	  isolation	  or	  for	  glucose-­‐stimulated	  insulin	  secretion	  experiments.	  	  
4.1.3.9.1	  Glucose-­‐stimulated	  insulin	  secretion	  	  
For	  in	  vitro	  or	  ex	  vivo	  glucose-­‐stimulated	  insulin	  secretion	  experiments,	  25	  islets	  or	  200’000	  
INS-­‐1E	   cells/well	   were	   seeded	   in	   quadruplicates.	   At	   the	   next	   day,	   INS-­‐1E	   cells	   were	  
preincubated	  in	  INS-­‐1E	  medium	  containing	  2.8	  mM	  glucose	  overnight.	  At	  day	  2	  after	  plating,	  
supernatants	   of	   INS-­‐1E	   cells	   or	   islets	   were	   collected	   and	   stored	   at	   -­‐20°C	   (chronic	   insulin	  
release).	   Cells	   were	   incubated	   for	   30	   min	   in	   modified	   Krebs-­‐Ringer	   bicarbonate	   buffer	  
(mKRBB	  =	  115	  mM	  sodium	  chloride,	  4.7	  mM	  potassium	  chloride,	  2.6	  mM	  calcium	  chloride	  
dihydrate,	   1.2	   mM	   mono	   potassium	   sulfate,	   1.2	   mM	   magnesium	   sulfate	   heptahydrate,	  
10	  mM	   HEPES	   and	   0.5%	   bovine	   serum	   albumin	   [pH	   7.4])	   containing	   2.8	   mM	   glucose.	  
Supernatants	   were	   discarded	   and	   cells	   or	   islets	   were	   incubated	   in	   new	   mKRBB	  
supplemented	  with	  2.8	  mM	  glucose	  for	  1	  h	  (basal	  insulin	  release),	  followed	  by	  1	  h	  in	  mKRBB	  
containing	  16.7	  mM	  glucose	  (stimulated	  insulin	  release).	  Islets	  or	  INS-­‐1E	  cells	  were	  extracted	  
with	  0.18	  N	  hydrogen	  chloride	   in	  70%	  ethanol	   (HCl/EtOH)	   for	  2	  h	   in	   room	  temperature	   to	  
determine	   insulin	   content.	   Insulin	   concentrations	   were	   measured	   using	   rat	   insulin	  
ultrasensitive	   ELISA	   (Mercodia,	   Uppsala,	   Sweden)	   or	   mouse/rat	   insulin	   kit	   (Mesoscale	  
Discovery,	   Rockville,	  MD).	   Stimulatory	   index	  was	  determined	   as	   the	   ratio	   of	   stimulated	   to	  
basal	  insulin	  release.	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4.1.3.9.2	  RNA	  isolation	  and	  quantitative	  PCR	  	  
80	   islets	   isolated	   as	   described	   above	   were	   plated	   on	   extracellular	   matrix-­‐coated	   24-­‐well-­‐
plates	   for	   36	   h.	   Medium	   was	   changed	   and	   islets	   were	   treated	   with	   or	   without	   1	   ng/ml	  
recombinant	   mouse	   IL-­‐1β	   (R&D	   Systems,	   401-­‐ML)	   for	   24	   h.	   For	   total	   RNA	   extraction	   the	  
Nucleo	  Spin	  RNA	  kit	   (Macherey-­‐Nagel	  GmBH,	  Düren,	  Germany)	  was	  used	  and	   the	   isolated	  
RNA	  was	  reverse	  transcribed	  using	  Superscript	  II	  (Invitrogen)	  and	  random	  hexamer	  primers	  
(Microsynth,	   Balgach,	   Switzerland).	   Quantitative	   PCR	   was	   done	   with	   the	   real-­‐time	   PCR	  
system	  7500	  (Applied	  Biosystems)	  and	  following	  TaqMan	  gene	  expression	  assays	  were	  used:	  
mouse:	   β-­‐actin:	  Mm00607939_s1,	   Sirt1:	  Mm01168519_m1,	   IL-­‐6:	  Mm00446190_m1,	   IL-­‐1β:	  
Mm00434228_m1,	   IL-­‐1Rn:	   Mm00446185_m1,	   IL-­‐22R:	   Mm01192943_m1,	   IL-­‐2R:	  
Mm01340213_m1,	   Ins2:	   Mm00731595_gH,	   Pdx1:	   Mm00435565_m1,	   Foxo1:	  
Mm00490672_m1.	   Rat:	   β-­‐actin:	   Rn00667869_m1,	   Sirt1:	   Rn01428096_m1,	   Cxc1:	  
Rn00578225_m1	   and	   Ucp2:	   	   Rn01754856_m1.	   Human:	   18S:	   Hs99999901_s1	   and	   Sirt1:	  
Hs01009006_m1.	  
	  
4.1.3.9.3	  Peritoneal	  macrophages	  	  
After	   sacrifice	   of	   the	   mice	   peritoneal	   macrophages	   were	   isolated	   by	   infusion	   of	   the	  
peritoneum	  with	   10	  ml	   PBS	   +	   1%	   FCS	   and	   filtering	   the	   lavage	   through	   a	   70	   µm	   filter	   (BD	  
Biosciences).	   200’000	   cells/well	   were	   cultured	   in	   48-­‐well	   plates	   in	   macrophage	   medium	  
(RPMI-­‐1640	   medium	   containing	   11.1	   mM	   glucose,	   100	   units/ml	   penicillin,	   100	   mg/ml	  
streptomycin,	   2	  mM	   glutamax,	   50	  mg/ml	   gentamicin,	   1:1000	   Fungizone	   (Gibco),	   and	   10%	  
FCS)	  and	  incubated	  overnight.	  Macrophages	  were	  activated	  with	  100	  ng/ml	  LPS	  +	  10	  ng/ml	  
recombinant	  mouse	   IFNy	   for	   5	   h	   with	   or	   without	   adding	   5	  mM	   ATP	   for	   the	   last	   30	  min.	  
Supernatants	   were	   collected	   and	   used	   for	   measurements	   of	   IL-­‐10	   protein	   (Mesoscale	  
Discovery).	  	  	  
4.1.3.9.4	  Flow	  cytometry	  for	  immune	  cell	  phenotyping	  	  
After	  sacrifice	  of	  the	  mice,	  inguinal	  lymph	  node	  cells	  were	  collected	  by	  passing	  them	  through	  
a	  70	  μm	  filter	  (BD	  Falcon).	  Cell	  suspensions	  were	  resuspended	  in	  isolation	  buffer	  (PBS	  +	  2%	  
FCS	  +	  5	  mM	  EDTA)	  and	  Fc	  receptor	  blocked	  with	  anti-­‐mouse	  CD16/CD32	  antibodies.	  Surface	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staining	  was	  performed	  for	  30	  min	  at	  4°C	  with	  anti-­‐CD3e	  (clone	  145-­‐2C11),	  anti-­‐CD4	  (clone	  
GK1.5),	  anti-­‐CD8	  (clone	  53-­‐6.7),	  anti-­‐CD25	  (clone	  PC61.5)	  and	  anti-­‐B220	  (clone	  RA3-­‐6B2)	  or	  
anti-­‐CD19	   (clone	   eBio1D3)	   antibodies	   or	   appropriate	   isotype	   controls;	   all	   antibodies	  were	  
purchased	   from	   eBioscience	   or	   Biolegend.	   For	   intracellular	   staining,	   cells	   were	   fixed	   and	  
permeabilized	   with	   the	   Foxp3	   staining	   buffer	   set	   (eBioscience	   Cat.	   No.	   00-­‐5523-­‐00),	   and	  
incubated	   for	   30	   min	   at	   room	   temperature	   with	   anti-­‐Foxp3	   antibodies	   (clone	   MF-­‐14).	  
Stained	  cells	  were	  washed	  twice	  with	  FACS	  buffer	  (PBS	  +	  0.5%	  BSA	  +	  5	  mM	  EDTA)	  prior	  to	  
analysis	   on	   a	   BD	   Accuri	   C6	   cytometer	   (BD	   Biosciences)	   using	   FACS	   Diva	   software	   (BD	  
Biosciences).	  Data	  were	  analyzed	  using	  Flow	  Jo	  9.4	  software	  (Tree	  Star).	  
	  
4.1.3.9.5	  Statistics	  	  
Statistical	   analysis	  was	   performed	  using	  GraphPad	   Prism	  6	   (GraphPad	   Software).	   Data	   are	  
presented	   as	   mean	   ±	   SEM	   and	   were	   analyzed	   using	   one-­‐way	   ANOVA.	   Differences	   were	  
considered	  statistically	  significant	  when	  p	  <	  0.05.	  
	  
	  
4.1.4	  Results	  	  
4.1.4.1	  L107P	  INS1E	  cells	  are	  more	  prone	  to	  inflammation	  and	  have	  impaired	  insulin	  
secretion	  compared	  to	  cells	  overexpressing	  wildtype	  SIRT1	  	  	  
In	  a	  previous	  study,	  transduced	  mouse	  insulinoma	  MIN6	  cells	  were	  generated	  to	  develop	  a	  
cell	  model	  for	  a	  familial	  Sirt1	  mutation	  leading	  to	  autoimmune	  diabetes	  and	  colitis	  [215].	  In	  
the	  present	  study,	  we	  transduced	  rat	  insulinoma	  INS-­‐1E	  cells	  with	  the	  same	  virus	  stocks	  that	  
were	  used	  for	  the	  MIN6	  cells.	  Three	  INS-­‐1E	  cell	   lines	  were	  created	  by	  puromycin	  selection:	  
an	  empty	  vector	  control	  (“empty”),	  a	  human	  SIRT1	  overexpressing	  line	  (“WT”)	  and	  a	  cell	  line	  
overexpressing	   the	  human	  mutated	  SIRT1	  L107P	   (“L107P”).	  All	   three	   cell	   lines	  were	   stably	  
transduced	  and	  the	  ectopic	  expression	  of	  human	  SIRT1	  protein	  in	  the	  WT	  and	  L107P	  cell	  line	  
was	  comparable	  as	  detected	  with	  anti-­‐human	  SIRT1	  (Fig.	  2A)	  and	  anti-­‐FLAG	  antibodies	  and	  









Figure	  2.	  Transduction	  of	  INS-­‐1E	  cells	  resulted	  in	  equal	  levels	  of	  human	  SIRT1	  protein	  in	  L107P	  cells	  compared	  
to	   wildtype	   SIRT1	   overexpressing	   cells.	   (A)	   Representative	   pictures	   for	   protein	   levels	   of	   human	   SIRT1	   in	  
transduced	  INS-­‐1E	  cells	  (WT,	  empty	  and	  L107P)	  stained	  with	  anti-­‐human	  SIRT1	  antibodies	  from	  Santa	  Cruz	  or	  
(B)	  with	  anti-­‐FLAG	  antibodies	  (A9594,	  SIGMA).	  (C)	  Gene	  expression	  levels	  of	  human	  Sirt1	  are	  slightly	   lower	  in	  
transduced	   L107P	   INS-­‐1E	   cells	   compared	   to	   the	  wildtype	   control.	   Bar	   graphs	   are	   expressed	   as	  mean	  ±	   SEM.	  





Since	  decreased	  anti-­‐inflammatory	  activities	  of	  mouse	  insulinoma	  MIN6	  cells	  overexpressing	  
the	   human	   mutated	   L107P	   SIRT1	   compared	   to	   the	   WT	   SIRT1	   were	   shown	   [215],	   we	  
examined	   if	   we	   see	   similar	   effects	   in	   the	   rat	   β-­‐cell	   line	   INS-­‐1E	   after	   transduction.	   Upon	  
treatment	   with	   1	   ng/ml	   IL-­‐1β	   for	   24	   h,	   the	   mutated	   INS-­‐1E	   cells	   (L107P)	   reacted	   with	   a	  
slightly	   lower	   reduction	   of	   Cxcl1	   gene	   expression	   levels	   than	   the	   wildtype	   SIRT1	   cell	   line	  
compared	   to	   the	   empty	   control	   (Fig.	   3A).	   Furthermore,	   the	   induction	   of	   reactive	   oxygen	  
species	   (ROS),	  detected	  by	  CM-­‐H2DCFDA	  staining,	  was	  elevated	   in	  untreated	  L107P	   INS-­‐1E	  
cells	   compared	   to	  both	  controls	   (Fig.	  3B).	  The	  overexpression	  of	  WT	  SIRT1	  did	  not	   change	  
the	   levels	   of	   ROS	   compared	   to	   the	   empty	   control	   (Fig.	   3B).	   Glucose-­‐stimulated	   insulin	  
secretion	  experiments	  revealed	  lower	  insulin	  secretion	  capacity	  of	  the	  L107P	  cells	  compared	  
to	   the	   controls	   (Fig.	   3C).	   Again,	   overexpression	   of	   WT	   SIRT1	   did	   not	   change	   the	   insulin	  
secretion	  of	  INS-­‐1E	  cells	  compared	  to	  the	  empty	  control	  (Fig.	  3C).	  Chronic	  insulin	  release	  into	  
the	  culture	  medium	  and	   islet	   insulin	  content	  were	  comparable	   in	   the	  three	  cell	   lines	   (data	  
not	  shown).	  To	  test	  if	  elevated	  uncoupling	  contributed	  to	  the	  diminished	  insulin	  secretion	  of	  
L107P	  INS-­‐1E	  cells,	  we	  measured	  the	  basal	  gene	  expression	  levels	  of	  Ucp2	  and	  did	  not	  reveal	  













Figure	  3.	  L107P	  INS1E	  cells	  are	  more	  prone	  to	  inflammation	  and	  have	  insulin	  secretion	  defects	  compared	  to	  
cells	  overexpressing	  wildtype	  SIRT1.	  (A)	  Gene	  expression	  of	  Cxcl1	   in	  transduced	  INS1-­‐E	  cells	  (empty,	  WT	  and	  
L107P),	  expressed	  relative	  to	  18S.	  Cells	  were	  treated	  with	  1	  ng/ml	  IL-­‐1β	  for	  24	  h.	  (B)	  Measurements	  of	  reactive	  
oxygen	   species	   in	   transduced	   INS1-­‐E	   cells	   via	   CM-­‐H2DCFDA	   staining	   and	   flow	   cytometry.	   Each	   symbol	  
represents	   one	   separate	   experiment	   and	  data	   is	   normalized	   to	   the	  mean	   fluorescence	   intensity	   of	   each	  WT	  
data,	   expressed	   as	   percent.	   (C)	   Glucose-­‐stimulated	   insulin	   secretion	   assays	   of	   transduced	   INS1-­‐E	   cells,	  
expressed	  as	  stimulatory	  index	  (stimulated	  to	  basal	  insulin	  secretion).	  Statistics	  were	  performed	  using	  one-­‐way	  
ANOVA.	   Bar	   graphs	   are	   expressed	   as	   mean	   ±	   SEM.	   Data	   are	   averages	   of	   four	   (A),	   three	   (B)	   and	   five	   (C)	  





To	   further	   understand	   the	   lower	   insulin	   secretion	   capacity	   of	   the	   INS-­‐1E	   L107P	   cells,	   we	  
assessed	   the	   function	   and	   morphology	   of	   the	   mitochondria.	   First,	   we	   performed	  
experiments	  with	  the	  Seahorse	  technology	  (Bucher	  AG)	  to	  test	  oxygen	  consumption	  of	  the	  
INS-­‐1E	   cell	   lines.	   No	   significant	   differences	   in	   oxygen	   consumption	   rates	   (OCR)	   were	  
observed	  between	  the	  three	  overnight	  starved	   INS-­‐1E	  cell	   lines	  after	   injection	  of	  16.7	  mM	  
glucose	   (HG),	   oligomycin	   and	   rotenone	   plus	   myxothiazol	   (rot	   +	   myx).	   The	   maximal	  
respiratory	  capacity	  was	  mildly	  increased	  in	  both	  WT	  and	  L107P	  SIRT1	  cells	  compared	  to	  the	  
empty	  control	  cells,	  indicated	  through	  injection	  of	  the	  uncoupler	  FCCP	  (Fig.	  4A).	  However,	  no	  
differences	   in	   oxygen	   consumption	   were	   observed	   between	   the	   WT	   and	   L107P	   SIRT1	  
overexpressing	  cells.	  Second,	  we	  measured	  basal	  ATP	  levels	  of	  the	  three	  INS-­‐1E	  cell	  lines	  to	  
investigate	   the	  bioenergetic	   state	  of	   the	  cells	  but	  we	  did	  not	  detect	  any	  changes	  between	  
the	   cell	   lines	   (Fig.	   4B).	   Additionally,	   mitochondrial	   mass	   and	   membrane	   potential	   were	  
examined	   by	   MitoTracker	   Green	   and	   Red	   stainings,	   respectively	   (Life	   Technologies).	   No	  






Figure	  4.	  L107P	  INS1E	  cells	  exhibit	  similar	  oxygen	  consumption	  rates,	  ATP	  levels	  and	  mitochondrial	  mass	  and	  
membrane	  potential	  compared	  to	  cells	  overexpressing	  wildtype	  SIRT1.	  (A)	  Oxygen	  consumption	  rates	  of	  INS-­‐
1E	   cells	   (empty,	  WT,	   L107P)	   after	   18h	   starvation	   in	   low	   glucose	  medium.	   Successive	   injections	   of	   16.7	  mM	  
glucose	  (HG),	  oligomycin,	  FCCP	  and	  rotenone	  together	  with	  myxothiazol	  (rot+myx).	   (B)	  ATP	  levels	  under	  basal	  
conditions	   in	   the	   three	   INS-­‐1E	   cell	   lines,	   expressed	   per	   mg	   protein.	   Mitochondrial	   mass	   was	   detected	   by	  
MitoTracker	  Green	   (C)	  and	  mitochondrial	  membrane	  potential	  by	  MitoTracker	  Red	   (D)	   staining	   in	  the	   INS-­‐1E	  
cell	   lines	   under	   basal	   conditions.	   Results	   are	   normalized	   to	   the	  WT	   cells	   and	   expressed	   as	   percent	   of	  mean	  
fluorescent	   intensity.	   (E)	   Representative	   transmission	   electron	   microscopy	   pictures	   of	   the	   three	   cell	   lines	  
during	  starvation	  (5	  h	  PBS	  with	  1	  mM	  sodium	  pyruvate).	   (F)	  Aspect	  ratio	  is	  defined	  as	  mitochondrial	  length	  to	  
width.	  Statistics	  were	  performed	  using	  one-­‐way	  ANOVA.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  
averages	  of	  three	  (A+B),	  five	  (D)	  and	  six	  (C)	  independent	  experiments.	  *p	  <	  0.05	  WT	  to	  empty.	  
63	  	  
However,	   the	   L107P	   cells	   tended	   to	   have	   a	   lower	   mitochondrial	   membrane	   potential	  
compared	   to	   the	   two	   other	   cell	   lines,	   without	   reaching	   significance	   (Fig.	   4D).	   Third,	   we	  
characterized	  the	  morphology	  of	  the	  mitochondria	  after	  starvation	  by	  transmission	  electron	  
microscopy	  (Fig.	  4E).	  The	  aspect	  ratio	  of	  the	  mitochondria,	  which	   is	  defined	  as	  the	  ratio	  of	  
mitochondrial	   length	   to	  width,	  was	  decreased	   in	   the	  WT	  SIRT1	  but	  not	   in	   the	  L107P	  SIRT1	  
overexpressing	  cells	  compared	  to	  the	  empty	  controls	  during	  starvation	  conditions	  (Fig.	  4F).	  
	  
	  
4.1.4.2	  Homozygous	  L102P	  SIRT1	  mice	  exhibit	  mildly	  improved	  glucose	  and	  insulin	  
tolerance	  and	  enhanced	  β-­‐cell	  function	  	  	  
To	   obtain	   an	   animal	  model	   system	   reflecting	   the	   SIRT1	  mutation	   in	   the	   diabetic	   patients	  
[215],	  we	   generated	   heterozygous	   and	   homozygous	   SIRT1	   L102P	   knock-­‐in	  mice	   that	   carry	  
the	  corresponding	  mouse	  mutation.	  To	  metabolically	  phenotype	  these	  mice,	  we	  performed	  
glucose	  and	  insulin	  tolerance	  tests	  with	  mice	  of	  different	  sex	  and	  age.	  At	  the	  age	  of	  12	  and	  
20	   weeks,	   we	   saw	   no	   differences	   of	   glucose	   or	   insulin	   tolerance	   between	   WT	   (green),	  
heterozygous	   (black)	   and	  homozygous	   (red)	   knock-­‐in	  male	  mice	   (Fig.	   5A-­‐F),	   despite	  higher	  
basal	  and	  glucose-­‐stimulated	  plasma	   insulin	   levels	   in	   the	  homozygous	  mice	  during	  glucose	  


























Figure	  5.	  Homozygous	  L102P	  SIRT1	  male	  mice	  exhibit	  slightly	  improved	  glucose	  and	  insulin	  tolerance	  at	  the	  
age	  of	  30	  weeks	  compared	  to	  wildtype	  mice	  when	  fed	  a	  chow	  diet.	  Intraperitoneal	  glucose	  tolerance	  tests	  of	  
the	  L102P	  mice	  (WT	  green,	  het	  black	  and	  homo	  red)	  at	  the	  age	  of	  12	  (A),	  20	   (D),	  30	   (G)	  and	  50	   (J)	  weeks	  and	  
the	   corresponding	   insulin	   measurements	   at	   time	   points	   0,	   15	   and	   30	   (B,	   E,	   H,	   K).	   Intraperitoneal	   insulin	  
tolerance	  tests	  at	  the	  age	  of	  12	  (C),	  20	  (F),	  30	  (I)	  and	  50	  (L)	  weeks.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  
Data	  are	  averages	  of	  two	  independent	  cohorts	  with	  a	  total	  of	  10	  (WT),	  12	  (het)	  and	  8	  (homo)	  mice.	  Single	  mice	  
were	  excluded	  when	  the	  injection	  of	  glucose/	  insulin	  obviously	  did	  not	  work.	  
	  
	  
A	  slight	  improvement	  of	  both	  the	  glucose	  and	  insulin	  tolerance	  was	  observed	  at	  the	  age	  of	  
30	  weeks	   in	  male	  homozygous	  knock-­‐in	  mice	  compared	  to	  the	  WT	  mice	  (Fig.	  5G+I	  and	  Fig.	  
6A+B),	   even	   if	   the	   insulin	   levels	  were	   comparable	   (Fig.	  5H).	  50-­‐weeks-­‐old	  male	  mice	  of	   all	  
strains	  did	  not	  react	  differently	  to	  glucose	  or	  insulin	  (Fig.	  5J+L).	  
	  
	  
Figure	   6.	   Glucose	   and	   insulin	   tolerance	   tests	   of	   L102P	   SIRT1	  
male	   mice	   at	   the	   age	   of	   30	   weeks	   fed	   a	   chow	   diet.	  
Intraperitoneal	   glucose	   (A)	   and	   insulin	   (B)	   tolerance	   tests	   are	  
expressed	   as	   area	   under	   the	   curve	   (AUC).	   Bar	   graphs	   are	  




In	  female	  mice,	   insulin	  tolerance	  tests	  at	  the	  ages	  12,	  20,	  30	  and	  50	  weeks	  (Fig.	  7C,	  F,	   I,	  L)	  
and	   glucose	   tolerance	   tests	   at	   the	   age	   of	   12	   weeks	   (Fig.	   7A)	   did	   not	   reveal	   differences	  
between	  the	  three	  groups.	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Figure	  7.	  Homozygous	  L102P	  SIRT1	  female	  mice	  exhibit	  improved	  glucose	  and	  insulin	  tolerance	  at	  the	  age	  of	  
30	  and	  50	  weeks	   compared	   to	  wildtype	  mice	  when	   fed	  a	   chow	  diet.	   Intraperitoneal	   	   (ip)	  glucose	  tolerance	  
tests	  at	  the	  age	  of	  12	  (A),	  20	  (D),	  30	  (G)	  and	  50	  (J)	  weeks	  and	  the	  corresponding	  insulin	  measurements	  at	  time	  
points	  0,	  15	  and	  30	  (B,	  E,	  H,	  K).	  Ip	  insulin	  tolerance	  tests	  at	  the	  age	  of	  12	  (C),	  20	  (F),	  30	  (I)	  and	  50	  (L)	  weeks.	  Bar	  
graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  three	  (two	  for	  J,	  K	  and	  L)	  independent	  cohorts	  with	  
a	   total	   of	   20	   (WT),	   19	   (het)	   and	   15	   (homo)	   mice.	   Single	   mice	   were	   excluded	   when	   the	   injection	   of	  




Glucose-­‐stimulated	   insulin	   levels	  did	  not	  alter	   throughout	   the	  whole	   testing	  at	   the	  ages	  of	  
12,	   20,	   30	   and	   50	   weeks	   (Fig.	   7B,	   E,	   H,	   K).	   However,	   slight	   improvements	   of	   the	   glucose	  
tolerance	  in	  female	  homozygous	  compared	  to	  wildtype	  mice	  started	  at	  the	  age	  of	  20	  weeks	  
and	  became	  more	  pronounced	  at	   the	  ages	  of	   30	  and	  50	  weeks	   (Fig.	   7G,	   J	   and	  Fig.	   8A+B),	  





Figure	  8.	  Glucose	   tolerance	   tests	  of	  L102P	  SIRT1	   female	  
mice	   at	   the	   age	   of	   30	   and	   50	   weeks	   fed	   a	   chow	   diet.	  
Intraperitoneal	   glucose	   tolerance	   tests	   at	   the	   age	   of	   30	  
(A)	   and	   50	   (B)	   weeks	   are	   expressed	   as	   area	   under	   the	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Furthermore,	  we	  challenged	  the	  L102P	  SIRT1	  mice	  with	  a	  high-­‐fat	  diet	  feeding	  starting	  at	  the	  
age	  of	  5	  weeks	  to	  see	  if	  the	  previously	  described	  effects	  would	  be	  more	  pronounced	  or	  if	  we	  
could	  induce	  the	  precipitation	  of	  a	  disease.	  Glucose	  and	  insulin	  tolerance	  were	  tested	  at	  the	  
same	  ages	  as	  the	  mice	  fed	  a	  chow	  diet	  (Fig.	  5+7).	  At	  the	  tested	  ages	  of	  12,	  20	  and	  30	  weeks,	  
male	  mice	  fed	  a	  high-­‐fat	  diet	  did	  not	  reveal	  differences	  in	  glucose	  or	   insulin	  tolerance	  (Fig.	  
9A-­‐I).	   However,	   30-­‐week-­‐old	   male	   homozygous	   mice	   tended	   to	   have	   impaired	   glucose	  
tolerance	  compared	  to	  the	  wildtype	  mice	  (Fig.	  9G).	  
	  
Figure	   9.	   Homozygous	   L102P	   SIRT1	   male	   mice	   exhibit	   no	   significant	   differences	   in	   glucose	   and	   insulin	  
tolerance	  at	  the	  age	  of	  12,	  20	  and	  30	  weeks	  compared	  to	  the	  wildtype	  and	  heterozygous	  mice	  when	  fed	  a	  
high-­‐fat	   diet.	   Intraperitoneal	   glucose	   tolerance	   tests	   at	   the	   age	  of	   12	   (A),	   20	   (D)	   and	  30	   (G)	  weeks	   and	   the	  
corresponding	   insulin	  measurements	   at	   time	   points	   0,	   15	   and	   30	   (B,	   E,	   H).	   Intraperitoneal	   insulin	   tolerance	  
tests	  at	  the	  age	  of	  12	  (C),	  20	  (F)	  and	  30	  (I)	  weeks.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  
of	   two	   independent	  cohorts	  with	  a	   total	  of	  12	   (WT),	  11	   (het)	  and	  7	   (homo)	  mice.	  Single	  mice	  were	  excluded	  
when	  the	  injection	  of	  glucose	  or	  insulin	  obviously	  did	  not	  work.	  
	  
	  
In	  female	  homozygous	  L102P	  SIRT1	  mice	  that	  were	  fed	  a	  high-­‐fat	  diet,	  glucose	  tolerance	  was	  
improved	  at	  the	  age	  of	  12	  weeks	  (Fig.	  10A	  and	  Fig.	  11A)	  and	  impaired	  at	  the	  age	  of	  20	  weeks	  
(Fig.	  10D	  and	  Fig.	  11B)	  compared	  to	  wildtype	  mice	  fed	  a	  high-­‐fat	  diet.	  

























































































































































Figure	   10.	   In	   homozygous	   L102P	   SIRT1	   female	   mice	   at	   the	   age	   of	   12	   weeks	   glucose	   tolerance	   is	   slightly	  
improved	  and	  at	  the	  age	  of	  20	  weeks	  slightly	  impaired	  compared	  to	  the	  wildtype	  mice	  when	  fed	  a	  high-­‐fat	  
diet.	   Intraperitoneal	   glucose	   tolerance	   tests	   at	   the	   age	   of	   12	   (A),	   20	   (D)	   and	   30	   (G)	   weeks	   and	   the	  
corresponding	   insulin	  measurements	   at	   time	   points	   0,	   15	   and	   30	   (B,	   E,	   H).	   Intraperitoneal	   insulin	   tolerance	  
tests	  at	  the	  age	  of	  12	  (C),	  20	  (F)	  and	  30	  (I)	  weeks.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  
of	   two	   independent	   cohorts	  with	   a	   total	   of	   9	   (WT),	   8	   (het)	   and	  10	   (homo)	  mice.	   Single	  mice	  were	   excluded	  




However,	   no	   significant	   differences	   were	   observed	   in	   glucose	   tolerance	   at	   the	   age	   of	   30	  
weeks	  (Fig.	  10G)	  and	  in	  insulin	  tolerance	  at	  all	  tested	  ages	  (Fig.	  10C,	  F,	  I).	  Glucose-­‐stimulated	  




Figure	  11.	  Glucose	  tolerance	  tests	  of	  L102P	  SIRT1	  female	  mice	  
at	   the	   age	   of	   12	   and	   20	   weeks	   fed	   a	   high-­‐fat	   diet.	  
Intraperitoneal	  glucose	  tolerance	  tests	  at	  the	  age	  of	  12	  (A)	  and	  
20	  (B)	  weeks	  are	  expressed	  as	  area	  under	  the	  curve	  (AUC).	  Bar	  
graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  
	  
















































































































































































To	   investigate	   the	   islet	   function	   ex	   vivo,	   we	   isolated	   islets	   of	   12-­‐week-­‐old	  male	  mice	   and	  
performed	   glucose-­‐stimulated	   insulin	   secretion	   assays.	   In	   agreement	   with	   the	   improved	  
glucose	   tolerance	   in	   vivo,	   islets	   isolated	   from	   the	   homozygous	   knock-­‐in	   mice	   showed	  
improved	   insulin	   secretion	   function	   compared	   to	   islets	   of	   WT	   and	   heterozygous	   mice	  
(Fig.	  12A).	  The	  stimulatory	   index,	   that	   is	  defined	  as	  high	  glucose	  stimulated	  to	   low	  glucose	  
stimulated	   insulin	   release,	   was	   elevated	   in	   islets	   of	   heterozygous	   and	   homozygous	   mice	  
compared	   to	   the	   control	   (Fig.	   12B),	  whereas	   the	   total	   insulin	   content	  was	   the	   same	   in	   all	  
three	   groups	   (Fig.	   12C).	   However,	  we	   observed	   a	   decreased	   chronic	   insulin	   release	   in	   the	  


















Figure	   12.	   Glucose-­‐stimulated	   insulin	   secretion	   function	   is	   enhanced	   in	   isolated	   islets	   of	   the	   homozygous	  
L102P	  SIRT1	  mice	  compared	  to	  the	  wildtype	  and	  heterozygous	  mice.	  (A)	  Glucose-­‐stimulated	  insulin	  secretion	  
assay	  in	  WT	  (white),	  heterozygous	  (grey)	  and	  homozygous	  mice	  (black).	  Basal	  =	  2.8	  mM	  glucose,	  stimulated	  =	  
16.7	  mM	  glucose.	  (B)	  Stimulatory	  index	  of	  the	  insulin	  secretion	  was	  defined	  as	  high	  glucose	  stimulated	  to	  low	  
glucose	   stimulated	   insulin	   release.	   (C)	   Total	   insulin	   content	   was	   extracted	   by	   HCl/EtOH.	   (D)	   Chronic	   insulin	  
release	  was	  determined	  after	  36	  h	  of	  culturing.	  Statistics	  were	  performed	  using	  one-­‐way	  ANOVA.	  Bar	  graphs	  
are	   expressed	   as	   mean	   ±	   SEM.	   Data	   are	   averages	   of	   four	   (het)	   and	   six	   (WT	   and	   homo)	   independent	  




































































































4.1.4.3	  Islets	  of	  homozygous	  L102P	  SIRT1	  mice	  display	  elevated	  expression	  levels	  of	  
inflammatory	  and	  metabolic	  genes	  	  
	  
	  
Since	   both	   transduced	   INS-­‐1E	   and	   MIN6	   cells	   were	   more	   prone	   to	   inflammation,	   we	  
examined	   if	   isolated	   islets	   of	   L102P	   SIRT1	   knock-­‐in	   mice	   ex	   vivo	   exhibit	   changes	   in	  
inflammatory	  gene	  expression.	  Therefore,	  we	  isolated	  islets	  of	  the	  three	  mouse	  strains	  (WT,	  
het	  and	  homo),	  plated	   them	   for	  36	  h	  and	   treated	   them	  with	  or	  without	  1	  ng/ml	   IL-­‐1β	   for	  
24	  h	  prior	  to	  RNA	  isolation.	  Gene	  expression	  assays	  revealed	  a	  strong	  basal	  induction	  of	  islet	  
cytokines,	   specifically	   IL-­‐1β,	   IL-­‐6,	  Nos2	  and	   TNFα,	   chemokines	  and	   immune	  cells,	   including	  
CD45	   (Ptprc	   gene)	   and	   receptors	   for	   IL-­‐22	   and	   IL-­‐2,	   in	   islets	   of	   homozygous	   knock-­‐in	  mice	  
compared	  to	  wildtype	  or	  heterozygous	  mice	  (Fig.	  13A-­‐H).	  After	  stimulation	  of	  the	  islets	  with	  
IL-­‐1β	   to	   mimic	   cytokine	   stress,	   all	   tested	   genes	   were	   upregulated	   (Fig.	   13,	   lower	   part)	  
compared	  to	  the	  basal	  levels	  (Fig.	  13,	  upper	  part),	  except	  Ptprc	  that	  did	  not	  change	  (data	  not	  
shown).	  The	  above	  described	  differences	  between	  the	  groups	  at	  gene	  expression	  level	  were	  
even	  more	  pronounced	  after	  treatment	  with	  IL-­‐1β,	  especially	  true	  for	  IL-­‐1β,	  Cxcl1,	  IL-­‐22	  and	  
IL-­‐2	   receptor	   (Fig.	  13J,	  M,	  N,	  O).	   There	  are	  no	  differences	   in	  gene	  expression	   levels	  of	   the	  
macrophage	   chemoattractant	   protein-­‐1	   (Ccl2	   gene)	   between	   the	   groups	   in	   untreated	   or	  




























Figure	  13.	  Islets	  of	  homozygous	  L102P	  SIRT1	  mice	  have	  elevated	  levels	  of	  genes	  related	  to	  islet	  inflammation.	  
Basal	  gene	  expression	  levels	  of	  (A)	  IL-­‐1β,	  (B)	  IL-­‐6,	  (C)	  Nos2,	  (D)	  TNFα,	  (E)	  Cxcl1,	  (F)	  Ptprc,	  (G)	  IL-­‐22R,	  (H)	  IL-­‐2Rα	  
and	  gene	  expression	  levels	  of	  (I)	  18S,	  (J)	  IL-­‐1β,	  (K)	  Nos2,	  (L)	  TNFα,	  (M)	  Cxcl1,	  (N)	  IL-­‐22R	  and	  (O)	  IL-­‐2Rα	  during	  
cytokine	   stress	   were	   determined	   in	   80	   islets	   of	   WT	   (white),	   het	   (grey)	   and	   homo	   (black)	   mice.	   Data	   is	  
normalized	  to	  18S	  and	  to	  the	  unstimulated	  WT	  control.	  Statistics	  were	  performed	  using	  one-­‐way	  ANOVA.	  Bar	  
graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  three	  independent	  experiments	  with	  a	  total	  of	  13	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Several	  key	  metabolic	  genes,	  including	  Ins2,	  Pdx1,	  glucagon	  and	  Foxo1,	  were	  upregulated	  at	  
mRNA	   level	   in	   islets	  of	  homozygous	  L102P	  mice	   (Fig.	  14B-­‐E).	  Expression	   levels	  of	  Sirt1	  and	  
other	  members	  of	  the	  sirtuin	  family,	  such	  as	  Sirt2	  and	  Sirt6	  but	  not	  Sirt3	  (data	  not	  shown),	  
were	  also	  elevated	   in	  homozygous	  mice	  compared	  to	  the	  wildtype	  and	  heterozygous	  mice	  
(Fig.	   14F-­‐H).	  Gene	  expression	  of	   the	  uncoupling	  protein	   2	   (Ucp2),	   that	   is	   known	   to	   inhibit	  
insulin	   secretion,	   was	   increased	   under	   basal	   conditions,	   contrasting	   to	   the	   higher	   basal	  






























Figure	  14.	   Islets	  of	  homozygous	  L102P	  SIRT1	  mice	  have	  elevated	  expression	   levels	  of	  key	  metabolic	  genes.	  
Basal	  gene	  expression	  levels	  of	  (A)	  18S,	  (B)	  Ins2,	  (C)	  Pdx1,	  (D)	  glucagon,	  (E)	  Foxo1,	  (F)	  Sirt1,	  (G)	  Sirt2,	  (H)	  Sirt6	  
and	  (I)	  Ucp2	   in	  80	   islets	  of	  WT	  (white),	  het	   (grey)	  and	  homo	  (black)	  mice	  were	  normalized	  to	  18S	  and	  to	  the	  
corresponding	  WT	  control.	  Statistics	  were	  performed	  using	  one-­‐way	  ANOVA.	  Bar	  graphs	  are	  expressed	  as	  mean	  
±	  SEM.	  Data	  are	  averages	  of	  three	  independent	  experiments	  with	  a	  total	  of	  13	  (WT),	  14	  (het)	  or	  15	  (homo)	  mice	  
and	  a	  total	  of	  9-­‐12	  replicates	  per	  condition.	  *p	  <	  0.05,	  **p	  <	  0.01	  as	  indicated.	  
	  
	  


































































































































































































































4.1.4.4	  Homozygous	  L102P	  SIRT1	  mice	  have	  an	  autoimmune-­‐like	  phenotype	  	  	  
Besides	  its	  role	  in	  metabolic	  control,	  SIRT1	  has	  been	  demonstrated	  to	  influence	  immunologic	  
processes	  such	  as	  T-­‐cell	  tolerance	  and	  regulatory	  T-­‐cell	  development	  [224].	  Since	  the	  familial	  
SIRT1	  mutation	   causes	   autoimmune	   diseases	   including	   T1D	   and	   colitis,	   we	   investigated	   if	  
there	  are	  alterations	  in	  the	  immune	  system	  of	  our	  mouse	  model.	  Thus,	  we	  isolated	  inguinal	  
lymph	   node	   cells	   of	   all	   three	  mouse	   strains	   (WT,	   het	   and	   homo)	   and	   performed	  multiple	  
stainings	   for	   flow	   cytometry	   to	   analyze	   the	   distribution	   of	   the	  main	   immune	   cell	   subsets	  
(Fig.	  15).	  	  
	  
















Figure	   15.	   Immune	   cell	   subsets	   in	   inguinal	   lymph	   node	   cells	   of	  WT,	   heterozygous	   and	   homozygous	   SIRT1	  
L102P	  mice	  are	  comparable.	  Inguinal	  lymph	  node	  cells	  were	  isolated	  and	  stained	  with	  antibodies	  (eBioscience)	  
for	   flow	   cytometry.	   B-­‐cells	  were	   defined	   as:	   CD19+	   or	   B220+,	   T-­‐cells	  were	   defined	   as:	   CD3+,	   cytotoxic	   T-­‐cells	  
were	   defined	   as:	   CD3+CD8+	   and	   helper	   T-­‐cells	  were	   defined	   as:	   CD3+CD4+.	  Graphs	   are	   expressed	   as	  mean	   ±	  
















































































The	  percentage	  of	  B-­‐cells	   (defined	  as	  CD19+	  or	  B220+)	   among	  all	   lymphocytes	  was	   slightly	  
decreased	  in	  the	  homozygous	  mice	  compared	  to	  the	  WT	  and	  heterozygous	  mice	  (Fig.	  15A),	  
whereas	  the	  percentage	  of	  T-­‐cells	  (defined	  as	  CD3+)	  was	  slightly	  increased	  (Fig.	  15B),	  without	  
reaching	   statistical	   significance.	  Thus,	   the	  B-­‐	  and	  T-­‐cell	   ratio	  was	   shifted	   towards	  T-­‐cells	   in	  
the	  homozygous	  mice.	  No	  differences	  were	  observed	   in	   the	  proportion	  of	  cytotoxic	  T-­‐cells	  
(defined	  as	  CD3+CD8+)	  and	  helper	  T-­‐cells	   (defined	  as	  CD3+CD4+)	  between	   the	   three	  groups	  
(Fig.	   15C+D).	   To	   further	   investigate	   the	   composition	   of	   the	   CD4+	   T-­‐cells,	   we	   additionally	  























Figure	   16.	   Homozygous	   L102P	   SIRT1	  mice	   have	   lower	   levels	   of	   regulatory	   T-­‐cells	   in	   inguinal	   lymph	   nodes	  
compared	   to	   the	   wildtype	  mice.	   Inguinal	   lymph	   node	   cells	  were	   isolated	   from	  WT	   (green),	   het	   (black)	   and	  
homo	  (red)	  mice	  and	  stained	  with	  antibodies	  (ebioscience)	  for	  flow	  cytometry.	  Regulatory	  T-­‐cells	  (Tregs)	  were	  
defined	  as:	  CD4+CD25+Foxp3+	  (one	  experiment	  was	  done	  without	  Foxp3	  staining).	  (A)	  Schematic	  gating	  strategy	  
for	  Tregs.	   (B)	  Percentage	  of	  Tregs	  among	  all	  lymphocytes.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  









































We	  detected	  lower	  levels	  of	  CD4+CD25+Foxp3+	  cells,	  defined	  as	  Tregs,	  in	  the	  lymph	  nodes	  of	  
the	  homozygous	  knock-­‐in	  mouse	  compared	  to	  the	  wildtype	  and	  heterozygous	  mice	  (Fig.	  16).	  
Since	  we	  observed	  reduced	  numbers	  of	  Tregs	  in	  the	  homozygous	  L102P	  SIRT1	  mice	  pointing	  
to	   a	   dysregulation	   of	   T-­‐cell	   homeostasis,	   we	   compared	   the	   production	   of	   general	  
immunoregulatory	   cytokines	   in	   the	  mice.	   Hence,	   we	  measured	   IL-­‐2	   concentrations	   in	   the	  
circulation	  of	  the	  mice	  and	  observed	  significantly	  higher	  levels	  in	  the	  plasma	  of	  homozygous	  
L102P	  mice	  compared	  to	  wildtype	  mice	  (Fig.	  17A).	  Furthermore,	  the	  ex	  vivo	  secretion	  of	  the	  
anti-­‐inflammatory	  cytokine	  IL-­‐10	  by	  peritoneal	  macrophages	  upon	  stimulation	  with	  LPS,	  IFNγ	  
and	   with	   or	   without	   ATP	   was	   measured	   and	   homozygous	   mice	   revealed	   lower	   IL-­‐10	  






















Figure	   17.	   Homozygous	   L102P	   SIRT1	   mice	   have	   elevated	   levels	   of	   IL-­‐2	   in	   the	   circulation	   and	   peritoneal	  
macrophages	  secrete	   less	   IL-­‐10	  upon	  stimulation	  compared	  to	  wildtype	  mice.	  (A)	  Plasma	  levels	  of	  IL-­‐2	  were	  
measured	  from	  heart	  blood	  after	  sacrifice	  of	  the	  mice	  (WT	  green,	  het	  black,	  homo	  red).	  (B)	  Isolated	  peritoneal	  
macrophages	   of	   WT	   (green)	   and	   homozygous	   (red)	   mice	   were	   plated	   overnight	   and	   levels	   of	   IL-­‐10	   upon	  
activation	  were	  measured	   in	   the	   supernatants.	   Statistics	  were	  performed	  using	  one-­‐way	  ANOVA.	  Bar	  graphs	  
are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  two	  independent	  cohorts	  with	  total	  numbers	  of	  mice:	  WT	  

























































4.1.5	  Discussion	  	  
In	   this	   work	   we	   investigated	   the	   role	   of	   SIRT1	   in	   the	   development	   of	   inflammation	   and	  
autoimmune	  diseases	  including	  type	  1	  diabetes	  (T1D)	  and	  how	  a	  single	  Sirt1	  point	  mutation	  
can	  modulate	   it.	  For	  our	  study,	  we	  used	  transduced	  rat	   INS-­‐1E	  cells	  and	  a	  knock-­‐in	  mouse	  
model,	   which	   is	   carrying	   a	   SIRT1	   point	   mutation	   that	   was	   shown	   to	   be	   associated	   with	  
familial	   autoimmune	   diseases	   including	   diabetes	   and	   colitis	   [215].	   We	   demonstrate	   that	  
SIRT1	  modulation	  by	  the	  SIRT1	  point	  mutation	  causes	  higher	  susceptibility	  to	  inflammation	  
and	   reduced	   β-­‐cell	   function	   in	   the	   INS-­‐1E	   cell	   model	   and	   metabolic	   overactivation	   with	  
increased	  inflammation	  and	  an	  autoimmune-­‐prone	  phenotype	  in	  the	  knock-­‐in	  mouse	  model.	  
In	  line	  with	  a	  previous	  study	  using	  transduced	  MIN6	  cells	  ectopically	  expressing	  the	  mutated	  
human	  Sirt1	  gene	   [215],	  we	  revealed	  reduced	  anti-­‐inflammatory	  activities	  of	   the	   INS-­‐1E	  β-­‐
cell	   line	  overexpressing	  the	  mutated	  SIRT1	  compared	  to	  the	  wildtype	  SIRT1	  overexpressing	  
cell	   line.	   This	  was	   indicated	   by	   higher	   gene	   expression	   levels	   of	   the	   chemokine	  Cxcl1	  and	  
enhanced	  production	  of	  reactive	  oxygen	  species	  (ROS).	  These	  results	  support	  the	  hypothesis	  
that	   islet	   inflammation	   participates	   in	   the	   development	   of	   autoimmune	   diseases	   in	   the	  
patients	  carrying	  the	  SIRT1	  mutation.	  Furthermore,	  glucose-­‐stimulated	  insulin	  secretion	  was	  
impaired	  in	  the	  mutated	  INS-­‐1E	  cell	  line,	  possibly	  caused	  by	  less	  protection	  against	  oxidative	  
stress	   and	   inflammation.	   These	   findings	   imply	   that	   the	   SIRT1	   mutation	   causes	   a	   loss	   of	  
function,	   which	   is	   in	   line	   with	   various	   studies	   reporting	   a	   beneficial	   role	   of	   SIRT1	  
overexpression	  in	  the	  context	  of	  inflammatory	  processes	  and	  insulin	  secretion	  [167],	  [194].	  
Surprisingly,	  the	  overexpressing	  of	  wildtype	  SIRT1	  in	  our	  INS-­‐1E	  cell	  line	  did	  not	  protect	  from	  
the	  induction	  of	  ROS	  and	  did	  not	  enhance	  glucose-­‐stimulated	  insulin	  secretion	  compared	  to	  
cells	   with	   endogenous	   SIRT1	   expression	   (empty	   vector	   control).	   As	   described	   in	   previous	  
studies,	  overexpression	  of	  SIRT1	  appears	  to	  be	  a	  delicate	  issue,	  since	  the	  resulting	  effects	  are	  
strongly	  dependent	  on	  the	  level	  of	  overexpression	  and	  on	  the	  tissue	  [243].	  Due	  to	  the	  fact	  
that	   SIRT1	   has	   been	   shown	   to	   regulate	   mitophagy,	   specific	   autophagic	   processes	   in	  
mitochondria,	  and	  mitochondrial	  biogenesis	  and	  function	  [244],	  we	  questioned	  if	  the	  cause	  
of	   lower	   insulin	   secretion	   besides	   elevated	   inflammatory	   processes	   could	   be	   impaired	  
mitochondrial	   function	   in	   the	  mutated	  SIRT1	  overexpression	  cell	   line.	  No	  differences	  were	  
detected	   in	   oxygen	   consumption,	   ATP	   production,	   mitochondrial	   mass	   and	   membrane	  
potential	  between	  the	  cell	  lines.	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However,	  mitochondrial	  morphology	  was	  changed	  in	  wildtype	  SIRT1	  but	  not	  in	  the	  mutated	  
cells	  during	  starvation.	  The	  aspect	  ratio,	  which	  is	  defined	  as	  mitochondrial	  length/width,	  was	  
decreased	   in	   wildtype	   SIRT1	   cells	   during	   starvation,	   meaning	   that	   the	   elongation	   of	   the	  
mitochondria	   was	   decreased	   in	   wildtype	   cells	   but	   not	   in	   the	   mutated	   cells.	   Starvation	  
elevates	   levels	   of	   cyclic	   adenosine	   monophosphate	   and	   protein	   kinase	   A	   leading	   to	  
mitochondrial	   fusion	   and	   elongation	   and	   thereby	   determines	   mitochondrial	   fate.	   Longer	  
mitochondria	  are	  protected	  from	  degradation,	  have	  more	  cristae	  and	  exhibit	  optimized	  ATP	  
production	   during	   nutrient	   restriction	   [245].	   However,	   mitophagy,	   which	   is	   the	   selective	  
degradation	  of	   damaged	  mitochondria,	   is	   an	   important	  process	   to	  maintain	  mitochondrial	  
function	   and	   to	   reduce	   ROS	   production	   [246].	   SIRT1	   has	   been	   shown	   to	   regulate	   the	  
mitochondrial	  fusion-­‐fission	  cycle	  by	  inducing	  mitophagy	  to	  reduce	  inflammation	  and	  defect	  
mitochondria	  during	   starvation	   [247].	   Sirt	   -­‐/-­‐	  mouse	  embryonic	   fibroblasts	   are	  not	   able	   to	  
induce	  autophagy	  in	  response	  to	  starvation	  conditions	  [248].	  Based	  on	  this	  knowledge,	  it	  is	  
likely	  that	  the	  mutated	  INS-­‐1E	  cells	  may	  not	  sufficiently	  activate	  mitophagy	  during	  starving	  
conditions	  compared	  to	  the	  wildtype	  SIRT1	  overexpressing	  cells.	  
Our	   findings	   suggest	   that	   the	   system	  of	   overexpressing	  human	  SIRT1	  ectopically	   in	   INS-­‐1E	  
cells	  reflects	  the	  pathophysiological	  situation	  in	  the	  patients	  in	  the	  context	  of	  inflammation	  
and	  β-­‐cell	  dysfunction.	  
However,	  our	  in	  vivo	  data	  with	  the	  SIRT1	  L102P	  knock-­‐in	  mice,	  which	  is	  a	  less	  artificial	  model	  
organism	  closer	  resembling	  the	  patients,	   revealed	  new	  perspectives	  to	  the	  SIRT1	  mutation	  
and	  its	  effects	  on	  immune	  responses	  and	  diabetes.	  In	  apparent	  contrast	  to	  the	  in	  vitro	  data	  
with	   the	   transduced	   INS-­‐1E	   cells,	   we	   observed	   enhanced	   glucose-­‐stimulated	   insulin	  
secretion	  in	  isolated	  islets	  of	  the	  heterozygous	  and	  homozygous	  knock-­‐in	  mice	  compared	  to	  
the	   control	   mice.	   Additionally,	   intraperitoneal	   glucose	   and	   insulin	   tolerance	   tests	   did	   not	  
reveal	   differences	   between	   wildtype,	   heterozygous	   and	   homozygous	   knock-­‐in	   mice,	   if	  
anything,	  at	  certain	  ages	  homozygous	  compared	  to	  wildtype	  mice	  performed	  better.	  Given	  
the	   clinical	   phenotype	   of	   the	   patients	   carrying	   the	   SIRT1	   mutation,	   this	   finding	   was	  
unexpected	   and	   led	   us	   to	   the	   hypothesis	   that	   normal	   function	   of	   SIRT1	   is	   constitutively	  
enhanced	  in	  our	  homozygous	  mouse	  model,	  possibly	  leading	  to	  metabolic	  deterioration	  with	  
increasing	  age	  or	  additional	  triggers.	  
Further	  supporting	  our	  hypothesis,	  nearly	  all	  key	  metabolic	  genes	  were	  basally	  upregulated	  
in	  isolated	  islets	  of	  homozygous	  mice	  compared	  to	  the	  controls.	  In	  parallel,	  expression	  levels	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of	  numerous	  genes	  involved	  in	  islet	  inflammation	  were	  strongly	  induced,	  such	  as	  IL-­‐1β,	  nitric	  
oxide	  synthase	  (Nos2)	  and	  the	  chemokine	  Cxcl1,	  in	  line	  with	  the	  data	  of	  the	  INS-­‐1E	  cells.	  Of	  
note,	  expression	  of	  the	  uncoupling	  protein	  2	  (Ucp2)	  was	  upregulated	  at	  mRNA	  level,	  possibly	  
compensatory	   to	   suppress	   the	  production	  of	  ROS	   in	   the	   inflammatory	  environment	  of	   the	  
islets.	   Additionally,	   receptors	   for	   IL-­‐2	   and	   IL-­‐22,	   which	   participate	   in	   the	   regulation	   of	  
adaptive	  immune	  regulation	  and	  immune	  tolerance,	  were	  elevated	  in	  islets	  of	  homozygous	  
mice	   at	   gene	   expression	   level.	   IL-­‐2	   is	   a	   cytokine	   that	   supports	   effector	   T-­‐cell	   (Teff)	  
differentiation	   but	   also	   the	   development	   of	   immune	   suppressive	   regulatory	   T-­‐cells	   (Treg)	  
[225].	   IL-­‐22	   belongs	   to	   the	   IL-­‐10	   family	   of	   cytokines	   and	   is	   classically	   involved	   in	   Th17-­‐
induced	  immune	  responses;	  however,	  recently	  it	  was	  linked	  to	  the	  protection	  from	  obesity-­‐
induced	  metabolic	   deteriorations	   [28].	   The	   upregulation	   of	   these	   receptors	   in	   islets	   could	  
point	   to	   a	   compensatory	  mechanisms	   caused	  by	   the	   lack	  of	   IL-­‐2	   and	   IL-­‐22	   in	  homozygous	  
mice.	   In	   line	  with	   this	   thinking,	  ex	  vivo	  macrophages	  of	  homozygous	  mice	  exhibited	   lower	  
secretion	   of	   the	   anti-­‐inflammatory	   cytokine	   IL-­‐10	   upon	   stimulation	   compared	   to	  wildtype	  
mice	  in	  our	  study.	  Since	  SIRT1	  is	  able	  to	  inhibit	  the	  production	  of	  IL-­‐2	  [218],	  [224]	  and	  since	  
the	  lack	  of	  IL-­‐2	  has	  been	  shown	  to	  play	  a	  crucial	  role	  in	  the	  development	  of	  T1D	  [227],	  our	  
mouse	  model	  supports	  the	  hypothesis	  that	  overactivation	  of	  SIRT1	  caused	  by	  the	  mutation	  
may	   lead	  to	  decreased	   IL-­‐2	  and	  therefore	  promotes	  autoimmunity	  and	  T1D.	   In	  contrast	   to	  
our	  hypothesis,	  we	  observed	  elevated	  IL-­‐2	  levels	  in	  the	  circulation	  of	  homozygous	  knock-­‐in	  
mice	   compared	   to	  wildtype	  mice.	   Since	   IL-­‐2	   is	   also	   regulating	   effector	   T-­‐cell	   development	  
and	   since	   suppression	   of	   IL-­‐2-­‐induced	   activation	   of	   autoreactive	   T-­‐cell	   has	   been	   used	   as	  
immunotherapeutical	   treatment	   in	  T1D	  patients	   [226],	   it	  may	  well	  be	  that	   IL-­‐2	  has	  diverse	  
functions	   in	   β-­‐cells	   compared	   to	   other	   tissues	   and	   the	   circulation.	   In	   turn,	   IL-­‐2	   can	   also	  
inhibit	  Sirt1	   transcription	  [218],	  possibly	  explaining	  the	  high	   IL-­‐2	   levels	   in	  the	  circulation	  as	  
answer	  to	  overactivation	  of	  SIRT1.	  Due	  to	  the	  fact	  that	  low-­‐dose	  IL-­‐2	  treatment	  can	  increase	  
Treg	   recovery	   [231],	   the	   systemic	   increase	   of	   IL-­‐2	   in	   homozygous	   mice	   could	   also	   be	   a	  
compensatory	  reaction	  to	  the	  low	  numbers	  of	  Tregs.	  
To	   evaluate	   our	   hypothesis	   of	   reduced	   immune	   suppressive	   function	   in	   the	   homozygous	  
knock-­‐in	  mice,	  we	  determined	  the	  immune	  cell	  subsets	  in	  lymph	  node	  cells	  and	  we	  indeed	  
found	   less	  Tregs,	  defined	  as	  CD4+CD25+Foxp3+	   cells,	   in	  homozygous	   compared	   to	  wildtype	  
mice.	  SIRT1	  was	  shown	  to	  deacetylate	  and	  degrade	  the	  transcription	  factor	  Foxp3,	  which	  is	  
constitutively	  expressed	  by	  Tregs	  [23],	  whereas	  blockage	  of	  SIRT1	  improved	  Treg	  suppressive	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function	   [232].	   These	   studies	   are	   in	   line	   with	   the	   theory,	   that	   the	   mutated	   SIRT1	   in	   our	  
mouse	  model	   is	  overactivated	  and	  inhibits	  Foxp3	  leading	  to	  a	  reduced	  capacity	  of	  Tregs	  to	  
maintain	   self-­‐tolerance.	   This	   is	   consistent	   with	   the	   results	   in	   the	   patients	   carrying	   the	  
mutation;	  they	  also	  exhibited	   lower	  Treg	   levels	   in	  the	  blood.	  Additionally,	  preliminary	  data	  
from	  our	  lab	  revealed	  reduced	  Treg	  function	  in	  homozygous	  SIRT1	  L102P	  mice	  compared	  to	  
the	  controls.	  Both	  the	  number	  of	  IL-­‐10	  producing	  Tregs	  and	  the	  functional	  protein	  cytotoxic	  
T-­‐lymphocyte	   antigen	   4	   (CTLA-­‐4),	   that	   is	   highly	   expressed	   by	   Tregs	   and	   that	   is	   known	   to	  
decrease	   the	   inflammatory	   response	   of	   antigen-­‐presenting	   cells,	   were	   reduced	   in	   a	   pilot	  
experiment.	   Furthermore,	   ex	   vivo	   activated	   T-­‐cells	   from	   isolated	   lymph	   nodes	   of	  
homozygous	  knock-­‐in	  mice	  secreted	  less	  IL-­‐10	  than	  the	  ones	  from	  control	  mice.	  Our	  data	  are	  
supported	  by	  recent	  studies;	  it	  has	  been	  shown	  that	  SIRT1	  enhances	  the	  Th17/Treg	  ratio	  and	  
the	   susceptibility	   to	   autoimmune	   diseases	   [233].	   Additionally,	   inhibition	   of	   histone	  
deacetylases	   (HDACs),	   the	   group	   of	   enzymes	   SIRT1	   belongs	   to,	  was	   suggested	   to	   improve	  
Treg	   function	   in	   autoimmune	  diseases	   including	   colitis	   [234],	   [235].	  However,	  whole	   body	  
and	  liver-­‐specific	  SIRT1	  knock-­‐out	  mice	  were	  shown	  to	  develop	  autoimmune-­‐like	  phenotypes	  
[238],	   [249].	  These	  discrepancies	  along	  with	   the	  divergent	   results	  of	  our	   INS-­‐1E	  cell	  model	  
concerning	  β-­‐cell	  function	  further	  illustrate	  that	  SIRT1	  has	  a	  variety	  of	  effects	  on	  the	  body,	  
dependent	  on	  the	  tissue	  and	  the	  intensity	  of	  modulation.	  
However,	  all	  of	  this	  is	  indicative	  for	  a	  central	  and	  complex	  role	  of	  SIRT1	  in	  T-­‐cell	  biology	  and	  
in	  the	  context	  of	  autoimmune	  diseases	  including	  T1D.	  Based	  on	  recent	  knowledge,	  inhibition	  
of	   SIRT1	   may	   improve	   the	   function	   and	   development	   of	   Tregs	   partly	   via	   IL-­‐2	   and	   Foxp3	  
enhancement	  and	  suppress	  the	  activity	  of	  Th17	  effector	  cells.	  One	  could	  imagine	  to	  treat	  the	  
patients	  carrying	  the	  SIRT1	  mutation	  with	  low-­‐dose	  IL-­‐2	  to	  increase	  Treg	  recovery,	  as	  it	  was	  
tested	  in	  other	  autoimmune	  conditions	  [231].	  
We	  conclude	  that	  besides	  its	  function	  in	  defining	  metabolic	  changes	  during	  stress	  responses,	  
SIRT1	   is	   essentially	   involved	   in	   the	   regulation	   of	   immune	   reactions	   and	   inflammation.	  We	  
suggest	   that	   the	  modification	  of	  SIRT1	   through	  one	  single	  point	  mutation	   in	  a	  whole	  body	  
knock-­‐in	  mouse	  model	  causes	  overactivation	  of	  SIRT1	  leading	  to	  enhanced	  insulin	  expression	  
and	   secretion,	   islet	   inflammation	   and	   an	   autoimmune-­‐like	   phenotype	   along	  with	   reduced	  
regulatory	  T-­‐cells.	  Thus,	  inhibition	  of	  SIRT1	  may	  have	  therapeutic	  value	  in	  autoimmunity	  and	  
the	  development	  of	  diabetes.	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  Abstract	  	  	  
There	   is	   increasing	   evidence	   that	   inflammation	   plays	   a	   crucial	   effector	   role	   in	   the	  
development	  of	  both	  type	  1	  and	  type	  2	  diabetes	  (T1D	  and	  T2D)	  leading	  to	  β-­‐cell	  damage	  and	  
β-­‐cell	  death	  but	  the	  exact	  mechanisms	  remain	  to	  be	  elucidated.	  The	  NAD+	  dependent	  class	  III	  
histone	  and	  protein	  deacetylase	  sirtuin	  1	  (SIRT1)	  has	  been	  abundantly	  studied	  in	  the	  context	  
of	   longevity	   and	  metabolism	  but	   it	   is	   increasingly	   recognized	  as	   regulator	  of	   inflammation	  
and	  the	  immune	  system.	  In	  this	  work,	  we	  used	  inducible	  β-­‐cell	  specific	  SIRT1	  knock-­‐out	  mice	  
to	  investigate	  how	  β-­‐cell-­‐derived	  SIRT1	  influences	  glucose	  metabolism	  and	  the	  initiation	  and	  
progression	  of	  diabetes.	  The	  knock-­‐out	  of	  SIRT1	  in	  β-­‐cells	  caused	  impaired	  glucose	  tolerance	  
and	   lower	   insulin	   levels	  along	  with	  defects	   in	  mitochondrial	  glucose	  sensing	  and	   increased	  
cytokine	  and	  chemokine	  production	  in	  islets.	  However,	  in	  the	  context	  of	  T1D,	  SIRT1	  in	  β-­‐cells	  
seems	   to	  be	  detrimental	   since	  our	  SIRT1	  KO	  mice	  displayed	  a	   strong	  protection	   from	  STZ-­‐
induced	   diabetes	   and	   diminished	   loss	   of	   body	   weight.	   We	   propose	   that	   reduced	   SIRT1	  
activation	   and	   therefore	   insulin	   secretion	   during	   the	   detrimental	   situation	   of	   diabetes	  
development	  may	   induce	   a	   “β-­‐cell	   rest”	   leading	   to	   the	   recovery	   of	   exhausted	   islets	   along	  
with	   resistance	   to	   T1D.	   Thus,	   SIRT1	   expressed	   in	   β-­‐cells	   is	   a	   central	   regulator	   of	   glucose	  
homeostasis,	   islet	   inflammation	   and	   the	   development	   of	   diabetes.	   Based	   on	   our	   data,	  
inhibition	  of	  SIRT1	  in	  the	  development	  of	  T1D	  may	  have	  beneficial	  therapeutic	  effects.	  	  




Diabetes	   mellitus	   is	   a	   multifactorial	   metabolic	   disease	   characterized	   by	   elevated	   blood	  
glucose	   due	   to	   pancreatic	   β-­‐cell	   dysfunction	   and	   insulin	   resistance.	   There	   is	   increasing	  
evidence	  that	   inflammation	  plays	  a	  crucial	  effector	  role	   in	  the	  development	  of	  both	  type	  1	  
and	   type	   2	   diabetes	   (T1D	   and	   T2D)	   leading	   to	   β-­‐cell	   damage	   and	   β-­‐cell	   death	   [33],	   [250].	  
Remaining	   β-­‐cells	   compensate	   for	   the	   higher	   insulin	   demand	   until	   they	   fail.	   In	   T1D,	  
additionally	   autoimmune	   components	   play	   a	   role	   and	   cause	   β-­‐cell	   destruction.	   The	  
mechanisms	  underlying	  the	  development	  of	  diabetes	  are	  not	  fully	  understood	  and	  curative	  
treatment	  possibilities	  are	  still	  lacking.	  
In	   the	   last	   years,	   abundant	   research	   was	   done	   on	   sirtuins,	   a	   family	   of	   proteins	   that	   are	  
involved	  in	  the	  regulation	  of	  metabolic	  homeostasis.	  Sirtuin	  1	  (SIRT1)	  is	  an	  NAD+	  dependent	  
class	   III	  histone	  and	  protein	  deacetylase	  which	  has	  various	  tissue	  specific	  functions	  ranging	  
from	   regulation	   of	  metabolism,	   circadian	   rhythm,	   cell	   cycle	   to	   inflammation	   and	   immune	  
response	  and	  to	  general	  stress	  resistance.	  It	  is	  the	  most	  studied	  sirtuin	  since	  it	  has	  attracted	  
a	   lot	   of	   interest	   since	   it	   was	   the	   first	   identified	   mammalian	   homolog	   of	   Sir2,	   which	   was	  
shown	  to	  influence	  longevity	  in	  yeast	  [144].	  SIRT1	  acts	  as	  energy	  sensor	  and	  has	  been	  linked	  
to	  the	  development	  of	  metabolic	  diseases,	  mainly	  T2D.	  SIRT1	  overexpression	  was	  reported	  
to	  improve	  islet	  function	  by	  enhancing	  insulin	  secretion	  [167],	  [150],	  [251]	  or	  by	  inhibition	  of	  
inflammatory	   processes	   [194].	   In	   many	   animal	   models	   of	   T2D,	   SIRT1	   was	   shown	   to	   be	   a	  
central	   regulator	   in	   the	   adaptation	   to	   diet-­‐induced	   metabolic	   dysfunctions	   [172],	   [173];	  
transgenic	  mice	  lacking	  SIRT1	  deacetylase	  activity	  are	  not	  able	  to	  acclimate	  to	  high-­‐fat	  diet	  
leading	  to	  accumulation	  of	  adipose	  tissue	  and	  insulin	  resistance	  [174].	  It	  has	  been	  described	  
that	   activation	   of	   SIRT1	   by	   nicotinamide	   ribose	   (NR),	   a	   precursor	   of	   nicotinamide	  
dinucleotide	   (NAD+),	   can	  protect	   from	  HFD-­‐induced	  metabolic	   damages	   through	   increased	  
oxidative	  metabolism	  and	  mitochondrial	  function	  [175].	  Nevertheless,	  the	  SIRT1	  area	  is	  full	  
of	  contradictory	   findings.	  SIRT1	  null	  mice,	  which	  show	  developmental	  defects	  and	  sterility,	  
have	   lower	   glucose	   and	   insulin	   levels	   and	   improved	   glucose	   tolerance	   [176],	   [150],	   [177].	  
Erion	  et	  al.	  showed	  that	  knockdown	  of	  hepatic	  SIRT1	  in	  the	  context	  of	  T2D	  is	  beneficial,	  as	  
indicated	  by	  decreased	  liver	  glucose	  production	  and	  increased	  whole	  body	  insulin	  sensitivity	  
in	   a	   rat	   model	   [185].	   SIRT1	   activation	   in	   an	   obese	   mouse	   model	   of	   T2D	   reduced	  
hyperglycemia	  but	  worsened	   insulin	  resistance	  and	  caused	  further	  body	  weight	  gain	  [252].	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Besides	   its	   role	   as	   a	  metabolic	  modulator	   SIRT1	   is	   also	   implicated	   in	   innate	   and	   adaptive	  
immune	   response	   and	   autoimmunity	   via	   the	   regulation	   of	   NF-­‐kB	   and	   AP-­‐1	   pathways	   and	  
differentiation	   of	   regulatory	   T-­‐cells	   [23].	   Sirt1	   -­‐/-­‐	   mice	   develop	   an	   autoimmune-­‐like	  
phenotype	   with	   increased	   anti-­‐nuclear	   antigen	   antibodies	   [238]	   and	   recently,	   a	   point	  
mutation	  in	  the	  Sirt1	  gene	  was	  linked	  to	  a	  familial	  form	  of	  T1D	  and	  autoimmune	  colitis	  [215].	  	  
In	   the	   multiple	   low	   dose	   streptozotocin	   (mldSTZ)	   model,	   a	   T1D	   model	   in	   animals,	   it	   is	  
proposed	   that	   the	   SIRT1	   cofactor	  NAD+	  is	   depleted	  by	   activation	  of	   PARP	  and	  DNA	   repair,	  
leading	   to	   β-­‐cell	   death	   and	   the	   induction	   of	   diabetes.	   In	   line	  with	   that,	   resistance	   to	   STZ-­‐
induced	   diabetes	   has	   been	   shown	   in	   PARP-­‐1	   knock-­‐out	  mice	   [204],	   [205].	   Several	   studies	  
have	   proven	   that	   nicotinamide	   (Nam),	   a	   precursor	   of	   NAD+	   and	   at	   the	   same	   time	   end-­‐
product	   inhibitor	   of	   SIRT1,	   protects	   against	   STZ-­‐induced	   β-­‐cell	   damage	   and	   diabetes	   in	  
rodents,	  T1D	  patients	  and	  in	  individuals	  with	  high	  risk	  [206],	  [207],	  [208],	  [209],	  [210]	  but	  it	  
failed	  to	  prevent	  T1D	  in	  a	  large	  clinical	  trial	  [211].	  It	  is	  still	  matter	  of	  debate	  if	  SIRT1	  or	  PARP	  
inhibition	   along	   with	   re-­‐filling	   of	   the	   NAD+	   stocks	   is	   the	   predominant	   cause	   of	   the	   Nam-­‐
driven	  effects	  [212],	  [213].	  However,	  an	  Nam	  derivative,	  isonicotinamide,	  which	  antagonizes	  
Nam-­‐induced	   SIRT1	   inhibition,	   protects	   against	   STZ-­‐induced	  hyperglycemia	   in	  high	   fat	   diet	  
animals	  and	  β-­‐cell	  damage	  in	  isolated	  islets	  [214].	  Finally,	  whole	  body	  SIRT1	  null	  mice	  but	  at	  
the	  same	  time	  mice	  overexpressing	  SIRT1	  in	  the	  β-­‐cells	  are	  more	  prone	  to	  mldSTZ-­‐induced	  
autoimmune	  diabetes	  compared	  to	  SIRT1	  +/-­‐	  mice	  [215],	  [216].	  Based	  on	  this	  contrary	  data,	  
the	   complex	   role	   of	   SIRT1	   in	   the	   context	   of	   diabetes	   is	   not	   fully	   understood	   and	   further	  
investigation	  is	  needed.	  	  
In	  this	  work,	  we	  focused	  on	  the	  diverse	  functions	  of	  SIRT1	  on	  glucose	  metabolism	  and	  in	  the	  
development	  of	  T1D.	  We	  used	   inducible	  β-­‐cell	  specific	  SIRT1	  knock-­‐out	  mice	  to	   investigate	  









4.2.3	  Methods	  	  
4.2.3.1	  Animals	  	  
The	  Pdx1creER:flxSirt1	  mice	  were	   kindly	  provided	  by	  M.B.	  Wheeler	   [170]	   and	  backcrossed	  
for	  five	  generations	  to	  obtain	  mice	  with	  a	  clean	  C57Bl/6N	  background.	  The	  background	  was	  
monitored	  and	  confirmed	  by	  array	  testing	  at	  Biolytix.	  In	  the	  adult	  pancreas,	  Pdx1	  promoter	  is	  
expressed	   specifically	   in	   β-­‐cells.	   According	   to	   the	   commonly	   used	   cre-­‐loxP	   system,	   the	  
injection	   of	   tamoxifen	   causes	   β-­‐cell	   specific	   deletion	   of	   the	   loxP-­‐flanked	   exon	   4	   of	   Sirt1	  
which	   encodes	   the	   catalytic	   domain	   of	   SIRT1.	   Heterozygous	   animal	   breeding	   for	   the	   cre	  
insertion	   was	   done	   to	   obtain	   flxSirt+/+_cre+/-­‐	   (hereafter	   referred	   to	   as	   Cre+)	   and	  
flxSirt+/+_cre-­‐/-­‐	  (hereafter	  referred	  to	  as	  Cre-­‐)	  littermates.	  The	  knock-­‐out	  of	  SIRT1	  in	  β-­‐cells	  
was	   induced	   in	   8-­‐11	   weeks	   old	   mice	   by	   daily	   intraperitoneal	   injections	   of	   75	   mg	  
tamoxifen/kg	  body	  weight	  (T5648,	  Sigma)	  dissolved	  in	  corn	  oil	  or	  pure	  corn	  oil	  as	  control	  for	  
five	   consecutive	   days.	   Earliest	   14	   days	   after	   the	   last	   injection,	   mice	   were	   used	   for	  
experiments.	   In	   the	   beginning,	   both	   Cre+	   and	   Cre-­‐	   animals	   were	   used	   with	   and	   without	  
tamoxifen	  treatment.	  Since	  we	  did	  not	  see	  effects	  by	  the	  presence	  of	  cre	  alone	  or	  tamoxifen	  
alone,	  we	  stopped	  using	  all	  the	  controls	  and	  only	  used	  Cre+	  animals	  with	  corn	  oil	  (“WT”)	  or	  
with	  tamoxifen	  (“KO”)	  injections.	  All	  animals	  were	  housed	  in	  a	  temperature-­‐controlled	  room	  
with	   a	   12	   h	   light/12	   h	   dark	   cycle,	   were	   allowed	   free	   access	   to	   food	   and	   water	   and	  
experiments	   were	   conducted	   according	   to	   the	   swiss	   veterinary	   law	   and	   to	   institutional	  
guidelines.	  
	  
4.2.3.2	  Multiple	  low	  dose	  streptozotocin	  experiments	  	  
At	  the	  age	  of	  10-­‐13	  weeks	  mice	  were	  injected	  intraperitoneally	  with	  40	  mg/kg	  body	  weight	  
streptozotocin	  (STZ;	  S0130,	  Sigma)	  dissolved	  in	  20	  mM	  sodium	  citrate	  buffer	  (pH	  4.5)	  for	  five	  
consecutive	  days.	  Body	  weight	  and	  blood	  glucose	  levels	  were	  monitored	  every	  second	  day.	  
Cages	   and	   drinking	  water	  were	   changed	   according	   to	   the	   need	   but	   usually	   twice	   a	  week.	  
Mice	   were	   killed	   at	   day	   21	   after	   the	   first	   STZ	   injection	   or	   earlier	   if	   a	   continuation	   was	  




4.2.3.3	  Glucose	  tolerance	  tests	  	  
For	   intraperitoneal	   glucose	   tolerance	   tests,	  mice	   were	   fasted	   for	   6	   h	   in	   the	  morning	   and	  
injected	  intraperitoneally	  with	  2	  g	  glucose/kg	  body	  weight.	  Blood	  glucose	  was	  measured	  at	  
time	  points	  0,	  15,	  30,	  60,	  90,	  and	  120	  min	  using	  a	  glucometer	   (Freestyle;	  Abbott	  Diabetes	  
Care	  Inc.,	  Alameda,	  CA)	  and	  blood	  was	  taken	  at	  0,	  15	  and	  30	  min	  for	  measurement	  of	  plasma	  
insulin	  concentrations	  using	  mouse	  insulin	  assays	  (Mesoscale	  Discovery).	  	  	  	  
4.2.3.4	  Islet	  isolation	  	  
For	   mouse	   islet	   isolation,	   the	   pancreas	   was	   perfused	   with	   HBSS	   containing	   1.4	   mg/ml	  
collagenase	  (Worthington,	  Lakewood,	  NJ),	  10	  mg/ml	  DNase	  (1:3000	  to	  HBSS	  volume;	  Roche,	  
Cat.	  No.	  11284932001)	  and	  0.5%	  w/v	  BSA	  (Merck,	  1120180100)	  and	  digested	  for	  30	  min	  at	  
37°C	   and	   5%	   CO2,	   followed	   by	   washing	   steps	   and	   filtration	   through	   70	   and	   500	   μm	   cell	  
strainers.	  Mouse	  islet	  culture	  medium	  consisted	  of:	  RPMI-­‐1640	  medium	  containing	  11.1	  mM	  
glucose,	   100	   units/ml	   penicillin,	   100	   mg/ml	   streptomycin,	   2	   mM	   glutamax,	   50	   mg/ml	  
gentamicin,	  10	  mg/ml	  Fungizone	  (Gibco),	  and	  10%	  fetal	  calf	  serum	  (FCS).	  Islets	  were	  cultured	  
on	   extracellular-­‐matrix-­‐coated	   24	   well	   plates	   for	   36	   h	   prior	   to	   treatment	   with	   IL-­‐1β	   and	  
subsequent	   RNA	   isolation	   or	   they	   were	   used	   for	   glucose-­‐stimulated	   insulin	   secretion	  
experiments.	  
	  
4.2.3.5	  Glucose-­‐stimulated	  insulin	  secretion	  	  
For	  ex	  vivo	  glucose-­‐stimulated	   insulin	  secretion	  experiments,	  25	   islets/well	  were	  plated	  on	  
extracellular-­‐coated	   24-­‐well-­‐plates	   for	   2	   days.	   Supernatants	   were	   stored	   at	  -­‐20°C	   (chronic	  
insulin	  release).	  Cells	  were	  incubated	  for	  30	  min	  in	  modified	  Krebs-­‐Ringer	  bicarbonate	  buffer	  
(mKRBB	  =	  115	  mM	  sodium	  chloride,	  4.7	  mM	  potassium	  chloride,	  2.6	  mM	  calcium	  chloride	  
dihydrate,	   1.2	   mM	   mono	   potassium	   sulfate,	   1.2	   mM	   magnesium	   sulfate	   heptahydrate,	  
10	  mM	   HEPES	   and	   0.5%	   bovine	   serum	   albumin	   [pH	   7.4])	   containing	   2.8	   mM	   glucose.	  
Medium	  was	  changed	  and	  islets	  were	  incubated	  in	  new	  mKRBB	  supplemented	  with	  2.8	  mM	  
glucose	  for	  1	  h	  (basal	  insulin	  release),	  followed	  by	  1	  h	  in	  mKRBB	  containing	  16.7	  mM	  glucose	  
(stimulated	   insulin	   release).	   Islets	   were	   extracted	   with	   0.18	   N	   hydrogen	   chloride	   in	   70%	  
ethanol	   for	   2	   h	   in	   room	   temperature	   to	   determine	   insulin	   content.	   Insulin	   concentrations	  
84	  	  
were	   measured	   using	   mouse/rat	   insulin	   kits	   (Mesoscale	   Discovery,	   Rockville,	   MD).	  
Stimulatory	  index	  was	  determined	  as	  ratio	  of	  stimulated	  to	  basal	  insulin	  release.	  	  
4.2.3.6	  RNA	  isolation	  and	  quantitative	  PCR	  	  
After	   isolation,	  80	  islets	  were	  plated	  on	  extracellular	  matrix-­‐coated	  24-­‐well-­‐plates	  for	  36	  h.	  
Medium	  was	  changed	  and	  islets	  were	  treated	  with	  or	  without	  1	  ng/ml	  recombinant	  mouse	  
IL-­‐1β	  (R&D	  Systems,	  401-­‐ML)	  for	  24	  h.	  Total	  RNA	  was	  extracted	  using	  the	  Nucleo	  Spin	  RNA	  II	  
kit	   (Macherey-­‐Nagel,	   Düren,	   Germany).	   The	   isolated	   RNA	   was	   reverse	   transcribed	   using	  
Superscript	  II	  (Invitrogen)	  and	  random	  hexamer	  primers	  (Microsynth,	  Balgach,	  Switzerland).	  
Quantitative	   PCR	  was	  done	  with	   the	   real-­‐time	  PCR	   system	  7500	   (Applied	  Biosystems)	   and	  
the	   following	   mouse	   TaqMan	   assays	   (Life	   Technologies)	   were	   used:	   β-­‐actin:	  
Mm00607939_s1,	   Sirt1:	   Mm01168519_m1,	   Sirt2:	   Mm01149204_m1,	   Sirt3:	  
Mm00452131_m1,	   IL-­‐6:	   Mm00446190_m1,	   IL-­‐1β:	   Mm00434228_m1,	   Cxcl1:	  
Mm00433859_m1,	   Ins2:	   Mm00731595_gH,	   Gcg:	   Mm00801714_m1,	   UCP2:	  
Mm00627599_m1,	   Emr1:	   Mm00802529_m1,	   Ptprc:	   Mm01293577_m1	   and	   Ccl2:	  
Mm00441242_m1.	  	  	  
4.2.3.7	  Oxygen	  consumption	  assay	  	  
Seahorse	  Bioscience	   technology	  was	  used	   to	   test	  mitochondrial	   function	  of	   isolated	   islets.	  
Pancreatic	  mouse	   islets	  were	   isolated	   and	   incubated	   in	  mouse	   islet	  medium	   (see	   chapter	  
“Islet	  isolation”)	  over	  night	  at	  37°C.	  The	  next	  day,	  islets	  were	  handpicked	  and	  70	  islets/well	  
were	  seeded	   in	  a	  XF24	   islet	  capture	  microplate	   (Seahorse	  Bioscience)	   in	  unbuffered	  RPMI-­‐
1640	  medium	   (R1383,	   SIGMA)	   supplemented	  with	   3	  mM	  glucose	   and	  0.5%	  BSA	  and	  were	  
incubated	  at	  37°C	  without	  CO2	  for	  2	  h.	  To	  test	  the	  reaction	  to	  high	  glucose	  conditions,	  ATP	  
turnover,	   maximal	   respiratory	   capacity	   and	   non-­‐mitochondrial	   respiration	   of	   the	   islets,	  
20	  mM	   glucose,	   5	   µM	   oligomycin,	   3	   µM	   of	   the	   uncoupler	   carbonyl	   cyanide-­‐4-­‐
(trifluoromethoxy)phenylhydrazone	   (FCCP),	   and	  5	  µM	   rotenone	  were	   injected	   successively	  




4.2.4	  Results	  	  
4.2.4.1	  Deletion	  of	  SIRT1	  in	  β-­‐cells	  does	  not	  influence	  the	  vitality	  of	  the	  mice	  	  
The	  knock-­‐out	  of	  SIRT1	  in	  β-­‐cells	  was	  induced	  via	  daily	   intraperitoneal	  tamoxifen	  injections	  
for	  five	  days	  in	  Cre+	  mice.	  The	  inducible	  deletion	  strategy	  is	  illustrated	  in	  Figure	  1A.	  Control	  
mice	   (Cre+)	  were	   injected	  with	   corn	  oil.	   Earliest	  14	  days	  after	   the	   last	   injection	  mice	  were	  
used	  for	  in	  vivo	  experiments	  or	  sacrificed	  for	  in	  vitro	  tests.	  The	  knock-­‐down	  of	  SIRT1	  in	  islets	  
was	   confirmed	   at	   the	   gene	   expression	   level	   by	   quantitative	   PCR	   (Fig.	   1B	   left)	   and	   at	   the	  
protein	   level	   by	  western	   blotting	   using	   anti-­‐mouse	   Sir2	   antibodies	   (corresponding	  murine	  




Figure	  1.	  SIRT1	  specifically	  knocked	  out	  in	  β-­‐cells	  does	  not	  influence	  vital	  functions	  of	  the	  mice.	  (A)	  Schematic	  
Sirt1	  exon	  4	  locus.	  Adapted	  from	  [170].	  (B)	  Confirmation	  of	  specific	  knock-­‐out	  of	  SIRT1	  in	  islets	  but	  not	  in	  liver	  
and	  spleen	  by	  qPCR.	  Gene	  expression	  levels	  are	  normalized	  to	  actin	  and	  to	  the	  WT	  control	  of	  each	  tissue.	  (C)	  
Absence	  of	  SIRT1	  protein	   in	   islets	  of	   the	  knock-­‐out	  mice,	   visualized	  by	  a	   representative	  western	  blot	  picture	  
using	  anti-­‐mouse	  Sir2	  antibodies	  (Millipore)	  and	  the	  actin	  control.	   (D)	  Body	  weight	  and	  (E)	  spleen	  weight	  two	  
weeks	  after	  the	  first	  tamoxifen	  injection.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  three	  
(B,	   liver	  &	  spleen)	  or	   five	   (B,	   islets)	   independent	  experiments.	   In	   (D)	  and	   (E)	  one	  dot	   represents	  one	  mouse.	  





There	   is	   still	   residual	   SIRT1	   gene	   and	   protein	   detection	   in	   the	   islets	   probably	   due	   to	  
expression	  in	  α-­‐cells	  and	  other	  non	  β-­‐cells.	  Sirt1	  gene	  expression	  levels	  in	  other	  tissues	  such	  
as	  liver	  and	  spleen	  were	  not	  changed	  in	  the	  SIRT1	  KO	  mice	  compared	  to	  the	  controls	  (Fig.	  1B	  
middle	   and	   right).	   Compensatory	   upregulation	   of	   genes	   of	   other	   sirtuin	   family	   members,	  
such	  as	  Sirt2	  or	  Sirt3,	  was	  not	  observed	  in	  the	  islets	  of	  SIRT1	  KO	  mice	  (data	  not	  shown).	  No	  
obvious	   change	   of	   behavior,	   health	   and	   body	   weight	   of	   the	   mice	   was	   noted	   due	   to	   the	  
knock-­‐out	  of	  SIRT1	  (Fig.	  1D).	  However,	  we	  observed	  splenomegaly	  in	  the	  mice	  with	  the	  SIRT1	  
deletion	  (Fig.	  1E)	  but	  not	  in	  Cre-­‐	  mice	  with	  or	  without	  tamoxifen	  treatment	  (data	  not	  shown),	  





4.2.4.2	  SIRT1	  knock-­‐out	  in	  β-­‐cells	  deteriorates	  glucose	  tolerance,	  changes	  metabolic	  
key	  gene	  expression	  and	  increases	  islet	  inflammation	  	  	  
It	  has	  been	  shown	  that	  SIRT1	  in	  β-­‐cells	   is	  an	  important	  regulator	  of	  metabolic	  homeostasis	  
[170].	   To	   confirm	   these	   data	   obtained	   with	   mice	   on	   a	   mixed	   genetic	   background	   in	   our	  
backcrossed	   mice,	   we	   performed	   intraperitoneal	   glucose	   tolerance	   tests	   in	   Cre+	   and	   Cre-­‐	  
mice	   with	   oil	   or	   tamoxifen	   injections.	   As	   shown	   in	   Figure	   2A+B,	   the	   β-­‐cell	   specific	   SIRT1	  
knock-­‐out	  mice	  (“SIRT1	  KO”)	  had	  a	  significantly	  impaired	  glucose	  tolerance	  and	  lower	  insulin	  
secretion	  when	  compared	  to	  the	  control	  mice	  treated	  with	  oil	  (“WT”).	  Cre	  or	  tamoxifen	  itself	  
did	  not	   influence	  metabolic	  parameters	  since	  Cre-­‐	  mice	  displayed	  no	  differences	   in	  glucose	  
tolerance	  or	   insulin	   secretion	  when	   injected	   either	  with	  oil	   or	  with	   tamoxifen	   (Fig.	   2C+D).	  
Therefore,	  we	  did	  not	  include	  Cre-­‐	  controls	  in	  the	  following	  experiments.	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Figure	   2.	   SIRT1	   knock-­‐out	   in	   β-­‐cells	   deteriorates	   glucose	   tolerance	   and	   insulin	   secretion.	   Intraperitoneal	  
glucose	  tolerance	  tests	  in	  Cre+	  (A)	  and	  Cre-­‐	  (C)	  mice	  with	  injections	  of	  tamoxifen	  (A	  in	  red,	  C	  solid	  line)	  and	  oil	  (A	  
in	  green,	  C	  dashed	  line)	  and	  corresponding	  blood	  insulin	  measurements	  at	  time	  points	  0,	  15	  and	  30	  min	   (B)	  +	  
(D).	  Statistics	  were	  performed	  using	  the	  student	  t	  test	  at	  the	  indicated	  time	  points.	  Bar	  graphs	  are	  expressed	  as	  
mean	   ±	   SEM.	   Data	   are	   averages	   of	   three	   independent	   experiments	   with	   a	   total	   of	   7-­‐10	   mice	   per	  







In	  line	  with	  the	  decreased	  basal	  plasma	  insulin	  in	  vivo,	  we	  saw	  lower	  gene	  expression	  levels	  
of	  Ins2,	  encoding	  insulin,	  in	  ex	  vivo	   isolated	  islets	  from	  the	  SIRT1	  KO	  mice	  compared	  to	  the	  
controls	   (Fig.	  3A).	  Additionally,	   relative	  gene	  expression	   levels	  of	  glucagon	  were	   increased	  
and	   levels	   of	   Pdx1,	   an	   insulin	   gene	   specific	   transcription	   factor,	   decreased	   (Fig.	   3B+C),	  
whereas	   there	  was	  no	  difference	   in	  mRNA	   levels	  of	   the	  uncoupling	  protein	  Ucp2	   (Fig.	   3D)	  


















Figure	  3.	  SIRT1	   knock-­‐out	   in	  β-­‐cells	   influences	   the	  expression	  of	   key	  metabolic	   genes	  ex	   vivo.	   (A)	   Ins2,	   (B)	  
glucagon,	   (C)	  Pdx1	   and	   (D)	  Ucp2	   gene	  expression	   in	   islets	  of	  mice	   lacking	  SIRT1	   in	  β-­‐cells	   (KO	   in	   red)	   versus	  
controls	  (WT	  in	  black).	  Relative	  expression	  levels	  were	  normalized	  to	  actin.	  Statistics	  were	  performed	  using	  the	  
student	  t	  test.	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  three	  independent	  experiments.	  
*p	  <	  0.05.	  
	  
	  
However,	  ex	  vivo	  functional	  experiments	  with	  isolated	  islets	  of	  the	  knock-­‐out	  mice	  were	  not	  
consistent	  with	  the	  in	  vivo	  findings.	  Glucose-­‐stimulated	  insulin	  secretion	  assays	  revealed	  no	  
significant	   differences	   between	   the	   groups	   (Fig.	   4A).	   Unexpectedly,	   the	   stimulatory	   index	  
was	   slightly	   higher	   in	   the	   SIRT1	   KO	   islets	   (Fig.	   4B),	   whereas	   total	   insulin	   content	  was	   the	  
same	  (Fig.	  4C).	  We	  observed	  a	  mild	  decrease	  in	  chronic	  insulin	  release	  in	  the	  SIRT1	  KO	  group	  




















Figure	  4.	  SIRT1	  knock-­‐out	  in	  β-­‐cells	  does	  not	  change	  glucose-­‐stimulated	  insulin	  secretion	  ex	  vivo.	  (A)	  Glucose-­‐
stimulated	   insulin	   secretion	   assay	   in	   WT	   (white)	   and	   SIRT1	   KO	   mice	   (black),	   relative	   insulin	   amount	   is	  
normalized	   to	   total	   insulin	  content.	   	  Basal	  =	  2.8	  mM	  glucose,	   stimulated	  =	  16.7	  mM	  glucose.	   (B)	   Stimulatory	  
index	  of	  the	  insulin	  secretion	  was	  defined	  as	  stimulated	  to	  basal	   insulin	  release.	  (C)	  Total	   insulin	  content	  was	  
extracted	   by	  HCl/EtOH.	   (D)	   Chronic	   insulin	   release	   after	   36	   h	   culturing.	   Statistics	  were	   performed	   using	   the	  





To	  further	  understand	  these	  findings,	  we	  tested	  the	  mitochondrial	  function	  of	  the	  islets	  with	  
the	  Seahorse	  technology	  (Bucher	  AG).	  Starting	  with	  a	  higher	  basal	  oxygen	  consumption	  rate	  
(OCR),	  which	   reflects	  mitochondrial	   respiration,	  under	   low	  glucose	  conditions,	   the	   islets	  of	  
the	  SIRT1	  KO	  mice	  compared	  to	  the	  WT	  control	  mice	  reached	  a	  slightly	  lower	  OCR	  level	  after	  
injection	  of	  17	  mM	  glucose	   (Fig.	  5A).	  We	  did	  not	  observe	  differences	  after	   treatment	  with	  
oligomycin,	   FCCP	   and	   rotenone	   indicative	   for	   ATP	   turnover,	  maximal	   respiration	   rate	   and	  
non-­‐mitochondrial	  respiration,	  respectively	  (Fig.	  5A).	  Extracellular	  acidification	  rates	  (ECAR),	  
representing	  glycolytic	  processes,	  were	  slightly	  increased	  in	  islets	  of	  the	  KO	  mice	  upon	  high	  
glucose	  stimulation	  without	  reaching	  significance	  (Fig.	  5B).	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Figure	   5.	   Mitochondrial	   glucose	   sensing	   is	   impaired	   in	   islets	   of	   mice	   lacking	   SIRT1	   in	   β-­‐cells.	   (A)	  Oxygen	  
consumption	   rates	   (OCR)	   and	   (B)	   extracellular	   acidification	   rates	   (ECAR)	   of	   isolated	  WT	   and	   SIRT1	   KO	   islets	  
determined	  by	  the	  Seahorse	  instrument.	  Successive	  injections	  of	  17	  mM	  glucose	  (end	  concentration	  20	  mM),	  
the	   ATP	   synthase	   inhibitor	   oligomycin,	   the	   uncoupler	   FCCP	   (carbonyl	   cyanide-­‐4-­‐
(trifluoromethoxy)phenylhydrazone)	   and	   rotenone	   were	   done	   on	   70	   islets/well	   in	   unbuffered	   environment.	  





Since	  SIRT1	  was	  shown	  to	  protect	  β-­‐cells	  from	  the	  induction	  of	  pro-­‐inflammatory	  cytokines	  
in	   islets	   [192],	   [194]	   we	   wondered	   if	   there	   is	   a	   link	   between	   deterioration	   of	   glucose	  
tolerance	  and	  islet	  inflammation	  in	  our	  SIRT1	  KO	  mice.	  Therefore,	  we	  isolated	  islets	  of	  SIRT1	  
KO	  mice	  and	  controls	  and	  treated	  them	  with	  or	  without	  1	  ng/ml	  IL-­‐1β	  for	  24	  h	  ex	  vivo.	  The	  
induction	  of	  pro-­‐inflammatory	  cytokines	  and	  chemokines,	  such	  as	  IL-­‐1β,	  IL-­‐6	  and	  Cxcl1	  were	  
elevated	   in	   mice	   lacking	   SIRT1	   in	   β-­‐cells	   after	   stimulation	   with	   IL-­‐1β	   (Fig.	   6A-­‐C).	   Basally,	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mRNA	   levels	  of	   the	  macrophage	  marker	  Emr1,	  which	   is	  encoding	  F4/80,	  were	   increased	   in	  
the	   islets	  of	   the	  SIRT1	  KO	  mice	  and	  after	   stimulation	  Ptprc,	  which	   is	  encoding	   the	  general	  
immune	  cell	  marker	  CD45	  (Fig.	  6D+E).	  Interestingly,	  the	  gene	  expression	  of	  Ccl2,	  a	  monocyte	  
chemotactic	  protein,	  in	  islets	  of	  the	  SIRT1	  KO	  mice	  was	  significantly	  lower	  (Fig.	  6F).	  	  	  
	  
	  
Figure	  6.	  The	  induction	  of	  pro-­‐inflammatory	  cytokines,	  chemokines	  and	  immune	  cell	  markers	  is	  increased	  in	  
islets	  of	  mice	  lacking	  SIRT1	  in	  β-­‐cells.	  Relative	  gene	  expression	  levels	  of	  (A)	  IL-­‐1β,	  (B)	  IL-­‐6,	  (C)	  Cxcl1,	  (D)	  Emr1	  
encoding	  F4/80,	  (E)	  Ptprc	  which	  is	  encoding	  CD45	  and	  (F)	  Ccl2	  encoding	  MCP-­‐1	  in	  islets	  of	  mice	  lacking	  SIRT1	  in	  
β-­‐cells	  (red)	  and	  control	  mice	  (black)	  with	  and	  without	  treatment	  with	  1	  ng/ml	  IL-­‐1β	  for	  24	  h.	  Data	  are	  averages	  
of	   three	   independent	   experiments.	   Bar	   graphs	   are	   expressed	   as	   mean	   ±	   SEM.	   Statistics	   were	   done	   using	  
ANOVA.	  *p	  <	  0.05.	  
	  	  	  
4.2.4.3	   SIRT1	   knock-­‐out	   in	   β-­‐cells	   protects	   mice	   from	   multiple	   low	   dose	  
streptozotocin-­‐induced	  hyperglycemia	  	  
Since	  islet	  inflammation	  is	  also	  associated	  with	  T1D	  and	  the	  lack	  of	  SIRT1	  in	  mice	  was	  shown	  
to	  worsen	  [215]	  but	  also	  to	  decrease	  the	  susceptibility	  to	  T1D	  [216],	  we	  wanted	  to	  test	  the	  
influence	  of	  β-­‐cell	   specific	   SIRT1	  knock-­‐down	  on	   the	  onset	  of	  T1D.	   Therefore	  we	  used	   the	  
multiple	  low	  dose	  streptozotocin	  model	  (mldSTZ),	  which	  is	  characterized	  by	  destruction	  of	  β-­‐
cells	  and	   islet	   immune	  cell	   infiltrations.	  Two	  weeks	  after	   the	   induction	  of	   the	  SIRT1	  knock-­‐
out,	  mice	  were	  injected	  with	  STZ	  for	  five	  consecutive	  days	  and	  blood	  glucose	  was	  monitored	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the	  following	  21	  days.	  We	  observed	  a	  strong	  protection	  from	  the	  STZ-­‐induced	  hyperglycemia	  
(defined	  as	  blood	  glucose	  >10	  mM)	   in	   the	  SIRT1	  KO	  group	  compared	   to	   the	  WT	  mice	   (Fig.	  
7A).	  	  
	  
Figure	  7.	  Knock-­‐out	  of	  SIRT1	  in	  β-­‐cells	  protects	  mice	  from	  STZ-­‐induced	  hyperglycemia.	  (A)	   Incidence	  of	  STZ-­‐
induced	  hyperglycemia,	  defined	  as	  blood	  glucose	  >10	  mM.	  SIRT1	  KO	  mice	  are	  shown	  in	  red	  and	  control	  mice	  in	  
green.	  (B)	  Random	  blood	  glucose	  was	  taken	  in	  the	  afternoon	  during	  the	  STZ	  experiment.	  (C)	  Body	  weight	  of	  the	  
SIRT1	  KO	  (red)	  and	  control	  mice	  (green).	  Bar	  graphs	  are	  expressed	  as	  mean	  ±	  SEM.	  Data	  are	  averages	  of	  four	  
independent	  experiments	  with	  a	  total	  of	  12-­‐20	  mice	  dependent	  on	  the	  day,	  as	  described	  in	  the	  graph	  (d=day).	  




The	  difference	   in	  plasma	  glucose	  was	  already	  evident	  at	  day	  4	  after	   the	   first	   STZ	   injection	  
and	  was	  present	  until	  the	  end	  of	  the	  experiment.	  Contrasting	  to	  the	  WT	  mice,	  where	  100%	  
of	  the	  animals	  became	  diabetic,	  in	  the	  KO	  group	  only	  67%	  of	  the	  mice	  became	  diabetic.	  The	  
absolute	   values	   of	   random	   blood	   glucose	   measurements	   of	   the	   KO	   mice	   always	   stayed	  
below	  the	  values	  of	  the	  control	  group	  (Fig.	  7B).	  Mice	  of	  both	  groups	  were	  losing	  body	  weight	  
during	   the	   experiment,	   which	   is	   associated	   with	   the	   severity	   of	   the	   diabetes.	   The	   lower	  
number	  of	  diabetic	  mice	  was	  also	  reflected	  by	   less	  body	  weight	   reduction	   in	   the	  SIRT1	  KO	  
mice	  compared	  to	  the	  controls	  (Fig.	  7C).	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4.2.5	  Discussion	  	  
In	  this	  study	  we	  demonstrate	  that	  SIRT1	  expressed	   in	  β-­‐cells	  plays	  a	  crucial	  role	   in	  glucose	  
homeostasis,	  islet	  inflammation	  and	  the	  development	  of	  diabetes.	  The	  knock-­‐out	  of	  SIRT1	  in	  
β-­‐cells	   caused	   impaired	   glucose	   tolerance	   and	   lower	   insulin	   levels	   along	   with	   defects	   in	  
mitochondrial	   glucose	   sensing	   and	   increased	   cytokine	   and	   chemokine	  production	   in	   islets.	  
However,	  in	  the	  context	  of	  type	  1	  diabetes,	  SIRT1	  activity	  in	  β-­‐cells	  seems	  to	  be	  detrimental	  
since	   our	   SIRT1	   KO	  mice	  were	   protected	   from	   STZ-­‐induced	   diabetes	   and	   the	   loss	   of	   body	  
weight.	  
In	   line	  with	   former	   studies	   of	   Luu	   et	   al.	   [170],	   SIRT1	   deletion	   in	   β-­‐cells	   leads	   to	   impaired	  
glucose	   tolerance	   and	   insulin	   secretion	   in	   our	   mouse	   model.	   However,	   the	   differences	  
between	  SIRT1	  KO	  and	  WT	  mice	  were	  less	  pronounced	  than	  those	  reported	  by	  Luu	  et	  al.	  This	  
could	   be	   explained	   by	   different	  methods	   that	   have	   been	   used:	   In	   our	   experiments,	   mice	  
were	  fasted	  for	  6	  h	  and	  injected	  intraperitoneally	  with	  glucose,	  whereas	  Luu	  et	  al.	  fasted	  for	  
14	  h	  and	  performed	  oral	  glucose	  tolerance	  tests,	  which	  involve	  incretin	  release	  and	  thereby	  
boost	   insulin	   secretion.	  Furthermore,	  we	  have	  used	   littermate	  and	   fully	  backcrossed	  mice,	  
while	  to	  our	  knowledge	  Luu	  et	  al.	  used	  mice	  on	  a	  mixed	  background.	  	  
Ex	  vivo	  after	  islet	  isolation,	  we	  did	  not	  see	  differences	  in	  glucose-­‐stimulated	  insulin	  secretion	  
experiments.	   If	   anything,	   the	   stimulatory	   index	   of	   the	   SIRT1	   KO	   islets	   was	   increased	  
compared	  to	  the	  WT	  control	  mice.	  This	  finding	  contrasts	  previous	  studies	  showing	  that	  islets	  
of	  β-­‐cell	  specific	  SIRT1	  knock-­‐out	  mice	  and	  β-­‐cells	  treated	  with	  SIRT1	  siRNA	  exhibit	  blunted	  
insulin	   release	   upon	   glucose	   stimulation	   [170],	   [150].	   It	   has	   been	   discussed	   earlier	   that	  
pronounced	   in	  vivo	  effects	  can	  change	  in	  ex	  vivo	  experiments	  [253],	  [254];	  what	  likely	  may	  
be	   the	   case	   in	   our	   glucose-­‐stimulated	   insulin	   secretion	   experiments.	   Certain	   deteriorating	  
factors	  may	  be	  missing	  after	  islet	  isolation	  and	  plating	  on	  extracellular-­‐matrix-­‐coated	  plates	  
for	   36	   h	   may	   lead	   to	   islet	   recovery	   and	   improved	   function,	   covering	   negative	   effects	  
observed	  in	  vivo.	  
Furthermore,	   the	   basal	   expression	   of	   key	  metabolic	   genes	   including	   insulin,	  glucagon	   and	  
Pdx1	   was	   altered	   in	   isolated	   islets	   of	   the	   SIRT1	   KO	   compared	   to	   the	   control	  mice.	   Lower	  
insulin	   and	   Pdx1	   mRNA	   levels	   ex	   vivo	   are	   in	   agreement	   with	   lower	   insulin	   levels	   and	   the	  
deterioration	  of	  glucose	  tolerance	  in	  vivo.	  Accordingly,	  SIRT1	  has	  been	  reported	  to	  promote	  
insulin	  and	  Pdx1	  expression	  [193],	  [255].	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Previous	  studies	  have	  shown	  that	  the	  expression	  of	  Ucp2,	  which	  decreases	  insulin	  secretion,	  
is	   upregulated	   in	   SIRT1	   knock-­‐out	   models	   and	   downregulated	   in	   SIRT1	   overexpressing	  
models	   [167],	   [150].	   In	   contrast	   to	   that,	  Ucp2	   gene	   expression	  was	   unchanged	   in	   isolated	  
islets	  of	  our	  mice,	  which	  is	  congruent	  with	  the	  study	  from	  Luu	  et	  al.	  [170]	  and	  points	  to	  an	  
Ucp2	  independent	  mechanism	  in	  the	  deterioration	  of	  insulin	  secretion.	  The	  determination	  of	  
Ucp2	  protein	  levels	  would	  be	  helpful	  to	  further	  evaluate	  this	  finding.	  
However,	  in	  our	  study	  we	  revealed	  defects	  in	  mitochondrial	  function	  of	  the	  SIRT1	  KO	  islets.	  
There	  was	  a	  pronounced	  higher	  basal	  oxygen	   consumption	   rate	  and	  a	  decreased	   coupling	  
efficiency,	  indicating	  the	  translation	  of	  high	  glucose	  levels	  to	  elevated	  oxygen	  consumption.	  
In	  former	  studies,	  SIRT1	  has	  been	  shown	  to	  regulate	  mitochondrial	  biogenesis	  and	  function	  
in	  metabolically	  active	  tissues	  [256]	  including	  β-­‐cells	  [170].	  Since	  basal	  levels	  of	  insulin	  were	  
lower	  in	  islets	  and	  in	  the	  circulation	  of	  the	  SIRT1	  KO	  mice,	  the	  observed	  higher	  basal	  oxygen	  
consumption	  rates	  could	  be	  due	  to	  compensatory	  effects.	  These	  higher	  basal	  levels	  of	  OCR	  in	  
the	   islets	  of	   the	  SIRT1	  KO	  mice	  may	  blunt	   the	   reaction	   to	   the	  high	  glucose	   stimulation.	   In	  
parallel,	   glycolytic	  processes	  were	   slightly	   increased,	   as	   indicated	  by	  elevated	  extracellular	  
acidification	   rates.	   Since	   there	   were	   no	   differences	   in	   non-­‐mitochondrial	   and	   maximal	  
respiration,	  severe	  mitochondrial	  failure	  can	  be	  excluded.	  	  
There	  are	  several	  explanations	  why	  changed	  oxygen	  consumption	  rates	  are	  not	  reflected	  by	  
impaired	   glucose-­‐stimulated	   insulin	   secretion	   in	   isolated	   islets	   of	   SIRT1	   KO	   mice.	   As	  
described	   above,	   our	   ex	   vivo	   insulin	   secretion	   experiments	   may	   be	   misleading.	   Direct	  
comparison	   of	   glucose-­‐stimulated	   insulin	   secretion	   and	   oxygen	   consumption	   is	   biased	   by	  
experimental	  differences	  since	  the	  secretion	  assays	  are	  performed	  36	  h	  after	   islet	   isolation	  
and	   the	   mitochondrial	   testing	   12	   h	   afterwards.	   Possibly,	   the	   islets	   used	   for	   the	   glucose-­‐
stimulated	  insulin	  secretion	  experiments	  had	  more	  time	  to	  recover	  from	  the	  isolation	  stress	  
and	  may	  have	  improved	  their	  insulin	  secretion	  capacity.	  Additionally,	  islets	  used	  for	  glucose-­‐
stimulated	   insulin	  secretion	  experiments	  were	  plated	  on	  extracellular	  matrix-­‐coated	  plates	  
where	   they	   are	   less	   disturbed	  by	  hypoxia	   in	   the	   core	  of	   the	   islets,	   compared	   to	   the	   islets	  
cultured	  in	  suspension	  for	  functional	  mitochondrial	  testing.	  	  
Islet	  inflammation	  has	  been	  shown	  to	  be	  a	  main	  contributor	  to	  the	  development	  of	  glucose	  
intolerance	   and	   diabetes	   [257].	   Previous	   studies	   have	   linked	   the	   absence	   of	   SIRT1	   to	  
cytokine-­‐induced	  inflammation	  in	  various	  tissues	   including	  adipocytes,	  myeloid	  cells	  and	  β-­‐
cells	   [196],	   [199],	   [258],	   [194].	   We	   also	   observed	   increased	   gene	   expression	   of	   pro-­‐
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inflammatory	  cytokines	  and	  chemokines	  such	  as	   IL-­‐1β,	   IL-­‐6	  and	  Cxcl1	   in	   the	   islets	  of	  SIRT1	  
knock-­‐out	   mice	   upon	   stimulation	   with	   IL-­‐1β.	   Additionally,	   immune	   cell	   and	   macrophage	  
markers	   including	   Ptpcr	   and	   Emr1	   were	   upregulated	   in	   SIRT1	   KO	   islets,	   indicative	   for	  
elevated	   islet	   infiltration	   and	   inflammation,	   whereas	   the	   expression	   for	   the	   macrophage	  
chemoattractant	  Ccl2	  was	  significantly	  lower.	  We	  do	  not	  have	  an	  explanation	  for	  the	  lower	  
Ccl2	   levels	   but	   it	   may	   be	   due	   to	   compensatory	   effects	   to	   inhibit	   additional	   macrophage	  
infiltration.	   However,	   these	   findings	   further	   support	   the	   importance	   and	   the	   distinct	  
functions	  of	  β-­‐cell	  SIRT1	  in	  immunity	  and	  diabetes.	  
Finally,	  our	   in	  vivo	  data	  of	  the	  mldSTZ	  experiments	  led	  to	  a	  new	  way	  of	  thinking	  about	  the	  
role	   of	   SIRT1	   in	   the	   onset	   of	   T1D.	   The	  mice	   lacking	   SIRT1	   in	   β-­‐cells	   were	   protected	   from	  
mldSTZ-­‐induced	  hyperglycemia;	   in	   contrast	   to	   the	  wildtype	  mice	   they	  did	   not	   reach	   100%	  
diabetes	  induction	  and	  dropped	  less	  body	  weight	  throughout	  the	  experiment.	  The	  literature	  
on	   the	   role	   of	   SIRT1	   in	   the	   development	   of	   diabetes	   is	   contradictory	   and	   full	   of	   open	  
questions.	  Nonetheless,	  it	  has	  been	  shown	  in	  whole	  body	  knock-­‐out	  mice	  that	  lack	  of	  SIRT1	  
is	  increasing	  the	  susceptibility	  to	  STZ-­‐induced	  hyperglycemia	  [215].	  The	  comparison	  of	  these	  
global	   SIRT1	   knock-­‐out	  mice	   with	   our	   findings	   in	   the	   β-­‐cell	   specific	   SIRT1	   knock-­‐out	  mice	  
conveys	  a	  subordinate	  role	  of	  β-­‐cell-­‐derived	  SIRT1	  in	  the	  manifestation	  of	  the	  demonstrated	  
STZ-­‐induced	  deteriorations.	   In	   absolute	   agreement	  with	   our	   data,	   it	  was	   shown	   that	  mice	  
overexpressing	  SIRT1	  in	  β-­‐cells	  are	  more	  prone	  to	  STZ-­‐induced	  diabetes	  [216].	  	  
During	  the	  demanding	  process	  of	  diabetes	  induction,	  remaining	  islets	  have	  a	  high	  workload	  
but	  try	  to	  continue	  their	  hormone	  production.	  We	  hypothesize	  that	  this	  exhaustion	  may	  be	  
improved	   by	   the	   induction	   of	   a	   “β-­‐cell	   rest”	   via	   knock-­‐out	   of	   SIRT1	   in	   β-­‐cells,	   promoting	  
longer	  islet	  survival	  and	  function	  along	  with	  resistance	  to	  T1D.	  The	  positive	  effects	  of	  β-­‐cell	  
rest	  have	  been	  shown	  in	  vitro	  and	  in	  clinical	  studies	  [259],	  [260].	  It	  is	  suggested	  that	  β-­‐cells	  
with	   increased	   workload	   may	   recover	   when	   insulin	   secretion	   is	   inhibited	   or	   exogenous	  
insulin	  is	  offered.	  
One	   should	   take	   into	   consideration	   that	  mldSTZ	   experiments	   in	   the	   context	   of	   SIRT1	   are	  
delicate	   since	   both	   substances	   are	   known	   to	   consume	   NAD+,	   either	   by	   STZ-­‐induced	  
activation	  of	  PARP	  or	  because	  it	  is	  used	  as	  cofactor	  for	  SIRT1	  [204],	  [136].	  It	  is	  possible	  that	  
the	  beneficial	   effects	  of	   the	   SIRT1	  KO	   in	  β-­‐cells	   on	   STZ-­‐induced	  hyperglycemia	   arose	   from	  
increased	   availability	   of	   NAD+	   due	   to	   the	   lack	   of	   SIRT1.	   Based	   on	   occurring	   death	   cases	  
induced	  by	  the	  SIRT1	  activator	  SRT1720	  in	  a	  mouse	  model	  of	  T1D	  [166]	  and	  on	  unpublished	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experiments	   of	   our	   group	   with	   NOD	   mice,	   which	   are	   independent	   of	   NAD+	   depletion	   by	  
PARP,	  it	  is	  more	  likely	  that	  SIRT1	  activation	  itself	  is	  detrimental	  in	  the	  context	  of	  T1D.	  
It	  has	  been	  suggested	  in	  numerous	  studies	  that	  overexpression	  and	  overactivation	  of	  SIRT1	  
in	  different	  tissues	  and	  situations	  does	  not	  necessarily	  have	  beneficial	  effects.	  It	  was	  shown	  
that	   strong	   (12.5-­‐fold)	   heart-­‐specific	   overexpression	   of	   SIRT1	   leads	   to	   the	   induction	   of	  
oxidative	   stress	   and	   cardiac	   dysfunction	   [243].	   Furthermore,	   SIRT1	   was	   linked	   to	   the	  
attenuation	  of	  β-­‐cell	  expansion	  [261],	  to	  decreased	  insulin	  sensitivity	  [185]	  and	  to	  worsening	  
of	   insulin	   resistance	   in	  diabetic	  mice	   [252].	  Overexpression	  of	  SIRT1	   failed	   to	  protect	  mice	  
from	   HFD-­‐induced	   obesity	   [169],	   [172]	   and	   impairment	   of	   insulin	   sensitivity	   [182].	  
Additionally,	  SIRT1	  overexpression	  in	  rheumatoid	  arthritis	  is	  suggested	  to	  contribute	  to	  pro-­‐
inflammatory	  cytokine	  production	  and	  apoptosis	  resistance	  [262].	  As	  mentioned	  above,	  the	  
synthetic	  small	  SIRT1	  activator	  SRT1720	  that	  was	  shown	  to	  be	  beneficial	  for	  metabolic	  and	  
mitochondrial	  function	  in	  animal	  models	  of	  T2D	  [164],	  [160],	  [263],	  [165]	  failed	  to	  improve	  
metabolic	  conditions	  in	  other	  mouse	  studies	  and	  caused	  accumulated	  death	  cases,	  shown	  by	  
Pacholec	   et	   al.	   [166]	   and	   by	   our	   research	   group	   in	   NOD	  mice	   (unpublished	   data).	   These	  
findings	  further	  suggest	  a	  negative	  role	  of	  SIRT1	  overactivation	  in	  the	  context	  of	  diabetes.	  
In	   the	   last	   few	   years,	   it	   has	   been	   pointed	   out	   that	   inhibition	   of	   histone	   deacetylases,	   the	  
group	   of	   enzymes	   where	   SIRT1	   belongs	   to,	   can	   improve	   metabolic	   functions,	   β-­‐cell	  
inflammation	   and	   insulin	   sensitivity	   via	   enhanced	   activity	   of	   PPARγ	   or	   glucose	   uptake	   in	  
muscle	   [264],	   [200].	   Additionally,	   the	   inhibition	   of	   lysine	   deacetylases	   in	   the	   NOD	  mouse	  
model	  of	  T1D	  resulted	  in	  decreased	  pro-­‐inflammatory	  factors	  in	  β-­‐cells	  and	  leukocytes	  [265].	  
SIRT1	   inhibition	   as	   possible	   treatment	   has	   been	   tested	   in	   other	   disease	   areas	   as	   well.	  
Huntington`s	   disease	   (HD)	   is	   a	   neurodegenerative	   disease	   known	   to	   develop	   through	  
transcriptional	   dysregulation	   and	   dysfunctional	   protein	   acetylation.	   The	   inhibition	   of	  
deacetylation	  by	  SIRT1	  blockage	  was	  well	  tolerated	  in	  a	  human	  study	  [266]	  and	  resulted	  in	  
improvement	  of	  HD	  pathology	   in	   several	   cell	   and	  mouse	  models	   [267].	   Thus,	   inhibition	  of	  
SIRT1	   as	   histone	   and	   protein	   deacetylase	   may	   also	   have	   beneficial	   effects	   on	   the	  





To	  summarize,	  we	  propose	  that	  SIRT1	  expressed	   in	  β-­‐cells	   is	  a	  central	   regulator	  of	  glucose	  
homeostasis,	  islet	  inflammation	  and	  the	  development	  of	  diabetes.	  It	  has	  diverse	  effects:	  on	  
one	   hand,	   deletion	   of	   SIRT1	   in	   β-­‐cells	   causes	   impaired	   glucose	   tolerance,	   mitochondrial	  
defects	  and	  elevation	  of	   inflammatory	  gene	  expression	   in	   islets.	  On	  the	  other	  hand,	   in	   the	  
context	  of	  T1D,	  knock-­‐out	  of	   SIRT1	   in	  β-­‐cells	  prevents	   the	   induction	  of	  hyperglycemia	  and	  









































5	  General	  Discussion	  and	  Conclusion	  	  	  
5.1	  Angiotensin	  II	  	  	  
In	   the	   included	   publication	   (chapter	   3.1)	   we	   present	   the	   negative	   influence	   of	   Ang	   II	   on	  
glucose	   metabolism,	   independently	   of	   vasoconstriction	   and	   insulin	   sensitivity.	   In	   high-­‐fat	  
diet	  mice	  as	  a	  model	  of	   type	  2	  diabetes,	  Ang	   II	   treatment	  results	   in	  β-­‐cell	  dysfunction	  and	  
impaired	   insulin	   secretion	   along	   with	   islet	   inflammation.	   We	   uncover	   that	   Ang	   II	   is	   an	  
inflammatory	  modulator	   involved	   in	   NF-­‐κB	   and	   IL-­‐1β-­‐mediated	   islet	   inflammation	   in	   vitro	  
and	   in	   vivo.	   Furthermore,	  we	  demonstrate	  β-­‐cell	   specific	   pro-­‐apoptotic	   and	  mitochondria-­‐
damaging	  effects	  of	  Ang	  II.	  
The	   discrepancy	   between	  our	   in	   vivo	   and	  ex	   vivo	   observations	   showing	   a	   profound	  Ang	   II	  
effect	   on	   insulin	   secretion	   in	   vivo	   and	   only	   a	   moderate	   effect	   in	   vitro	   (see	   chapter	   3.1,	  
discussion	  part)	  is	  still	  not	  fully	  understood.	  Further	  explanations	  could	  be	  discussed:	  Aside	  
from	  the	  hypothesis	  of	  missing	  immune	  cells	  after	  islet	  isolation	  and	  the	  possible	  recovery	  of	  
the	   islets	   after	   plating,	   one	   may	   speculate	   about	   the	   lack	   of	   other	   known	   factors	   that	  
classically	  influence	  in	  vivo	  insulin	  secretion,	  including	  incretins	  or	  nerval	  innervation	  [268].	  	  
We	  tested	  the	  involvement	  of	  the	  incretin	  GLP-­‐1	  on	  Ang	  II-­‐mediated	  glucose	  intolerance	   in	  
vivo	  and	  could	  not	   find	  significant	  differences	  between	  the	  groups	  (Fig.	  12).	  Unexpectedly,	  
Ang	   II	   pretreatment	   even	   tended	   to	   increase	  GLP-­‐1	   secretion	   after	   an	  orally	   administered	  
glucose	  bolus.	  This	  finding	  could	  explain	  why	   insulin	  secretion	   is	  not	   impaired	   in	  the	  Ang	  II	  
treatment	   group	   in	   this	   experiment,	   possibly	  due	   to	   compensatory	  upregulation	  of	  GLP-­‐1.	  
Since	   the	   timespan	  of	   our	   in	   vivo	   experiments	  with	   the	  Ang	   II	   releasing	  pumps	  was	  much	  
longer	   compared	   to	   the	   weekly	   oral	   administration,	   the	   GLP-­‐1	   experiments	   may	   not	   be	  
comparable.	   To	   learn	  more	   about	   the	   role	   of	  GLP-­‐1	   in	   the	  Ang	   II-­‐mediated	   effects,	   active	  
GLP-­‐1	  should	  be	  measured	  acutely	  during	  an	  oral	  glucose	  tolerance	  test	  in	  the	  plasma	  of	  the	  
mice	  implanted	  with	  the	  osmotic	  minipumps.	  One	  could	  also	  speculate	  about	  a	  possible	  role	  
of	  other	   incretins	   such	  as	  gastric-­‐inhibitory	  polypeptide	   (GIP),	  being	   repressed	  by	  Ang	   II	   in	  
the	  in	  vivo	  setting.	  	  
Further	  research	  is	  needed	  to	  understand	  the	  underlying	  mechanisms	  of	  the	  different	  effects	  
on	  insulin	  secretion	  by	  Ang	  II	  ex	  vivo	  versus	  in	  vivo.	  
99	  	  
In	  our	   study,	  we	  demonstrated	   strong	  effects	  on	  glucose	  metabolism	  and	   islet	   function	   in	  
vivo,	  which	  are	  confirmed	  by	  many	  direct	  effects	  of	  Ang	  II	  on	  primary	  β-­‐cells,	  the	  β-­‐cell	  line	  
INS-­‐1E	  and	  pancreatic	   islets	   in	  vitro.	  However,	  one	  may	  speculate	  that	  some	  of	  the	  effects	  
seen	  in	  vivo	  but	  not	  ex	  vivo	  could	  be	  mediated	  via	  the	  steroid	  hormone	  aldosterone,	  which	  is	  
stimulated	   at	   the	   end	   of	   the	   RAS	   cascade	   [269].	   There	   is	   increasing	   evidence	   that	  
aldosterone	  has	  similar	  independent	  effects	  to	  that	  of	  Ang	  II	  or	  mediates	  the	  effects	  of	  Ang	  II	  
[270].	  Aldosterone	  is	  able	  to	  impair	  glucose-­‐stimulated	  insulin	  secretion	  and	  promote	  insulin	  
resistance	   [271],	   [272],	   even	   independently	   of	   the	   mineralocorticoid	   receptor	   [273].	   The	  
secretion	   of	   aldosterone	   is	   elevated	   in	   diabetic	   patients	   [274]	   and	   several	   clinical	   studies	  
describe	   impaired	   glucose	   tolerance	   and	   insulin	   response	   in	   patients	   with	  
hyperaldosteronism,	  which	  improved	  after	  adrenalectomy	  [275],	  [276].	  
	  
Altogether,	   Ang	   II	   appears	   to	   cause	   IL-­‐1β-­‐mediated	   inflammation	   and	   β-­‐cell	   disturbing	  



























5.2	  Sirtuin	  1	  	  
	  
In	   this	   work,	   we	   characterized	   SIRT1	   as	   essential	   inflammatory	   modulator	   in	   the	  
pathogenesis	  of	  type	  1	  diabetes	  and	  autoimmune	  diseases.	  The	  functions	  of	  SIRT1	  seem	  to	  
be	  complex	  and	  dependent	  on	  various	  factors	  including	  expression	  level,	  tissue	  and	  disease	  
context.	  	  
	  
In	   the	   first	   sirtuin	   study,	   we	   demonstrate	   that	   modulation	   of	   SIRT1	   by	   a	   single	   point	  
mutation	   in	   the	   Sirt1	   gene	   influences	   metabolism	   and	   inflammation.	   Therefore,	   we	   used	  
transduced	   rat	   INS-­‐1E	   cells	   and	   a	   knock-­‐in	  mouse	  model,	   which	   is	   carrying	   a	   SIRT1	   point	  
mutation	  (L107P)	  that	  was	  associated	  with	  familial	  autoimmune	  diseases	  including	  diabetes	  
and	  colitis	  [215].	  	  
We	   show	   that	   INS-­‐1E	   β-­‐cells	   ectopically	   overexpressing	   the	   human	  mutated	   SIRT1	   L107P	  
exhibited	   higher	   susceptibility	   to	   inflammation	   and	   reduced	   β-­‐cell	   function	   along	   with	  
mitochondrial	  glucose	  sensing	  defects.	  These	  findings	  imply	  that	  the	  SIRT1	  mutation	  causes	  
a	   loss	  of	   function,	  which	   is	   in	   line	  with	  various	   studies	   reporting	  a	  beneficial	   role	  of	   SIRT1	  
overexpression	  in	  the	  context	  of	  inflammatory	  processes	  and	  insulin	  secretion	  [167],	  [194].	  
Our	   results	   suggest	   that	   the	   system	   of	   overexpressing	   human	   SIRT1	   ectopically	   in	   INS-­‐1E	  
cells	  reflects	  the	  pathophysiological	  situation	  in	  the	  patients	  regarding	  inflammation	  and	  β-­‐
cell	  dysfunction.	  
However,	  the	  introduction	  of	  the	  mutation	  in	  the	  Sirt1	  gene	  in	  the	  knock-­‐in	  mice,	  which	  is	  a	  
less	  artificial	  model	  organism	  closer	  resembling	  the	  patients,	  revealed	  a	  new	  perspective	  to	  
the	  SIRT1	  mutation	  and	  its	  effects	  on	  immune	  responses	  and	  diabetes.	  In	  apparent	  contrast	  
to	   the	   in	   vitro	   data	   with	   the	   transduced	   INS-­‐1E	   cells,	   we	   observed	   enhanced	   glucose-­‐
stimulated	  insulin	  secretion	  in	  isolated	  islets	  of	  the	  heterozygous	  and	  homozygous	  knock-­‐in	  
mice	   compared	   to	   the	   control	   mice.	   Additionally,	   intraperitoneal	   glucose	   and	   insulin	  
tolerance	   tests	   did	   not	   reveal	   differences	   between	   the	   mice,	   if	   anything,	   at	   certain	   ages	  
homozygous	  compared	  to	  wildtype	  mice	  performed	  better.	  Given	  the	  clinical	  phenotype	  of	  
the	   patients	   carrying	   the	   SIRT1	   mutation,	   this	   finding	   was	   unexpected	   and	   led	   us	   to	   the	  
hypothesis	  that	  normal	  function	  of	  SIRT1	  may	  constitutively	  be	  enhanced	  in	  our	  homozygous	  
mouse	   model,	   possibly	   leading	   to	   islet	   exhaustion	   and	   metabolic	   deterioration	   with	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increasing	  age	  or	  additional	  triggers.	  Supporting	  this	  notion,	  nearly	  all	  key	  metabolic	  genes	  
were	  basally	  upregulated	  in	  isolated	  islets	  from	  homozygous	  mice	  compared	  to	  the	  controls.	  	  
In	  line	  with	  our	  proposed	  gain-­‐of-­‐function	  theory,	  the	  knock-­‐in	  mice	  exhibit	  an	  autoimmune-­‐
like	  phenotype.	  At	  a	   first	  glance	   this	  may	  sound	  contradictory	   since	  whole	  body	  and	   liver-­‐
specific	   SIRT1	   knock-­‐out	   mice	   were	   linked	   to	   autoimmunity	   [238],	   [249]	   and	   SIRT1	   was	  
shown	   to	   inhibit	   T-­‐cell	   proliferation	   and	   inflammation	   [224],	   [220].	   However,	   SIRT1	  
activation	  leads	  to	  deacetylation	  and	  degradation	  of	  the	  transcription	  factor	  Foxp3,	  which	  is	  
constitutively	   expressed	   by	   Tregs	   [23],	   whereas	   blockage	   of	   SIRT1	   led	   to	   improved	   Treg	  
function	  [232].	  	  
In	  accordance	  with	  the	  theory	  of	  overactivated	  SIRT1	  function	  in	  our	  knock-­‐in	  mice,	  numbers	  
of	  Foxp3+	  Tregs	  were	  decreased,	  which	  may	  lead	  to	  a	  reduced	  capacity	  of	  Tregs	  to	  maintain	  
self-­‐tolerance	   and	   inflammation.	   Expression	   levels	   of	   numerous	   genes	   involved	   in	   islet	  
inflammation	  were	   induced	   in	  the	  mice,	   in	  agreement	  with	  the	  data	  of	   the	   INS-­‐1E	  cells.	   In	  
accordance	  with	  our	  knock-­‐in	  mice,	  the	  patients	  carrying	  the	  mutation	  exhibited	  lower	  Treg	  
levels	  in	  the	  blood.	  	  
Our	   preliminary	   data	   support	   the	   idea	   of	   not	   only	   reduced	   number	   but	   also	   impaired	  
function	  of	  the	  Tregs	  in	  homozygous	  SIRT1	  L102P	  mice	  compared	  to	  the	  controls.	  Both	  the	  
number	  of	  IL-­‐10	  producing	  Tregs	  and	  the	  functional	  protein	  cytotoxic	  T-­‐lymphocyte	  antigen	  
4	  (CTLA-­‐4),	  that	  is	  highly	  expressed	  by	  Tregs	  and	  that	  is	  known	  to	  decrease	  the	  inflammatory	  
response	   of	   antigen-­‐presenting	   cells,	   were	   reduced	   in	   a	   pilot	   experiment.	   Confirming	   our	  
findings	   of	   diminished	   immune	   suppressive	   capacity	   in	   the	   homozygous	   knock-­‐in	  mice,	  ex	  
vivo	  macrophages	  of	  homozygous	  mice	  exhibited	   lower	  secretion	  of	   the	  anti-­‐inflammatory	  
cytokine	   IL-­‐10	   upon	   stimulation	   compared	   to	   wildtype	   mice	   in	   our	   study.	   Furthermore,	  
preliminary	   results	   suggest	   that	   ex	   vivo	   activated	   T-­‐cells	   from	   isolated	   lymph	   nodes	   of	  
homozygous	  knock-­‐in	  mice	  secret	   less	   IL-­‐10	  than	  the	  ones	   from	  control	  mice.	  Additionally,	  
receptors	   for	   IL-­‐2	   and	   IL-­‐22,	   which	   participate	   in	   the	   regulation	   of	   adaptive	   immune	  
regulation	   and	   immune	   tolerance,	   were	   elevated	   in	   islets	   of	   homozygous	   mice	   at	   gene	  
expression	  level.	  IL-­‐2	  is	  a	  cytokine	  that	  supports	  effector	  T-­‐cell	  (Teff)	  differentiation	  but	  also	  
the	   development	   of	   immune	   suppressive	   Tregs	   [225].	   IL-­‐22	   belongs	   to	   the	   IL-­‐10	   family	   of	  
cytokines	  and	  is	  classically	  involved	  in	  Th17-­‐induced	  immune	  responses;	  however,	  recently	  it	  
was	  linked	  to	  the	  protection	  from	  obesity-­‐induced	  metabolic	  deteriorations	  [28].	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The	   upregulation	   of	   these	   receptors	   in	   islets	   could	   point	   to	   a	   compensatory	   mechanism	  
caused	  by	  the	   lack	  of	   IL-­‐2	  and	   IL-­‐22	   in	  homozygous	  mice.	  Since	  SIRT1	   is	  able	   to	   inhibit	   the	  
production	  of	  IL-­‐2	  [218],	  [224]	  and	  since	  the	  lack	  of	  IL-­‐2	  has	  been	  shown	  to	  play	  a	  crucial	  role	  
in	   the	   development	   of	   T1D	   [227],	   our	   mouse	   model	   supports	   the	   hypothesis	   that	  
overactivation	  of	   SIRT1	   caused	  by	   the	  mutation	  may	   lead	   to	  decreased	   IL-­‐2	   and	   therefore	  
promotes	  autoimmunity	  and	  T1D.	  	  
In	   contrast	   to	   our	   hypothesis,	   we	   observed	   elevated	   IL-­‐2	   levels	   in	   the	   circulation	   of	  
homozygous	  knock-­‐in	  mice	  compared	  to	  wildtype	  mice.	  Since	  IL-­‐2	  is	  also	  regulating	  effector	  
T-­‐cell	  development	  and	  since	  the	  suppression	  of	  IL-­‐2-­‐mediated	  activation	  of	  autoreactive	  T-­‐
cells	  has	  been	  used	  as	  immunotherapeutical	  treatment	  in	  T1D	  patients	  [226],	  it	  may	  well	  be	  
that	   IL-­‐2	   has	   diverse	   functions	   in	   β-­‐cells	   compared	   to	  other	   tissues	   and	   the	   circulation.	   In	  
turn,	  IL-­‐2	  can	  also	  inhibit	  Sirt1	  transcription	  [218],	  possibly	  explaining	  the	  high	  IL-­‐2	  levels	  in	  
the	   circulation	   as	   answer	   to	   overactivation	   of	   SIRT1.	   Due	   to	   the	   fact	   that	   low-­‐dose	   IL-­‐2	  
treatment	   can	   increase	   Treg	   recovery	   [231],	   the	   systemic	   increase	   of	   IL-­‐2	   in	   homozygous	  
mice	  could	  also	  be	  a	  compensatory	  reaction	  to	  the	  low	  numbers	  of	  Tregs.	  
Our	   data	   are	   supported	   by	   recent	   studies;	   it	   has	   been	   shown	   that	   SIRT1	   enhances	   the	  
Th17/Treg	  ratio	  and	  the	  susceptibility	  to	  autoimmune	  diseases	  [233].	  Additionally,	  inhibition	  
of	  histone	  deacetylases	  (HDACs),	  the	  group	  of	  enzymes	  SIRT1	  belongs	  to,	  was	  suggested	  to	  
improve	  Treg	  function	  in	  autoimmune	  diseases	  including	  colitis	  [234],	  [235].	  	  
As	  mentioned	  above,	  there	  are	  contradictory	  findings	  about	  SIRT1	  and	  autoimmunity	  in	  the	  
literature.	   These	   discrepancies	   along	   with	   the	   divergent	   results	   of	   our	   INS-­‐1E	   cell	   model	  
concerning	  β-­‐cell	  function	  further	  illustrate	  that	  SIRT1	  has	  a	  variety	  of	  effects	  on	  the	  body,	  
depending	   on	   the	   tissue	   and	   the	   intensity	   of	  modulation.	   It	   is	   not	   easy	   to	   create	   a	   valid	  
model	   system	   that	   in	   all	   aspects	   reflects	   the	   situation	   of	   the	   patients	   with	   familial	  
autoimmune	   diseases.	   Interestingly,	   the	   patients	   are	   carrying	   the	   SIRT1	   mutation	  
heterozygous,	  whereas	  we	  see	  the	  most	  pronounced	  effects	  in	  homozygous	  knock-­‐in	  mice.	  
Besides	  the	  one	  mutated	  allele	  of	  Sirt1,	  there	  are	  possibly	  other	  factors	  contributing	  to	  the	  
human	  phenotype,	  which	  can	  not	  entirely	  be	  reproduced	  in	  the	  mice.	  
All	  of	  this	  supports	  the	  central	  and	  complex	  role	  of	  SIRT1	  in	  T-­‐cell	  biology	  and	  in	  the	  context	  
of	  autoimmune	  diseases	  including	  T1D.	  Based	  on	  recent	  knowledge,	  inhibition	  of	  SIRT1	  may	  
improve	   the	   function	  and	  development	  of	   Tregs	  partly	   via	   IL-­‐2	   and	   Foxp3	   stimulation	  and	  
suppress	  the	  activity	  of	  Th17	  effector	  cells.	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One	  could	   imagine	  to	   treat	   the	  patients	  carrying	   the	  SIRT1	  mutation	  with	   low-­‐dose	   IL-­‐2	   to	  
increase	  Treg	  recovery,	  as	  it	  was	  tested	  in	  other	  autoimmune	  conditions	  [231].	  
Based	  on	  our	  data,	  we	  propose	  that	  overactivation	  of	  SIRT1	  may	  lead	  to	  an	  autoimmune-­‐like	  
phenotype,	   overall	   increase	   of	   inflammation	   and	   metabolic	   deterioration,	   possibly	   age-­‐
dependently	   or	   through	   additional	   triggers.	   To	   induce	   the	   precipitation	   of	   a	   metabolic	  
disease	   in	   the	   knock-­‐in	   mice,	   we	   are	   currently	   setting	   up	   a	   RIPova:L102P	   SIRT1	   mouse	  
model,	  resulting	  in	  mice	  carrying	  the	  SIRT1	  mutation	  on	  an	  autoimmune	  background	  along	  
with	   controlled	   induction	   of	   diabetes.	   It	   will	   be	   interesting	   to	   see	   if	   we	   can	   mimic	   the	  
phenotype	  of	  the	  patients,	  including	  glucose	  intolerance	  and	  insulin	  resistance.	  Since	  we	  did	  
not	  see	  differences	  in	  the	  mldSTZ	  model	  between	  wildtype,	  heterozygous	  and	  homozygous	  
knock-­‐in	  mice,	  it	  may	  also	  be	  interesting	  to	  activate	  SIRT1	  through	  treatment	  with	  NMN	  or	  
resveratrol	  to	  provoke	  differences	  in	  the	  onset	  of	  T1D.	  Following	  our	  hypothesis,	  we	  would	  
expect	   the	   homozygous	   knock-­‐in	  mice	   to	   be	  more	   prone	   to	   hyperglycemia	   in	   the	  mldSTZ	  
model	  after	  treatment	  with	  additional	  SIRT1	  activators.	  
	  
	  
In	   our	   second	   sirtuin	   study,	   we	   show	   that	   the	   deletion	   of	   SIRT1	   specifically	   in	   β-­‐cells	  
negatively	   influenced	   the	   overall	   metabolic	   situation	   along	   with	   disturbances	   in	   glucose	  
homeostasis	   and	   the	   induction	   of	   islet	   inflammation.	   The	   knock-­‐out	   of	   SIRT1	   in	   β-­‐cells	  
caused	   impaired	   glucose	   tolerance	   and	   lower	   insulin	   levels	   along	   with	   defects	   in	  
mitochondrial	   glucose	   sensing	   and	   increased	   cytokine	   and	   chemokine	  production	   in	   islets.	  
However,	  in	  the	  context	  of	  type	  1	  diabetes,	  SIRT1	  activity	  in	  β-­‐cells	  seems	  to	  be	  detrimental	  
since	   our	   SIRT1	   KO	  mice	  were	   protected	   from	   STZ-­‐induced	   diabetes	   and	   the	   loss	   of	   body	  
weight.	   These	   in	   vivo	   data	   of	   the	   mldSTZ	   experiments	   further	   support	   the	   novel	   way	   of	  
thinking	  about	  the	  adverse	  role	  of	  SIRT1	  activity	  in	  the	  onset	  of	  T1D.	  
The	  mice	   lacking	   SIRT1	   in	   β-­‐cells	   were	   protected	   from	  mldSTZ-­‐induced	   hyperglycemia;	   in	  
contrast	   to	   the	   wildtype	  mice	   they	   did	   not	   reach	   100%	   diabetes	   induction	   and	   the	   body	  
weight	  was	  less	  decreased	  throughout	  the	  experiment.	  The	  literature	  on	  the	  role	  of	  SIRT1	  in	  
the	  development	  of	  diabetes	  is	  contradictory	  and	  full	  of	  open	  questions.	  Nonetheless,	  it	  has	  
been	  shown	  in	  whole	  body	  knock-­‐out	  mice	  that	  lack	  of	  SIRT1	  is	  increasing	  the	  susceptibility	  
to	  STZ-­‐induced	  hyperglycemia	  [215].	  The	  comparison	  of	  these	  global	  SIRT1	  knock-­‐out	  mice	  
with	  our	  findings	  in	  the	  β-­‐cell	  specific	  SIRT1	  knock-­‐out	  mice	  conveys	  a	  subordinate	  role	  of	  β-­‐
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cell-­‐derived	  SIRT1	   in	  the	  manifestation	  of	   the	  demonstrated	  STZ-­‐induced	  deteriorations.	   In	  
complete	  agreement	  with	  our	  data,	   it	  was	  shown	  that	  mice	  overexpressing	  SIRT1	  in	  β-­‐cells	  
are	  more	  prone	  to	  STZ-­‐induced	  diabetes	  [216].	  	  
During	   the	   process	   of	   diabetes	   initiation,	   remaining	   islets	   may	   have	   a	   high	   workload	   to	  
produce	  sufficient	  hormones.	  We	  hypothesize	  that	  this	  exhaustion	  may	  be	  prevented	  by	  the	  
induction	  of	  a	  “β-­‐cell	  rest”	  via	  knock-­‐out	  of	  SIRT1	   in	  β-­‐cells,	  promoting	   longer	   islet	  survival	  
and	   function	   along	   with	   resistance	   to	   T1D.	   The	   positive	   effects	   of	   β-­‐cell	   rest	   have	   been	  
shown	   in	  vitro	  and	  in	  clinical	  studies	  [259],	  [260].	  It	  is	  suggested	  that	  β-­‐cells	  with	  increased	  
workload	  may	  recover	  when	  insulin	  secretion	  is	  inhibited	  or	  exogenous	  insulin	  is	  offered.	  
mldSTZ	  experiments	   in	   the	   context	  of	   SIRT1	  may	  be	  delicate	   since	  both	  SIRT1	  activity	  and	  
mldSTZ	  are	  known	  to	  consume	  NAD+,	  either	  by	  STZ-­‐induced	  activation	  of	  PARP	  or	  because	  it	  
is	  used	  as	  cofactor	  for	  SIRT1	  [204],	  [136].	  It	  is	  possible	  that	  the	  beneficial	  effects	  of	  the	  SIRT1	  
KO	  in	  β-­‐cells	  on	  STZ-­‐induced	  hyperglycemia	  arose	  from	  increased	  availability	  of	  NAD+	  due	  to	  
the	   lack	   of	   SIRT1.	   Based	   on	   reported	   death	   cases	   by	   treatment	   with	   the	   SIRT1	   activator	  
SRT1720	  in	  a	  mouse	  model	  of	  T1D	  [166]	  and	  based	  on	  unpublished	  experiments	  of	  our	  group	  
with	  NOD	  mice,	  which	   are	   independent	   of	  NAD+	   depletion	   by	   PARP,	   it	   is	  more	   likely	   that	  
SIRT1	  activation	  itself	  is	  detrimental	  in	  the	  context	  of	  T1D.	  
Altogether,	   we	   propose	   that	   SIRT1	   expressed	   in	   β-­‐cells	   is	   a	   central	   regulator	   of	   glucose	  
homeostasis,	  islet	  inflammation	  and	  the	  development	  of	  diabetes.	  It	  has	  diverse	  effects:	  on	  
one	   hand,	   deletion	   of	   SIRT1	   in	   β-­‐cells	   causes	   impaired	   glucose	   tolerance,	   mitochondrial	  
defects	  and	  elevation	  of	   inflammatory	  gene	  expression	   in	   islets.	  On	  the	  other	  hand,	   in	   the	  
context	  of	  T1D,	  knock-­‐out	  of	   SIRT1	   in	  β-­‐cells	  prevents	   the	   induction	  of	  hyperglycemia	  and	  
reduced	  the	  loss	  of	  body	  weight.	  	  
In	   the	   last	   few	   years,	   the	   initially	   euphoric	   view	   of	   SIRT1	   being	   a	   positive	  metabolic	   and	  
inflammatory	   regulator	   has	   changed.	   It	   has	   been	   suggested	   in	   numerous	   studies	   that	  
overexpression	   and	   overactivation	   of	   SIRT1	   in	   different	   tissues	   and	   situations	   does	   not	  
necessarily	   have	   beneficial	   effects.	   It	   was	   shown	   that	   strong	   (12.5-­‐fold)	   heart-­‐specific	  
overexpression	  of	   SIRT1	   leads	   to	   the	   induction	  of	   oxidative	   stress	   and	   cardiac	  dysfunction	  
[243].	   Furthermore,	   SIRT1	   was	   linked	   to	   the	   attenuation	   of	   β-­‐cell	   expansion	   [261],	   to	  
decreased	   insulin	   sensitivity	   [185]	   and	   to	  worsening	   of	   insulin	   resistance	   in	   diabetic	  mice	  
[252].	  Overexpression	  of	  SIRT1	  failed	  to	  protect	  mice	  from	  HFD-­‐induced	  obesity	  [169],	  [172]	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and	  impairment	  of	  insulin	  sensitivity	  [182].	  Additionally,	  SIRT1	  overexpression	  in	  rheumatoid	  
arthritis	   is	  suggested	  to	  contribute	  to	  pro-­‐inflammatory	  cytokine	  production	  and	  apoptosis	  
resistance	  [262].	  As	  mentioned	  above,	  the	  synthetic	  small	  SIRT1	  activator	  SRT1720	  that	  was	  
shown	   to	  be	  beneficial	   for	  metabolic	   and	  mitochondrial	   function	   in	   animal	  models	  of	   T2D	  
[164],	  [160],	  [263],	  [165]	  failed	  to	  improve	  metabolic	  conditions	  in	  other	  mouse	  studies	  and	  
caused	  accumulated	  death	  cases,	  shown	  by	  Pacholec	  et	  al.	  [166]	  and	  by	  our	  research	  group	  
in	  NOD	  mice	  (unpublished	  data).	  	  
Additionally,	   it	   has	   been	  pointed	  out	   that	   inhibition	   of	   histone	  deacetylases,	   the	   group	  of	  
enzymes	  where	  SIRT1	  belongs	  to,	  can	  improve	  metabolic	  functions,	  β-­‐cell	  inflammation	  and	  
insulin	   sensitivity	  via	  enhanced	  activity	  of	  PPARγ	  or	  glucose	  uptake	   in	  muscle	   [264],	   [200].	  
Further,	   the	   inhibition	  of	   lysine	   deacetylases	   in	   the	  NOD	  mouse	  model	   of	   T1D	   resulted	   in	  
decreased	   pro-­‐inflammatory	   factors	   in	   β-­‐cells	   and	   leukocytes	   [265].	   SIRT1	   inhibition	   as	  
possible	  treatment	  has	  been	  tested	  in	  other	  disease	  areas	  as	  well.	  Huntington`s	  disease	  (HD)	  
is	  a	  neurodegenerative	  disease	  known	  to	  develop	  through	  transcriptional	  dysregulation	  and	  
dysfunctional	  protein	  acetylation.	  The	  inhibition	  of	  deacetylation	  by	  SIRT1	  blockage	  was	  well	  
tolerated	   in	  a	  human	  study	   [266]	  and	  resulted	   in	   improvement	  of	  HD	  pathology	   in	  several	  
cell	  and	  mouse	  models	  [267].	  	  
All	   of	   these	   findings	   suggest	   a	   negative	   role	   of	   SIRT1	   overactivation	   in	   the	   context	   of	  
diabetes.	  Thus,	   inhibition	  of	  SIRT1	  as	  histone	  and	  protein	  deacetylase	  may	  have	  beneficial	  
effects	  in	  the	  development	  of	  T1D.	  
	  
To	   interpret	   the	   data	   of	   our	   both	   sirtuin	   1	   studies,	   we	   revealed	   new	   perspectives	   for	  
understanding	   the	  complex	   functions	  of	  SIRT1	  as	  an	  essential	  player	   in	   immune	  responses	  
and	  type	  1	  diabetes.	  Based	  on	  our	  data	  of	   the	  knock-­‐in	  mice	  SIRT1	  L102P,	  we	  hypothesize	  
that	   SIRT1	   overactivation	   leads	   to	   an	   altered	   immunological	   balance	   with	   increased	  
inflammation,	  improved	  islet	  function	  and	  glucose	  tolerance.	  This	  may	  lead	  to	  exhaustion	  of	  
the	  β-­‐cells	   and	  may	  accelerate	   the	  development	  of	   type	  1	  diabetes,	   as	  we	   saw	  protective	  
effects	  through	  β-­‐cell	  specific	  SIRT1	  knock-­‐out.	  Accordingly,	  inhibition	  and	  not	  activation	  of	  
SIRT1	  in	  the	  context	  of	  type	  1	  diabetes	  could	  have	  beneficial	  effects.	  Nonetheless,	  targeting	  
SIRT1	  is	  a	  delicate	  issue	  and	  seems	  to	  depend	  on	  various	  factors.	  There	  is	  evidence	  that	  the	  
functions	   of	   SIRT1	   are	   required	   in	   physiological	   states	   and	   for	   adaptation	   to	   stress	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conditions.	  However,	  in	  certain	  inflammatory	  pathologies,	  such	  as	  the	  onset	  of	  T1D,	  it	  may	  
have	  therapeutical	  value	  to	  inhibit	  and	  not	  enhance	  SIRT1	  activity.	  
	  
Altogether,	   this	   study	   revealed	   the	   influence	   of	   two	   important	   inflammatory	  modulators,	  
sirtuin	   1	   and	   angiotensin	   II,	   on	   the	   development	   of	   diabetes.	   Several	   factors	   have	   been	  
implicated	   with	   islet	   inflammation	   and	   β-­‐cell	   damage,	   including	   glucose,	   free	   fatty	   acids,	  
amyloid	  and	  also	  β-­‐cell	  antigens.	  However,	  a	  variety	  of	  additional	  molecules	  may	  contribute	  
to	   the	  deterioration	  of	  glucose	  homeostasis	  by	  modulating	   inflammatory	  processes.	  Based	  
on	  our	  data,	  we	  propose	  that	   inhibition	  of	  angiotensin	   II	   in	   the	  context	  of	   type	  2	  diabetes	  
and	   lowering	   of	   sirtuin	   1	   activity	   in	   the	   development	   of	   type	   1	   diabetes	   may	   have	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  Christoph	  Handschin,	  dass	  er	  sich	  bereit	  erklärt	  hat,	  Teil	  meines	  
Thesis	  Komitees	  zu	  sein	  und	  diese	  Arbeit	  zu	  bewerten.	   Ich	  danke	  auch	  Prof.	  Ed	  Palmer	   für	  
den	  Beisitz	  während	  meiner	  Prüfung.	  
	  
Spezieller	   Dank	   geht	   an	   Nadine	   Sauter-­‐Zlinszky,	   die	   mir	   viele	   wertvolle	   Tips	   im	   Labor	  
mitgegeben	  hat	  und	  für	  jedes	  Problem	  eine	  Lösung	  wusste.	  Danke,	  dass	  du	  mir	  dein	  Projekt	  
übergeben	  hast	  und	  ich	  freu	  mich,	  euch	  mal	  wieder	  in	  Zürich	  zu	  besuchen!	  
	  
Danke	  Kaethi	  für	  die	  tolle	  Zeit	  mit	  dir,	  für	  die	  unzähligen	  kleinen	  und	  grossen	  Lebenshilfen,	  
Kaffi-­‐,	  Messe-­‐	  und	  Flohmarktrunden	  und	  deine	  ganze	   technische	  Hilfe!	   Ich	  werde	  die	   tolle	  
Zeit	  in	  Basel	  nie	  vergessen.	  
	  
Merci	  to	  Elise	  Dalmas	  for	  cheering	  me	  up	  every	  day,	  introducing	  me	  to	  the	  immune	  system	  
and	   for	   supporting	  me	   throughout	   the	  entire	   time.	  Thanks	   for	  all	   your	  help	  with	   the	  FACS	  
experiments,	   for	   your	   input	   and	  numerous	  Hugos.	   I	  will	  miss	   the	  evenings	   in	   the	   lab	  with	  
stupid	  conversation	  and	  philosophical	  considerations	  about	  crazy	  eyes.	  La	  vie	  est	  belle!	  
	  
Ich	   möchte	   mich	   bei	   der	   ganzen	   Diabetes	   Research	   Gruppe	   für	   die	   entspannte	  
Zusammenarbeit	  und	  gute	  Laune	  während	  der	  Arbeit	  bedanken.	  Auβerdem	  herzlichen	  Dank	  
an	  Marcela	  Borsigova	  und	  Stéphanie	  Häuselmann	  für	  all	  die	  technische	  Unterstützung.	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Special	  thanks	  to	  Prof.	  Christoph	  Hess	  and	  his	  group	  members	  Marco	  Fischer,	  Glenn	  Bantug	  
and	   Sarah	   Dimeloe	   for	   technical	   support	   concerning	   the	   Seahorse	   technology	   and	   flow	  
cytometry.	  
	  
Ich	   möchte	   mich	   ganz	   herzlich	   bei	   dem	   gesamten	   Team	   des	   Tierstalls	   des	   Department	  
Biomedizin/ZLF	  bedanken.	  Danke	  an	  Ueli	   Schneider,	  Nicole	  Caviezel,	  Corinna	  Bildl	  und	  das	  
ganze	   Team	   für	   das	   Versorgen	   meiner	   zahlreichen	   Mauszuchten	   und	   für	   die	   entspannte	  
Atmosphäre	  bei	  der	  Arbeit	  mit	  den	  Tieren.	  
	  
Thanks	  to	  our	  funding	  and	  collaboration	  partners	  Swiss	  National	  Science	  Foundation	  (SNF),	  
Juvenile	   Diabetes	   Research	   Foundation	   (JDRF),	   Schweizerische	   Gesellschaft	   für	  
Endokrinologie	  und	  Diabetologie	  (SGED)	  and	  the	  Sinclair	  group	  in	  Boston.	  
	  
Ich	   bin	   meinen	   Freunden	   und	   meiner	   Familie	   sehr	   dankbar	   für	   die	   Bereicherung	   meines	  
Lebens,	  für	  ihre	  Hilfe,	  Ermutigung	  und	  viele	  schöne	  gemeinsame	  Stunden.	  
	  
Ich	  möchte	  mich	  von	  Herzen	  bei	  meinen	  Eltern	  für	  ihre	  Unterstützung	  bedanken.	  Es	  ist	  nicht	  
selbstverständlich,	  bedingungslose	  Rückendeckung	  zu	  bekommen.	  Ich	  bin	  sehr	  dankbar	  und	  
stolz,	  eure	  Tochter	  zu	  sein.	  
	  
Danke	  Arne,	  dass	  du	  an	  meiner	  Seite	  bist.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
